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Preface
The loss of skeletal muscle mass and strength substantially impairs physical perfor-
mance and the quality of life, especially in older patients. The prevention and treat-
ment of muscle atrophy is a big challenge for clinicians and other professionals. The 
book chapters provide insight into the molecular, morphological, and functional 
changes under conditions that lead to muscular atrophy. The sarcopenia in older 
patients is highlighted in many chapters. The normal situation and the age-related 
changes in the motor unit (motor neuron, neuromuscular junction, and skeletal 
muscle) are demonstrated and the role of impaired bone remodeling are presented 
in some chapters. Other chapters present and discuss the tools for the management 
of muscular atrophy (sarcopenia) in older patients and other types of muscular 
atrophy. The pharmacological, nutritional, and physiotherapeutic approaches are 
demonstrated in detail, as well as the possible role of herbal antioxidants in the 
treatment of muscular atrophy. The chapters may be interesting for professionals 
in clinical practice, for medical and health care students as well as for researchers 
working in muscle-related fields of science.
Special thanks to Romina Rovan, Author Service Manager, for professional guid-
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Therapeutic Targets and 
Pharmacological Interventions:  
An Update
Mohit Kwatra, Sahabuddin Ahmed, Samir Ranjan Panda,  
Vegi Ganga Modi Naidu and Nitika Gupta
Abstract
Muscles are the enriched reservoir of proteins in the body. During any workout 
or exercise, the demand in the form of energy is essentially required by the muscle. 
Energy expenditure of skeletal muscle is more dependent on the type of demand. 
There is particular homeostasis within the body that avoid surplus energy expen-
diture and this prevents any muscle loss. Muscle atrophy is termed as the loss of 
skeletal muscle mass due to immobility, malnutrition, medications, aging, cancer 
cachexia, variety of injuries or diseases that impact the musculoskeletal or nervous 
system. Hence, atrophy within the skeletal muscle initiates further cause fatigue, 
pain, muscle weakness, and disability in human subjects. Therefore, starvation 
and reduced muscle mass further initiate numerous signaling pathways including 
inflammatory, antioxidant signaling, mitochondria bio-energetic failure, AMP-
activated protein kinase (AMPK), Sirtuin 1(SIRT1), BDNF/TrkB/PKC, Autophagy, 
ubiquitin-proteasome systems, etc. Here, in this chapter, we will mention molecu-
lar mechanisms involved in therapeutic targets and available Pharmacological 
Interventions with the latest updates.
Keywords: molecular mechanisms, therapeutic targets, pharmacological Interventions
1. Introduction
Muscles are enormous protein reservoirs within the body. It is a profound source 
of various amino acids required for energy production used by various organs (such 
as brain, liver, heart) during energy demand and disease conditions (cancer, AIDS, 
burn, heart failure). However, extensive protein requirement does not consider 
good in case of cachexia which might lead to increased morbidity and mortality. 
Skeletal muscle is an organ with plastic characteristics and regulated by several 
signaling pathways that control cell and protein turnover. The skeletal muscle 
atrophy may be due to lower muscle mass, disease. However, disuse muscle medi-
ated acute atrophy is reversed through exercise. Furthermore, chronic atrophy such 
as sarcopenia features as loss of muscle mass strength with age. Moreover, other 
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nerve damage to innervate to the muscle [1]. In muscle atrophy, a proteolytic system 
gets activated while contractile proteins and organelles are removed results in the 
shrinkage of muscle fibers.
Spinal muscular atrophy (SMA), a kind of intense neuromuscular disease 
depicts as chief genetic cause of death in infants. It is featured as alpha motor 
neuron degeneration within the anterior horn region of the spinal cord and brain 
stem that is the leading cause of progressive muscle weakness. SMA is inherited as 
autosomal recessive disorder and the most common form (95% cases) caused by 
certain mutations in the survival motor neuron 1 (SMN1, SMNT) gene localized 
on chromosome 5q12.2. The genetic deletion or carries a mutation of the SMN1 
gene resulting SMN protein deficit. On the other hand, the SMN2 gene develops 
a relatively small amount of functional SMN protein and SMN2 copy numbers 
further determine the severity of the disease. The incidence of SMA is approx. 1 
in 10,000 live births while prevalence estimates 1–2 in 100,000 affected individu-
als with extremely shortened life expectancy. SMA characterizes in various forms 
depending on the age of inception such as Infants being severely hypotonic possess 
feeding problems, further reach growing age of children does found with difficulty 
climbing stairs proceeded with frequent falls. The clinical manifestation of SMA is 
usually heterogeneous and scored to a range from severe to mild phenotype which is 
further divided into mainly 3 subtypes as Type I (also known as Werdnig-Hoffmann 
disease), type II and, type III (also called Kugelberg Welander disease). SMA cat-
egorized as type 0, a serious and rigorous form, lower/absent movements, abnormal 
muscle contractions, and immediate need for ventilation support. SMA type IV, a 
mild late (adult) onset [2]. Hence, improve understanding regarding the molecular 
pathogenesis mechanisms cause for muscle atrophy or muscle wasting attribute the 
efforts to designate the safe and effective therapy for affected human subjects.
2. Molecular key mechanisms in muscle and spinal muscular atrophy
Various signaling pathways participate in molecular pathogenesis of muscle 
atrophy (Figure 1).
Figure 1. 
Signaling Cascade Events in Muscle Atrophy.
5
Molecular Mechanisms, Therapeutic Targets and Pharmacological Interventions: An Update
DOI: http://dx.doi.org/10.5772/intechopen.95996
2.1 Oxidative stress and inflammatory signaling
Oxidative stress and inflammation are considered the foremost molecular 
mechanisms responsible for muscle atrophy [3]. Raised levels of reactive oxygen 
species (ROS) production within skeletal muscles substantially promote mitochon-
drial function impairment, stimulate forkhead box class O (FoxO) transcription 
factors leads to inactivity induced muscle atrophy [4]. Inflammation perturbs the 
muscle homeostasis and process of myogenesis via activating the family of FoxO 
transcription factors significantly contribute to skeletal muscle atrophy [5]. FoxO 
activation is vital for the muscle atrophy induced through denervation/fasting, 
which upon activation (FoxO3) cause induction of ubiquitin–proteasome system 
(UPS) and autophagy–lysosomal system (ALS) in a coordinate manner, especially 
lysosomal proteolysis [6]. Shreds of evidence, state that FoxO knockout was able 
to reverse the muscle degeneration process loss, also the markers of increased 
UPS process and autophagy dysfunction in streptozotocin-diabetes induced 
mice (O’Neill et al., 2019). Therefore, necessary steps must be taken to find an 
intervention that can curb the atrophy. During muscle wasting or cachexia, NFκB 
transcription factors activate with certain stimulants or facilitators (such as TNF-α). 
Upon TNFα response, the IκB complex gets phosphorylates by IκB kinase (IKKβ), 
ensuing ubiquitylation followed by its proteasomal degradation which further 
causes nuclear translocation of NFκB and induce transcription of inflammatory 
mediators [7]. Transgenic mice showing muscle-specific overexpression of IKKβ 
results in drastic muscle wasting due to ubiquitin ligase MuRF1 and not by atrogin-1 
[8]. Furthermore, muscle-specific inhibition of NFκB through transgenic expres-
sion of a typically active IκB mutant generated partial results due to denervation 
atrophy get substantially reduced [9]. Besides, mice deficient with p105/p50 subunit 
of NFκB reduced hindlimb unloading induced muscle atrophy [4, 10]. The pro-
inflammatory cytokines including TNF-α cause insulin resistance and repress the 
Insulin-like growth factor-AKT (IGF1-Akt) pathway [11]. Furthermore, hyperphos-
phorylation of AKT was found in IKKβ knockout mouse which develops resistance 
against muscular atrophy [12]. These findings signify the important crosstalk of two 
pathways, and further future studies are desirable for elucidating respective links of 
the IKKβ-NFκB and Akt-FoxO pathways in muscle atrophy.
Moreover, an inflammatory cytokine strongly concerned for muscle-wasting 
disease is the TNF-like weak inducer of apoptosis (TWEAK), which binds on the 
surface receptor FN14 and induces NF-κB activation. TWEAK deficient mice ablate 
atrophy upon denervation, a process that generally activates TWEAK [13, 14]. 
Furthermore, the TWEAK-F14 axis may be a potential therapeutic target in muscle 
wasting diseases [15].
2.2 Mitochondrial dysfunction
Mitochondrial functional impairment is a critical regulatory event that brings 
on activation of atrophic programs in inactivity-induced muscle atrophy. Prolonged 
muscle inactivity induces mitochondria suffers from prompt reduction in the 
respiratory capacity, coupling, lower mitochondrial volume, mitochondrial ROS 
overload, and destruct mitochondrial architectures. Muscle inactivity, promotes 
mitochondrial fission rather than fusion and therefore decays energy level and leads 
to muscle atrophy [16, 17].
Mitochondrial fusion and fission process need excessive refinement due to mito-
chondrial lipid bilayer hence need synchronization at inner as well as outer mem-
brane. Upon fusion process, mitofusin1 and 2 (MFN1 and MFN2) proteins facilitate 
fusion by attaching to an outer membrane in adjoining mitochondria, while the 
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inner membranes by optic atrophy 1 (OPA1). Additionally, MFN 1 and 2 also 
functions over junctions to create membrane-associated-sarcoplasmic reticulum 
membranes (MAM) to play keen role in mitochondrial Ca2+ management. Further, 
a major regulative component that regulate fusion with MFN proteins is the E3 
ligase Parkin, which ubiquitinates MFN1 and MFN2 cause its extraction from the 
outer membrane of mitochondria with subsequent degradation and thereby prevent 
mitochondrial fusion [18, 19]. The mitochondrial fission is largely coordinated by 
dynamin-related protein 1 (DRP1). DRP1 locates in the cytosol and upon certain 
signaling event, process induce it translocate to the outer mitochondrial membrane. 
Phosphorylation at Ser616 is believed to activate DRP1, while phosphorylation at 
Ser637 and Ser693 inactivate DRP1 and prevention of mitochondrial fission activity 
altered through sumoylation and S-nitrosylation [20]. The muscle inactivity results 
in alterations of the proteins involve in both fusion and fission [21]. Inactivity-
mediated muscle atrophy leads to increased total as well as phosphorylated (i.e., 
pDRP1-S616, active) DRP1 which explains it as an essential mediator of the 
mitochondrial division. Additionally, MFN1, MFN2, and OPA1 function as fusion 
promoters is found lower in protein content and hence limit the mitochondrial 
fusion process while promote mitochondrial fission.
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α), a key regulator of mitochondrial biogenesis is found significantly 
decreased with prolonged muscle immobility. PGC-1α, a transcriptional coactiva-
tor assists the regulation of genes involved in mitochondrial biogenesis, fatty acid 
oxidation, and glycolysis. The reduction in PGC-1α abundance markedly impaired 
mitochondrial biogenesis negatively influences mitochondrial structure and 
function. However, PGC-1α overexpression preserved mitochondria and improved 
muscle performance [22]. Furthermore, overexpression of PGC-1α ameliorates 
decreased MFN1, MFN2, and OPA1 in muscle wasting. This further outlooked the 
importance of upstream transcriptional activators [23, 24]. Importantly, muscle 
inactivity-induced dysfunctions in skeletal muscle mitochondria through elevations 
in mitochondrial ROS emission, the release of proteolytic-activating mitochondrial 
proteins, and triggering apoptotic cellular signaling cascade caused due to mito-
chondrial fragmentation [24].
2.3 TrκB/BDNF/PKC pathway
Neurotrophins always have been thought to work within neuronal cells and 
function as differentiators, nerve growth, neuronal survival, and apoptosis 
regulators [25–27]. Various evidence state that these neurotrophins have a diverse 
function in numerous cell populations across multiple tissue compartments than 
earlier thought. Among these, skeletal muscle seeks great importance as it act as a 
plentiful source with neurotrophic support throughout the development process. 
Neurotrophin knockout mice show unique defects in muscle growth and function. 
For instance, NT (4/5), NT-3 implicates for muscle fiber transformation and spindle 
formation and nerve growth factor (NGF) in muscle dystrophy [25]. Brain-derived 
neurotrophic factor (BDNF), a well-known member of the neurotrophin family, 
plays an utmost vital role in differentiation, synaptic plasticity, development, 
neuronal survival via activating tropomyosin-related kinase receptor B (TrkB) 
receptor. BDNF potentiates TrkB autophosphorylation leading to initiation of some 
signaling pathways, including the PI3K/Akt, Ras/Raf/ERK, and PLCγ/PKC.
Initially, BDNF is produced as a precursor (pro-BDNF), further cleaves to 
mBDNF (a mature isoform) by Intra/extracellular proteases. These two isoforms 
stimulate different and even opposite functions via interacting especially to low-
affinity nerve growth factor receptor (p75) or the tropomyosin-related kinase B 
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receptor (TrkB). Furthermore, alternative splicing of TrkB mRNA gives rise to a 
full-length TrkB isoform (TrkB.FL) and truncated TrkB isoforms T1 and T2 (TrkB.
T1 and TrkB.T2) [28, 29]. TrkB.T1 is considered to be main truncated isoform in 
skeletal muscle tissue while TrkB.T2 (variant) chief variant function within brain 
regions. Growing evidence mentions that exercise training ensures CNS health, 
such as improving synaptic function. BDNF is secreted in an activity-dependent 
and its expression in the rodent spinal cord and skeletal muscle surges after a 
physical workout. Correspondingly, normal levels of neuromuscular activity are 
required to maintain basal levels of BDNF within the neuromuscular structure. 
Lastly, one study found that contracting cultured myotubes stimulated to release 
the BDNF and justify the postsynaptic origin (Matthews et al., 2009). However, the 
skeletal muscles release BDNF in in-vivo models, after contraction, either synaptic 
activity provokes its liberation, or a combination of both, the exact mechanisms 
remains elusive. Exogenous BDNF intensifies acetylcholine (ACh) discharge at 
neuromuscular junction via coupling with TrkB receptor This supports well where 
neuromuscular activity endorses BDNF/TrkB retrograde signaling in maintain-
ing neuromuscular function [28, 30]. Furthermore, the nerve-stimulated muscle 
contraction is a chief regulator of the BDNF/TrkB signaling pathway, retrogradely 
activate conventional protein kinase C (cPKC) isoforms (in particular cPKCβI) in 
modifying synaptic function [31].
With embryonic development, primordial skeletal muscle cells express compar-
ative higher BDNF levels and later downregulates with maturation. Furthermore, 
expression of BDNF does associate with myofibers development, which later 
expresses myosin heavy chain IIB. BDNF was also found regulating food intake 
and blood glucose level in genetically modified (db/db) obese mice [32]. Thus, it is 
obvious that BDNF drivesregulatory role in neurobiology and metabolism. Recent 
reports established the fact that physical activity (exercise) raises the circulating 
BDNF levels in healthy humans as well as patients of multiple sclerosis, nevertheless 
cellular sources still vague. Certain reports evidenced the increased BDNF mRNA 
transcriptome within skeletal muscle in response to muscle contraction, however, 
this substantiates the fact with BDNF source within neurons does innervate skeletal 
muscle compartments. A Contrasting study explains the BDNF mRNA expresses in 
skeletal muscle of murine and was found increased with inhibiting histone deacety-
lases (HDACs) [33]. Physical exercise also tends to block histone deacetylases and 
contracted muscles release BDNF and mentions as novel contraction-induced 
myokine [34]. Moreover, BDNF was found to possess metabolic activity in the 
skeletal muscle. It increased phosphorylation of AMPK, acetyl-coenzyme A carbox-
ylase β (ACCβ), and raised the level of fatty acid oxidation studied in vitro, in-vivo 
(sex-dependent), and ex vivo. The impact of BDNF over fatty acid oxidation was 
AMPK-dependent, however, this increased energy regulation was found to repress 
inC2C12 cells infected with either AMPK dominant-negative form of adenovirus 
or employed AMPK inhibitor (Compound C). BDNF injected via electroporation 
within the tibialis cranialis muscle raises BDNF production and tropomyosin-
related kinase B (TrkBTyr706/707) and extracellular signal-regulated protein kinase 
(p44/42 Thr202/Tyr204) phosphorylation. Also, phosphorylation of ACCβ was also 
noticed in BDNF electroporated muscles [35, 36]. This raises the possibility that 
BDNF analogs or BDNF mimetic drugs can be a possible therapeutic intervention in 
metabolic diseases.
In the case of spinal bulbar muscular atrophy (SBMA) which is an androgen-
dependent neuromuscular disorder associates with polyglutamine expansion 
mutation in androgen receptor gene [37]. SMBA affects people with middle 
young age and is featured through persistent muscle weakness with lower 
androgen sensibility. The muscle-derived neurotrophic factors such as vascular 
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receptor. BDNF potentiates TrkB autophosphorylation leading to initiation of some 
signaling pathways, including the PI3K/Akt, Ras/Raf/ERK, and PLCγ/PKC.
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affinity nerve growth factor receptor (p75) or the tropomyosin-related kinase B 
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endothelial growth factor (VEGF), neurotrophin-4, insulin-like growth factor-1 
etc. expression is usually reduced in pathological condition and experimentally 
strengthen its expression within muscle improvised the condition in SBMA 
affected mice [37]. Further, a possible mechanism by which muscle-derived 
neurotrophic factors combat disease is by ameliorating it in retrograde axonal 
transport. The motor impairment in SBMA may disapprovingly depend upon 
lower levels of muscle-derived BDNF, concludes that neuromuscular function 
can be salvaged in disease condition via reloading with muscle BDNF. Probable 
locations of BDNF action for endorsing neuromuscular function are Schwann 
cells, motoneurons, and muscles. Despite muscle fiber or motor neurons gets 
damage, BDNF tends to promote regaining the function of residual motoneurons 
and muscle fibers as well. Nonetheless, the satellite cell population mobilize 
within muscle tissue is also induced by BDNF action [37].
2.4 SIRT1/AMPK/PGC-1α signaling
Starvation or energy deprivation limits glucose availability compensated by 
accelerating mitochondrial fatty acid oxidation within the skeletal muscle or 
peripheral tissues to reserve blood glucose amount and stream to the brain and red 
blood cells. Further, shortage of metabolic flexibility appropriately acclimatizes as 
per energy demands and nutrient availability forms a burden on energy homeo-
stasis, resulting in the development of the metabolic disease. Such, metabolic 
transformations within the muscle are pushed towards synchronized transcrip-
tional responses promote mitochondrial utilization of lipids as their substrates for 
the energy source. The variations in gene expression patterns are attained via the 
modulation of some transcriptional regulators such as coactivator PGC-1α and 
FOXO family of transcription factors, both are closely associated with the regula-
tion of mitochondria and fatty acid metabolism [38, 39]. The activities of PGC-1α 
and FOXOs are seriously influenced by controlling their acetylation levels through 
the silent information regulator/Sirtuin (SIRT1) type III (NAD+-dependent deacet-
ylase). SIRT1 knock-down averts induction of mitochondrial/fat oxidation genes in 
glucose-limited myocytes.
AMP-activated protein kinase (AMPK), metabolic sensing protein is found 
robustly influence the transcriptional responses. It is a heterotrimeric Ser/Thr 
kinase consists of one catalytic (α) with another non-catalytic subunits (β and 
γ). Further, two different isoforms are the α and β subunits (α1 and α2 or β1 and 
β2), and the γ subunits are determined by different genes (γ1, γ2, and γ3). The γ 
subunits usually interact with AMP/ATP competitively and work jointly. The AMP 
binding surges the catalytic activity of complex and augments phosphorylation of 
Thr172, crucial for activity. AMPK enhances SIRT1 activity by raising intracellular 
NAD+ levels. This leads to deacetylation of SIRT1 targets (NF-κB, PGC-1α, FOXO1) 
which corresponds physiological or pharmacological AMPK activation [40, 41]. 
Enhanced organ fibrosis comprises organ to malfunction in a variety of diseases. 
Tissue fibrosis is also an eminent pathological feature of dystrophic skeletal muscle 
seen in Duchenne muscular dystrophy (DMD) human subjects. Further, repression 
of muscle fibrosis may be a beneficial treatment strategy in patients suffers from 
muscular atrophy and dystrophy. Treatment with active flavonoid resveratrol sup-
presses interstitial fibrosis in the biceps femoris of mdx mice.
The muscle cells find to activate SIRT1 that reduces oxidative stress by prevent-
ing transforming growth factor-𝛽𝛽- (TGF-𝛽𝛽-) induced upregulation of NADPH 
oxidase (NOX), which congruently generates reactive oxygen species (ROS) [42]. 
SIRT1 inhibits inflammatory cascade mediator’s transcription factors via carrying 
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deacetylation of acetyl NF-κB to P-NFκB and repress inflammation within muscles. 
Furthermore, deacetylation of peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1𝛼𝛼) via SIRT1 induces transcription of mitochondrial and 
HIF2αgenes and hence promotes fast to slow fiber shift [43–45]. Tissue fibrosis is 
reduced by SIRT1 which function by two mechanisms in fibroblasts. One is SIRT1-
mediated deacetylation and inhibition of Smad transcription factors. Secondly, 
p300 deacetylation by SIRT1 following p300 protein degradation by the ubiquitin-
proteasome pathway. Hence, the anti-fibrotic effect linked to SIRT1 activation may 
be valuable in treating muscular dystrophies [44].
Silent information regulator 1 or sirtuin 1 (SIRT-1) have seemed as the 
auspicious target of these pathways. It was found inhibiting differentiation of 
mouse C2C12 myoblasts and then reduce myogenin expression, a chief regulator 
with myogenic speciality and differentiate activate satellite cells. Furthermore, 
SIRT-1 directly involves in proliferating satellite cells. The outcomes propose that 
SIRT-1 impart significant role to sustain or raise satellite cells proliferation [44]. 
Overexpression of SIRT-1 activates the PI3K/AKT/mTOR pathway or increases 
levels of JunB or PGC-1α and able to induce rapid growth. SIRT-1 excites growth 
within muscles by inhibiting basal protein degradation with minimal or no 
change in overall protein synthesis [46]. Though FoxOs induction is critical for 
proteolysis enhancement either by autophagy or ubiquitin-proteasome system 
(UPS) through muscle atrophy and hence, FoxO3 inhibition was observed with 
hypertrophy induction by increasing protein synthesis. SIRT1 activation inhibits 
atrophy while promote rapid muscle growth through inhibition of FoxOs and 
parallel activating PGC-1α, with appropriate therapeutic implication in muscle 
wasting diseases [46].
2.5 Ubiquitin-proteasome systems
Within muscles, the ubiquitin-proteasome system (UPS) functions as removing 
sarcomeric proteins with changing muscle performance [4]. Lower muscle mass 
is related to (1) raised attachment of ubiquitin to muscle proteins; (2) overactive 
proteasome ATP dependent activity; (3) higher proteolysis (4) increased transcripts 
encoding ubiquitin, some ubiquitin-conjugating enzymes (E2), a few ubiquitin-
protein ligases (E3) along with several proteasome subunits. E1 enzymes induce 
ubiquitin proteins after cleaving ATP to AMP [4]. The ubiquitin-protein makes 
a transfer to E2 via the E1 enzyme. The last step of the ubiquitylation reaction is 
finally catalyzed by E3 enzyme members. E3 interacts with E2 and the protein 
substrate; bring the ubiquitin transfer from E2 towards the substrate. As substrate 
becomes polyubiquitylated, with ZNF216 (upregulated by FoxO in muscle atrophy) 
recognition it is cropped to the proteasome systems following degradation during 
muscle atrophy. ZNF216-deficient mice are rather found resistant to muscle loss 
undergoing denervation. ZNF216 deficits in muscle cause accumulation of polyu-
biquitylated proteins [47]. Polyubiquitin protein chains can be detached through 
de-ubiquitylating enzymes [ubiquitin-specific processing proteases (USPs): USP14, 
USP19]. Atrogin-1 (specific ubiquitin ligase: MAFbx) regulates the t1/2 of the 
MyoD transcription factor and eIF3f (protein synthesis activator), which is a criti-
cal step in protein synthesis. The atrogin-1 knockdown avoids muscle loss during 
starvation in rodents [4, 48] while MuRF1 knockout (and not atrogin-1 knockout) 
are resilient against dexamethasone-provoke muscle atrophy [49]. Fbxo40 (ubiqui-
tin ligase) regulates the t1/2 of IRS1, a necessary factor for IGF1/insulin signaling, 
while MuRF1 (specific ubiquitin ligase) regulates the t1/2 of several sarcomeric 
proteins [50].
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2.6 Autophagy pathway
The discovery of autophagy in the year 1992 by Yoshinori Ohsumi changed the 
revolution of the machinery involved in orderly degradation and recycling of cel-
lular components [51]. From then on enormous research has been done proving the 
importance of autophagy in eliminating invading pathogens, damaged organelles 
and toxic protein clearance in neurodegenerative disorders, attenuating neuroin-
flammation in dementia, Parkinson’s, Alzheimer’s [52, 53]. Furthermore, autophagy 
imparts a crucial role in the production of nutrients (amino acids, lipids, nucleic 
acids) during fasting [54]. The involvement of autophagy in muscle proteolysis dur-
ing atrophy was recognized long back after the initial discovery of the mechanism 
of autophagy. Early studies significantly exhibit evidence that cathepsin L (lyso-
somal protease) was found with increased expression during muscle atrophy and 
lysosomal degradation was involved in protein breakdown in denervated muscles 
[55–57]. Molecular imaging techniques for visualization of autophagosome forma-
tion have improved the characterization of autophagy in atrophying muscles and 
normal cells. Multiple intracellular signaling mechanisms in diverse catabolic states 
and the role of atrogenes expression, protein degradation through the proteasome 
and autophagy pathways were studied.
The three major mechanisms involved in mammals for delivering autophagic 
cargo to lysosomes are macroautophagy, chaperone-mediated autophagy (CMA), 
and microautophagy [4]. The role of macroautophagy in muscle has been widely 
studied and microautophagy’s role is yet to be discovered although some findings 
reveal the potential role of microautophagy for glycogen uptake within lysosomes 
at a time when macroautophagy is blocked [58, 59]. Macroautophagy generally is 
facilitated by activation of a regulatory complex (composed of Ambra1, Vps34, 
Vps15, Beclin 1, and Atg14) which further leads to recruit LC3 towards nascent 
autophagosome. Mitophagy (a selective form of macroautophagy) requires PINK1 
and Bnip3 translocation factors. Scaffold protein p62 delivers the lysosomal degra-
dation proteins (BAG3 and filamin) labeled by polyubiquitin chains to the autopha-
gosome [60]. CMA majorly was studied for its crucial effects on neurodegenerative 
disorders, aging, and lysosomal storage diseases. In CMA, the damaged proteins due 
to excess ROS production express a definite amino acid sequence (KFERQ motif) 
which gets recognized by the Hsc70 chaperone and interacts with Lamp2a recep-
tors delivers them to the lysosome [61]. Microautophagy engulfs small cytoplasmic 
portions into the lysosomes apart from breaking down glycogen in skeletal muscles. 
All three subtypes are involved contributing to protein degradation and remove 
organelle in skeletal muscles.
Autophagy is considered as a non-selective degradation pathway but with the 
advancement, in research, it has been shown that it can promote selective eradica-
tion of specific organelles (mitochondria) via mitophagy [62]. Skeletal muscles 
display the highest amount of vesicle formation when compared to other tissues 
during fasting conditions, confirming that in fasting conditions autophagosome 
formation is higher in glycolytic muscles rather than β-oxidative muscles [4]. 
Increased ROS production due to oxidative stress and impairment in the antioxidant 
defense systems is frequently seen in pathological conditions of muscle atrophy thus 
causing an imbalance in protein synthesis and degradation [63]. High ROS levels 
result in inhibition of insulin’s actions acting as a putative mediator in the develop-
ment of insulin resistance [63]. The increased oxidative stress in the muscle cells 
promotes the expression of autophagy proteins activating proteolytic pathways like 
calpain and ubiquitin-proteasome system. Dodd et al., 2010 conferred in their work 
that ROS might be the activator of the FOXO pathway and NF-kB in skeletal muscle 
atrophy [64].
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The genes that regulate mitophagy are parkin, PINK1, Bnip3L, Bnip3 and 
inactivation in these genes may cause impaired mitochondria synthesis [65]. PINK1 
assists the recruitment of parkin to mitochondria, parkin promotes mitophagy 
through ubiquitylation of mitochondrial membrane proteins recognized by 
p62 and adds autophagic vesicles for ubiquitylated mitochondrial proteins [66]. 
Autophagosome recruitment to mitochondria occurs as a result of Bnip3 and Bip3L 
binding to the LC3 domain [67]. Mitochondria network is remodeled during fasting 
and denervation via Bnip3 promoting autophagy. Inhibiting mitochondrial fission 
in mice was sufficient to prevent muscle atrophy during denervation providing 
significant insights in the importance of mitochondrial fission machinery, an 
impairment in basal mitophagy may lead to a disruption in the muscle homeostasis 
[16]. Besides mitophagy, nucleophagy may prove to be essential for the nuclear 
remodeling of muscle fibers [68].
3. Therapeutic targets and pharmacological interventions
The growing era of both synthetic and natural agents, characterized for target-
ing different aspects of NF-κB signaling. Targeting activators of NF-κB activation, 
such as TNF-α, monoclonal antibodies against TNF-α (infliximab) or decoy TNF 
receptors (e.g., etanercept), both drugs were found putting useful effects in the 
mdx model of DMD – decreasing myonecrosis and inhibits overall inflammation. 
The patients, who suffer from myositis, find with the raised expression of TNF-α in 
the muscle, anti-TNF therapies are not preferred. NEMO-binding domain (NBD) 
peptide interrupts the association of the IKK complex – which thwarts canonical 
NF-κB pathway activation [69]. NBD peptide in the mdx model of DMD decreases 
the macrophage infiltration into muscle and prevented overall membrane damage/
lysis. Salicylates tend to inhibit NF-κB activation and ameliorate muscle damage. 
Natural compounds (curcumin, Aloe vera, berberine, apigenin, Quercetin, resve-
ratrol, 7,8-dihydroxyflavone, aspalathin, hesperidin, naringin, Epigallocatechin 
gallate, luteolin, rutin, Sulforaphane can target NF-κB signaling and harbors 
anti-NF-κB properties [70]. The use of antioxidants prevents inactivity-induced 
oxidative stress within skeletal muscles. Furthermore, antioxidants treatment to 
rodents could promote protein synthesis ad inhibits proteolysis. Numerous studies 
suggested that selected antioxidants such as vitamin E, Trolox and mitochondrial-
targeted antioxidants, can lower inactivity-induced muscle atrophy in limb and 
respiratory muscles as well [71].
BDNF mimetic natural compound (7,8-dihydroxyflavone), chronically activate 
muscular TrkB modulates cellular energy expense and prohibit the development of 
excess body weight in female mice. These results reveal the molecular mechanism 
of targeting the TrkB receptor regulates cellular energy metabolism and improved 
motor activity [36, 72].
Certain evidence from in vitro studies concludes that Ferulic acid (polyphenolic 
compound), quercetin, luteolin, kaempferol, baicalin, rutin, naringin, and hesperi-
din regulates muscle fiber formation via activating Sirt1/AMPK signaling pathway. 
It activates Sirt1, which further activates LKB1 and AMPK. Sirt1 and AMPK congre-
gate on enhancing the expression of PGC-1α and endorsing slow oxidative muscle 
fiber formation [72, 73]. Furthermore, Ex229 (a small molecule 991), PF-739, and 
MK-8722 activates AMPK within skeletal muscle [74].
Proteasome inhibitor such as MG132 significantly inhibits IκBα degradation 
and prevents NFκB activation in vitro. MG132 conserved muscle and its myofiber 
cross-sectional area via downregulating muscle-specific ubiquitin ligases: atro-
gin-1/MAFbx and MuRF-1 mRNA studied in vivo [75]. Furthermore, proteasome 
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2.6 Autophagy pathway
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imparts a crucial role in the production of nutrients (amino acids, lipids, nucleic 
acids) during fasting [54]. The involvement of autophagy in muscle proteolysis dur-
ing atrophy was recognized long back after the initial discovery of the mechanism 
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promotes the expression of autophagy proteins activating proteolytic pathways like 
calpain and ubiquitin-proteasome system. Dodd et al., 2010 conferred in their work 
that ROS might be the activator of the FOXO pathway and NF-kB in skeletal muscle 
atrophy [64].
11
Molecular Mechanisms, Therapeutic Targets and Pharmacological Interventions: An Update
DOI: http://dx.doi.org/10.5772/intechopen.95996
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inhibitor Velcade (also known as PS-341 and bortezomib) directly inhibits the 
proteasome complex without directly impacting ubiquitination. This compound 
is usually orally active and is currently approved for treating multiple myeloma. 
Velcade utilization reduces skeletal muscle atrophy observed in denervated skeletal 
muscle in rats [76].
Myostatin and activin A antagonists: Myostatin, autocrine factor which normally 
confines muscle size. With growing evidence, increased generation of myostatin and 
its analog, activin A, contribute to several forms of atrophy. Inhibition of myostatin–
activin A–GDF11 signaling is a hopeful therapy for multiple types of systemic wasting.
The SMA disease management utilizes a multidisciplinary and supportive 
approach, include neurologists (adult and pediatric), geneticists, respiratory physi-
cians, gastroenterologists, orthopedic surgeons, palliative care physicians, reha-
bilitation specialists, and allied health services [2] (Table 1). Furthermore, Table 2 
describes the list of clinical trials with different approaches to treat SMA. There are 
Complications Assessments Interventions
Respiratory Cough effectiveness; respiratory 
muscle function tests; overnight 




Overnight polysomnography if 
disordered breathing suspected; 
Acute respiratory infections
Airway clearance techniques and 
cough assistance- chest physiotherapy, 
postural drainage, mechanical or 
manual cough assistance
Noninvasive ventilation




Feeding and swallowing assessment Nutritional supplementation, 
modifying food consistency, optimal 
oral intake
Nasogastric, nasojejunal or 
percutaneous gastronomy – as reduced 
oral intake is observed
Nissen fundoplication
Assess caloric intake






Posture, mobility, function, 
Contractures, Scoliosis
Equipment to assist with mobility, 
self-care and function
Physiotherapy, standing frames, Spinal 
Surgery
Psychological Assess for depression or anxiety Counseling, Antidepressants, 
Antianxiety drug managements
Table 1. 
Current Management of Spinal Muscular Atrophy.
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Drug/target Disease Process Trial details Outcomes Ref. or Clinical  
Trials.gov.identifier
TNF-α
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Studies of myostatin–activin pathway inhibitors in rodents.
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ActRIIB, activin A receptor, type IIB; COPD, chronic obstructive pulmonary disease; IgG1, immunoglobulin G1; IV, 
ntravenous; IL-6, interleukin-6; mAb, monoclonal antibody; RCT, randomized controlled trial; SARM, selective 
androgen receptor modulator
Table 4. 
Clinical trials assessing treatments for muscle wasting.
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some preclinical and clinical trials evaluating treatments for muscle wasting [77, 78] 
mentioned in Tables 3 and 4.
The Stem-cell-related therapies provide prominent therapeutic benefits in the 
reversal of condition in muscle atrophy thereby promoting muscle regeneration. 
Stem cell therapy (e.g., umbilical cord blood stem cell transplantation) showed 
helpful results for treating Duchenne muscular dystrophy (DMD). In the setting 
of a first-in-class approved therapy, progress in developing second generation and 
combination therapies will be requisite for novel approaches in trial design [92, 93]. 
Also, current new challenges are for developing therapies, together with difficulties 
access to treatment allied with complications, costs, and expertise which is required 
for intrathecal administration. Further efforts to ascertain optimal routes of drug 
delivery, body distribution, and limit safety therapeutic window must be essential.
4. Conclusion
Further, future directions are needed for developing novel safe, efficacious 
therapies with innovative therapeutic approaches for establishing a quality life 
in patients. The foremost challenge with developing therapies that grow muscle 
is preventing misuse for enhancing athletic performance, particularly anabolic 
steroids and growth hormones. Novel methods along with specific guidelines must 
be developed to monitor the numerous agents with potential remedial benefits of 
such therapies are likely to be considerable.
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Abstract
Stem cells are defined as undifferentiated cells that are able to unlimitedly renew 
themselves within controlled conditions and to differentiate into a multitude of 
mature cell types. Skeletal muscle stem cells, represented predominantly by satellite 
cells, show a variable capability of self-renewal and myogenic differentiation. They 
were found to be involved not only in the growth of myofibers during neonatal 
and juvenile life but also in the regeneration of skeletal muscles after an injury. 
The microenvironment in which stem cells are nourished and maintained dormant 
preceding division and differentiation is known as “niche.” The niche consists of 
myofibers, which are believed to modulate the active/inactive state of the stem cells, 
extracellular matrix, neural networks, blood vessels, and a multitude of soluble 
molecules. It was observed that changes in the composition of the niche have an 
impact on the stem cell functions and hierarchy. Furthermore, it seems that its lay-
out is variable throughout the entire life, translating into a decrease in the regenera-
tive capacity of satellite cells in aged tissues. The scope of this chapter is to provide a 
detailed view of the changes that occur in the skeletal stem cell niche during life and 
to analyze their implications on tissue regeneration. Future studies should focus on 
developing new therapeutic tools for diseases involving muscle atrophy.
Keywords: stem cells, niche, skeletal, aging, regeneration, muscle fibers
1. Introduction
Being crucial for the survival, the striated muscle tissue that forms skeletal 
muscles takes up to 40% of the human body weight and is responsible for locomo-
tion, maintaining the posture of the body, breathing, swallowing, micturition, and 
defecation [1, 2]. Furthermore, skeletal muscles were found to present endocrine 
and paracrine functions through the secretion of myokines, as well as thermogen-
esis abilities [3]. Each muscle comprises a multitude of myofibers that organize 
themselves into fascicles by wrapping with a layer of connective tissue known as 
perimysium [4]. Myofibers are long, cylindrical multinucleated cells that are indi-
vidually enveloped in another layer of connected tissue called endomysium [4]. The 
myofibers provide skeletal muscles with contractile abilities and are formed in the 
prenatal life by the fusion of a number of cell progenitors known as myoblasts [2].
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While the myofibers enable the muscle to contract and exert its functions, there 
are other types of cells, known as skeletal muscle stem cells that were proved to 
be responsible for muscle regeneration after injury [5]. Stem cells were defined as 
undifferentiated cells that present self-renewal abilities when proper stimuli exist 
and can generate various mature cell types through differentiation [6]. The environ-
ment in which stem cells are found is known as “niche” and its changes in composi-
tion were found to consequently influence their behavior [1]. Previous research 
regarding the characteristics of the niche found that its composition is highly 
heterogenic, varying not only with age, but also with the demands of the body [7]. 
In general, the muscular niche comprises an extracellular matrix known as the basal 
lamina, various interstitial cells such as fibroblasts and adipocytes, blood vessels, 
neural fibers, and a multitude of growth factors and signaling molecules [5].
Satellite cells, which are the most frequent stem cells found in the skeletal 
muscles, were first observed on the electron microscope by Alexander Mauro over 
50 years ago [8]. They were given this name due to their sublaminar position and 
their close connection to myofibers [2]. Following their discovery, numerous studies 
were conducted in order to uncover the role they play in muscle repair and regen-
eration and how the stem cell niche is modulating their behavior [2]. In addition to 
their involvement in muscle repair, recent studies suggest that the skeletal muscle 
stem cells might even play a secondary role in bone regeneration [9]. Although 
satellite cells are the most frequent and easiest to study, other stem cell populations 
residing either in the skeletal muscle, or in other tissues, were found to possess 
variable muscle regenerative abilities [10]. Satellite cell properties as well as the 
different types of muscle progenitors will be described in detail in this chapter.
Studies showed that the number of myofibers does not change during the first 
stages of life and that the growth of the muscular system is obtained through 
the fusion of satellite cells with myofibers, resulting in an increase in size of the 
latter [2]. After the physiological growth of the organism stops, the skeletal stem 
cells are maintained in an inactivated state by various factors in the stem cell 
niche until they are needed for muscle repair or to participate in the daily muscle 
turnover [11].
The satellite cells are activated by growth stimuli or by the physical trauma 
located in the muscle, leading them to enter the mitotic phase and start to 
divide into myoblasts, which through differentiation will be able to fuse among 
themselves and with other myofibers and repair the damaged muscle [12, 13]. In 
addition, satellite cells can expand their stem cell pool through asymmetric divi-
sion, thus demonstrating their self-renewal abilities and ensuring the continuance 
of the muscle regeneration process [12]. However, with aging and also in various 
degenerative muscle diseases, the regenerative abilities of satellite cells diminish, 
leading to muscle atrophy and the replacement of muscle fibers with connective 
tissue [7, 14]. These changes were attributed to a multitude of changes in the 
composition of the stem cell niche that occur during life, which will be further 
described in this chapter [7, 14].
The alteration of the skeletal stem cell niche and thus of satellite cell functions 
can be seen not only in aged muscle but also in a multitude of degenerative diseases. 
One example is Duchenne muscular dystrophy (DMD), a genetic disorder with no 
existing curative treatment in which a specific gene mutation causes the synthesis 
of an altered protein known as dystrophin, thus leading to progressive muscle 
degeneration and fibrosis which will result in loss of ambulation and cardiorespira-
tory insufficiency [15]. Dystrophin is known to be responsible for the basal lamina-
myofibers connection; however, recent studies showed that it is also involved in the 
modulation of muscle stem cell division [13]. Additional research is needed in order 
to fully understand how satellite cells and their niches are affected by DMD.
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It is crucial to understand all the pathways that are involved in the functioning of 
the skeletal stem cell niche and the way they are altered with the aging of the human 
body in order to be able to develop new treatment strategies for muscle degenera-
tive diseases and maybe delay the effects that time has on the muscular system. 
Extensive research has been made in the field of regenerative medicine, making the 
idea of bioengineered muscle regeneration increasingly plausible. However, there 
are still many unanswered questions that prevent the applications of satellite cell’s 
regenerative and self-renewal abilities to reach their full potential.
2. The skeletal muscle stem cell niche: structure and roles
The stem cell niche concept was first described in 1978 by Schofield, as an expla-
nation to a series of experimental findings focusing on hematopoiesis and the bone 
marrow cells, which outlined notions concerning the anatomic site of reproduction, 
sustenance, and differentiation of the stem cells [16–18]. According to this theory, 
the niche represents a versatile environment, where the states change cyclically, in 
order to either support the quiescence of the stem cells or to activate them, according 
to the local or systemic stimuli [14]. Each type of tissue has a specific support system 
characterized by distinct cellular components; some of the most studied ones belong-
ing to sites which present a high turnover rate such as the skin, with the matrix stem 
cells and the dermal papilla, the gut with the crypt stem cells and the mesenchymal 
and Paneth cells, or the hematopoietic stem cell niche and osteoblasts [14, 19, 20].
The skeletal muscle stem cell niche is also an example of a highly designated 
niche, consisting not only of specialized stem cells such as the satellite cells, but also 
of a complex milieu of elements ranging from the neural-vascular framework and 
surrounding cells to the extracellular matrix and diverse soluble molecules [2, 21]. In 
this chapter, we discuss in detail the cellular structure of the niche and the various 
roles that every type of constituent plays in the muscle behavior in regards to growth, 
maintenance, and regeneration [22].
2.1 Satellite cells and other muscle progenitors
During embryogenesis, the paraxial segmental mesoderm gives rise to the 
somites, which subsequently divide into the dermomyotome, which further gener-
ates the skeletal muscle of the body and limbs as well as the overlying derma, and 
the sclerotome, which contributes to the cartilage and bone formation of the spine 
and rib cage [10, 23, 24]. In the first stages of muscle development, a primary myo-
tome is formed by delamination of muscle progenitor cells, expressing MYf5 and 
Mrf4, from the epithelial dermomyotome [25]. Subsequently, another subtype of 
muscle progenitors that express Pax7 and Pax3 migrate from the central dermomy-
otome toward the primary myotome, where some contribute to the further differ-
entiation and growth and of the muscle, while others maintain a continuous pool of 
muscle progenitors that represent the largest reservoir of adult satellite cells for the 
muscles of the trunk and limbs [26, 27]. During the last decades, extensive research 
has been conducted in order to determine other types of non-somitic muscle stem 
progenitors, concluding that the embryonic dorsal aorta [28] can also serve as origin 
for the stem cells, along with various cells that exhibit myogenic potential such as 
the bone marrow stem cells [29, 30], pericytes [31], mesangioblasts [32], specific 
side population cells [33], and interstitial and mesenchymal cells [34, 35].
The first description of a satellite cell was made in 1961, when Katz and Mauro 
discovered a mononucleated cell positioned at the outer edge of the muscle 
fiber, while studying the muscle tissue in frogs and rats with the help of electron 
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microscopy [8, 36]. Using the same imaging technique, it was established not only 
the cell’s location between the basal lamina and the exterior plasma membrane of 
the myocyte, but also the morphological features: a small nucleus with elevated 
levels of heterochromatin, an abundant cytoplasm, and scarce organelles [37]. 
Since their discovery, extensive efforts have been made in order to demonstrate the 
stem cell characteristics and to identify the role they play in muscle growth and 
regeneration. In this regard, [3H]thymidine labeling and tracing experiments in 
regenerating or growing muscle proved that satellite cells contribute to this process 
by yielding myonuclei to emerging myofibers [38, 39]. To strengthen this evidence, 
in vitro cultures of isolated myofibers and their adjacent satellite cells showed that 
renewed myotubes arise from the satellite cell-derived myoblasts clonal expansion 
and fusion, demonstrating thus the stem cell’s regenerative capacity [40–44].
Regeneration of the muscle tissue is a complex process that can be induced by 
either disease, injury, or exercise, involving a series of events like cellular degenera-
tion, inflammation, further stem cell activation, and differentiation, followed by 
maturation and remodeling of the new fibers and the surrounding environment 
[45–47]. Activation of the satellite cells implies transitioning from the quiescent 
phase to a mitotic phase, event in which a series of signaling pathways and molecu-
lar elements, such as notch signaling pathway and map kinase phosphorylation pro-
cess by the hepatocyte growth factor activation (HGF) and fibroblast growth factor 
2 (FGF2), among others, participate [48–52]. Upon activation, satellite cells start 
expressing MyoD, a transcription factor promoting genes involved in the progres-
sion of the cell cycle, and along with preexisting expression of Pax7, M-cadherin, 
and Myf5, they start dividing [53, 54]. The differentiation process of the newly 
created myoblasts is governed by the Wnt signaling pathway, FGF, myostatin, an 
important regulator of muscle stem cell proliferation [55–57], which works together 
with myogenin and MyoD to generate multinucleated myofibers [58–60].
Apart from the regenerative capacity, satellite cells possess the ability to renew 
themselves, generating thus a continuous pool of stem cells. This theory of self-
renewal was first stipulated in the pulse-chase experiments of Moss and Leblond, 
being further supported by the studies of other lineages such as the skin and gut that 
showed similarities between the transit amplifying cells and satellite cells [38, 61–63]. 
Another study focusing on transplanted myofibers in a myopathic mouse model 
found that a new population of satellite cells was generated after the resident muscle 
stem cells were inactivated by radiation, demonstrating thus the self-regenerating 
ability of the satellite cells [64]. As mentioned before, in restoring muscle tissue, 
satellite cells undergo a transition from a quiescent state to an activated state. Recent 
studies have demonstrated that the reverse process can also take place, as the acti-
vated satellite cells can exit the cell cycle and reenter the quiescent state, replenish-
ing thus the progenitor pool [65–67], still, further research is required in order to 
elucidate the exact mechanisms of the self-renewal process.
Extensive research concluded that the satellite cells do not represent the only type 
of cell capable of muscle regeneration; several other cells exhibiting similar charac-
teristics of which bone marrow stem cells [29, 30], pericytes [31], mesangioblasts 
[32] and specific side population cells [33] are some of the most studied ones. In 
this regard, strong evidence coming from lineage experiments indicated that bone 
marrow-derived stem cells, when administered intravenously or intramuscularly in 
irradiated mice, have the capacity to generate myofibers and to restore the satellite 
cell pool [68]. Following a study regarding the GFP-labeled bone marrow transplan-
tation into mice, LaBarge and Blau et al. also concluded that bone marrow stem cells 
display myogenic potential by reconstructing the stem cell niche [68]. Recent studies 
suggest that pericytes, the contractile cells responsible for the regulation of capil-
lary blood flow, exhibit a multipotent trait, allowing them to differentiate not only 
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toward the skeletal bone and adipose tissue precursors but also into skeletal stem cells 
[69–71]. Prototype experiments involving pericyte transplantation in mice with dys-
trophic muscles proved that pericytes may represent a promising candidate for future 
treatments for similar affliction in humans due to their myogenic potential [31, 72].
2.2 Satellite cell cellular and acellular environment
The skeletal muscle stem cell niche is the biologic environment of the satellite 
cells and other muscle progenitor cells where biochemical and biophysical factors 
sustain cellular processes such as quiescence, self-renewal, multiplication and dif-
ferentiation, necessary for maintenance, and repair of the muscle. Apart from stem 
cells and myofibers, the niche is a home to a variety of other cellular and acellular 
components ranging from the basal lamina, connective tissue, nerves, vessels, 
extracellular matrix, or immune cells that together design the optimal conditions to 
assist the transition through the various processes of the niche.
In this respect, one of the most intimate structures within the niche is the basal 
lamina, a network of extracellular matrix composed of collagen IV, laminin α2, 
fibronectin, and tenascin, linked together through a glycoprotein core of heparan 
sulfate [18, 73, 74]. This structure enables not only the anatomical sustenance of the 
myofibers through integrin linkage but also accumulations of growth factors such 
as FGF, HGF, VEGF, and TGFβ1 [75–77]. Several studies concluded that the loss or 
deficiency of laminin α2 impacts the muscle stem niche quiescence by reducing the 
number of stem cells during development, as well as increased myogenin expres-
sion, inhibiting proper differentiation [78, 79].
Another major component of the niche environment is represented by the 
interstitial cells, of which the most abundant types are the fibroblasts and the adi-
pocytes. Both of these types of cells increase in number due to the transdifferentiat-
ing potential of the myoblasts and satellite cells showed by in vitro studies [80, 81], 
supporting the hypothesis that the muscle is able to sustain a balanced environment 
during regenerative processes. Nevertheless, surplus in number regarding adipo-
cytes and excess connective tissue produced by the fibroblasts have been thoroughly 
linked to conditions, such as aging or muscular dystrophy [82–84].
The vascular network is one of the main nourishment suppliers for the stem 
cell muscle niche, playing an important role not only in angiogenesis but also in 
myogenesis. It has been shown that these two processes emerge simultaneously 
during muscle regeneration, the most important factors involved in this event being 
represented by VEGF, IGF-I, PDGF, and HGF [85]. VEGF has been observed to 
stimulate not only angiogenesis but also cell migration and differentiation, myofi-
ber hypertrophy to prevent apoptosis [86–88].
Several studies have observed that stem cells tend to group around the neu-
romuscular junction, suggesting that the motor neurons interact with the niche 
during specific times. Denervation studies portrayed that the modifications in 
membrane potential, ion channel conductance, and distribution of acetylcholine 
receptors lead to the remodeling of the niche composition, following the activation 
of the muscle stem cells [89]. A combination between the absence of neurotrophic 
factors and a prolonged state of loss in neural communication has been also proved 
to lead to structural alterations, more specifically to myofiber atrophy [90].
This dynamic environment can be also influenced by a number of systemic fac-
tors, some of them being represented by immune cells and inflammation, andro-
gens or nitric oxide [2]. Upon injury, satellite cells release the proinflammatory 
cytokines that promote immune cell migration to the muscle that in turn help the 
stem cells to detach from the basal lamina through a series of diffusible molecules, 
in order for them to further proliferate, differentiate, and repair the muscle in 
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microscopy [8, 36]. Using the same imaging technique, it was established not only 
the cell’s location between the basal lamina and the exterior plasma membrane of 
the myocyte, but also the morphological features: a small nucleus with elevated 
levels of heterochromatin, an abundant cytoplasm, and scarce organelles [37]. 
Since their discovery, extensive efforts have been made in order to demonstrate the 
stem cell characteristics and to identify the role they play in muscle growth and 
regeneration. In this regard, [3H]thymidine labeling and tracing experiments in 
regenerating or growing muscle proved that satellite cells contribute to this process 
by yielding myonuclei to emerging myofibers [38, 39]. To strengthen this evidence, 
in vitro cultures of isolated myofibers and their adjacent satellite cells showed that 
renewed myotubes arise from the satellite cell-derived myoblasts clonal expansion 
and fusion, demonstrating thus the stem cell’s regenerative capacity [40–44].
Regeneration of the muscle tissue is a complex process that can be induced by 
either disease, injury, or exercise, involving a series of events like cellular degenera-
tion, inflammation, further stem cell activation, and differentiation, followed by 
maturation and remodeling of the new fibers and the surrounding environment 
[45–47]. Activation of the satellite cells implies transitioning from the quiescent 
phase to a mitotic phase, event in which a series of signaling pathways and molecu-
lar elements, such as notch signaling pathway and map kinase phosphorylation pro-
cess by the hepatocyte growth factor activation (HGF) and fibroblast growth factor 
2 (FGF2), among others, participate [48–52]. Upon activation, satellite cells start 
expressing MyoD, a transcription factor promoting genes involved in the progres-
sion of the cell cycle, and along with preexisting expression of Pax7, M-cadherin, 
and Myf5, they start dividing [53, 54]. The differentiation process of the newly 
created myoblasts is governed by the Wnt signaling pathway, FGF, myostatin, an 
important regulator of muscle stem cell proliferation [55–57], which works together 
with myogenin and MyoD to generate multinucleated myofibers [58–60].
Apart from the regenerative capacity, satellite cells possess the ability to renew 
themselves, generating thus a continuous pool of stem cells. This theory of self-
renewal was first stipulated in the pulse-chase experiments of Moss and Leblond, 
being further supported by the studies of other lineages such as the skin and gut that 
showed similarities between the transit amplifying cells and satellite cells [38, 61–63]. 
Another study focusing on transplanted myofibers in a myopathic mouse model 
found that a new population of satellite cells was generated after the resident muscle 
stem cells were inactivated by radiation, demonstrating thus the self-regenerating 
ability of the satellite cells [64]. As mentioned before, in restoring muscle tissue, 
satellite cells undergo a transition from a quiescent state to an activated state. Recent 
studies have demonstrated that the reverse process can also take place, as the acti-
vated satellite cells can exit the cell cycle and reenter the quiescent state, replenish-
ing thus the progenitor pool [65–67], still, further research is required in order to 
elucidate the exact mechanisms of the self-renewal process.
Extensive research concluded that the satellite cells do not represent the only type 
of cell capable of muscle regeneration; several other cells exhibiting similar charac-
teristics of which bone marrow stem cells [29, 30], pericytes [31], mesangioblasts 
[32] and specific side population cells [33] are some of the most studied ones. In 
this regard, strong evidence coming from lineage experiments indicated that bone 
marrow-derived stem cells, when administered intravenously or intramuscularly in 
irradiated mice, have the capacity to generate myofibers and to restore the satellite 
cell pool [68]. Following a study regarding the GFP-labeled bone marrow transplan-
tation into mice, LaBarge and Blau et al. also concluded that bone marrow stem cells 
display myogenic potential by reconstructing the stem cell niche [68]. Recent studies 
suggest that pericytes, the contractile cells responsible for the regulation of capil-
lary blood flow, exhibit a multipotent trait, allowing them to differentiate not only 
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toward the skeletal bone and adipose tissue precursors but also into skeletal stem cells 
[69–71]. Prototype experiments involving pericyte transplantation in mice with dys-
trophic muscles proved that pericytes may represent a promising candidate for future 
treatments for similar affliction in humans due to their myogenic potential [31, 72].
2.2 Satellite cell cellular and acellular environment
The skeletal muscle stem cell niche is the biologic environment of the satellite 
cells and other muscle progenitor cells where biochemical and biophysical factors 
sustain cellular processes such as quiescence, self-renewal, multiplication and dif-
ferentiation, necessary for maintenance, and repair of the muscle. Apart from stem 
cells and myofibers, the niche is a home to a variety of other cellular and acellular 
components ranging from the basal lamina, connective tissue, nerves, vessels, 
extracellular matrix, or immune cells that together design the optimal conditions to 
assist the transition through the various processes of the niche.
In this respect, one of the most intimate structures within the niche is the basal 
lamina, a network of extracellular matrix composed of collagen IV, laminin α2, 
fibronectin, and tenascin, linked together through a glycoprotein core of heparan 
sulfate [18, 73, 74]. This structure enables not only the anatomical sustenance of the 
myofibers through integrin linkage but also accumulations of growth factors such 
as FGF, HGF, VEGF, and TGFβ1 [75–77]. Several studies concluded that the loss or 
deficiency of laminin α2 impacts the muscle stem niche quiescence by reducing the 
number of stem cells during development, as well as increased myogenin expres-
sion, inhibiting proper differentiation [78, 79].
Another major component of the niche environment is represented by the 
interstitial cells, of which the most abundant types are the fibroblasts and the adi-
pocytes. Both of these types of cells increase in number due to the transdifferentiat-
ing potential of the myoblasts and satellite cells showed by in vitro studies [80, 81], 
supporting the hypothesis that the muscle is able to sustain a balanced environment 
during regenerative processes. Nevertheless, surplus in number regarding adipo-
cytes and excess connective tissue produced by the fibroblasts have been thoroughly 
linked to conditions, such as aging or muscular dystrophy [82–84].
The vascular network is one of the main nourishment suppliers for the stem 
cell muscle niche, playing an important role not only in angiogenesis but also in 
myogenesis. It has been shown that these two processes emerge simultaneously 
during muscle regeneration, the most important factors involved in this event being 
represented by VEGF, IGF-I, PDGF, and HGF [85]. VEGF has been observed to 
stimulate not only angiogenesis but also cell migration and differentiation, myofi-
ber hypertrophy to prevent apoptosis [86–88].
Several studies have observed that stem cells tend to group around the neu-
romuscular junction, suggesting that the motor neurons interact with the niche 
during specific times. Denervation studies portrayed that the modifications in 
membrane potential, ion channel conductance, and distribution of acetylcholine 
receptors lead to the remodeling of the niche composition, following the activation 
of the muscle stem cells [89]. A combination between the absence of neurotrophic 
factors and a prolonged state of loss in neural communication has been also proved 
to lead to structural alterations, more specifically to myofiber atrophy [90].
This dynamic environment can be also influenced by a number of systemic fac-
tors, some of them being represented by immune cells and inflammation, andro-
gens or nitric oxide [2]. Upon injury, satellite cells release the proinflammatory 
cytokines that promote immune cell migration to the muscle that in turn help the 
stem cells to detach from the basal lamina through a series of diffusible molecules, 
in order for them to further proliferate, differentiate, and repair the muscle in 
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regards to muscle [91]. Androgens seem to impact the satellite cell nice by stimulat-
ing the stem cell activation and proliferation, while nitric oxide has been shown to 
provide a protective effect against fibrosis [92, 93].
3. Alterations of the skeletal stem cell niche during aging
Satellite cells, known as muscle specific stem cells, take the responsibility of gen-
erating new muscle fibers as a response to injury in the adult human body. However, 
the regenerative abilities of an aged muscle are significantly reduced, while the sus-
ceptibility of developing age-related pathologies is increased [14]. In order to better 
understand the mechanisms that contribute to declining stem cell function with age, 
it is important to firstly identify the cell-extrinsic and cell-intrinsic factors that have 
an influence on stem cell activity. Conditions within the niche are extremely impor-
tant in order to maintain stem cell activity, and they need to be conducive to main-
taining stem cell quiescence in the absence of any external activating cues while also 
promoting proliferation, maturation, and ensuring the self-renewal of the stem cell 
pool. Thus, the niche represents an inherently dynamic environment, which switches 
between the quiescent and the activated niche as a response to local and systemic 
influences. Any perturbation between the cell resident in the immediate vicinity 
and in direct contact with the stem cell is predicted to alter stem cell function [94]. 
Some previous research was focused on describing the characteristics of satellite cells 
residing in aged muscle, thus providing critical information on the transformations 
that occur with the passing of time. One study conducted on old mice revealed that 
the nuclear-cytoplasmic ratio is significantly higher compared to other cytological 
features that are almost identical with the ones identified in younger mice [95]. 
During the aging process, satellite stem cells display a delayed response to activating 
stimuli and also have a reduced proliferative expansion due to the fact that some 
progenitors tend to adopt alternate lineages [80, 82, 96, 97]. Furthermore, satellite 
cells were described to have higher apoptosis rates in the aged muscles [98].
In aging muscles, due to the accumulation of toxic products derived from the 
degradation of connective tissue components, some essential functions of the 
basal lamina are compromised. Necrosis is the result of the cleavaged fibronectin 
and elastin products present in the connective tissue of aging mice [99]. Studies on 
aged muscle sections revealed the presence of extra lamina encroaching into the 
satellite cell-myofiber interspace and mononucleated cells completely enveloped by 
the basal lamina [95]. Although the functional consequences of this less intimate 
association of satellite cells with myofibers in aged muscles are still unknown, it is 
believed that this phenomenon can be correlated to the decreasing percent of satel-
lite cells in the later stages of life [82].
Numerous studies were conducted focusing on the molecular mechanisms that 
underline satellite cell aging. Heterochronic satellite cells were transplanted from old 
mice into young specimens, indicating that the mechanisms that modulate the satel-
lite cell regeneration potential may be cell-extrinsic. Furthermore, various changes 
were observed regarding the availability of Wnt, Notch, FGF, and TGF-β-superfamily 
ligands, and also in cytokine signaling through the JAK-STAT pathway. Moreover, the 
self-renewal defects may be cell-intrinsic, as satellite cell aging was associated with an 
increase in stress-induced p38-MAPK signaling and cellular senescence [100].
3.1 Niche composition and functions at birth and in the early life
Myogenesis is a well-controlled process in which the dermomyotome is formed 
from the dorsolateral side of the somite, and from there, the progenitor cells will 
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differentiate in order to form multinucleated myofibers [24, 101, 102]. Even if it was 
thought to be an interrelation between the existence of multipotent cells and tissue 
development, a group of somatic stem cells was discovered both in mature and early 
post-natal skeletal muscle. These are believed to have important contribution in 
regeneration, homeostasis, and muscle growth [103].
The first remarks about a stem cell population that originate in skeletal muscle 
were made by Mauro and Katz in 1961 [8, 104]. They analyzed the muscle samples 
from frog and rat, and using electron microscopy for identification, they postulated 
that satellite stem cells are located in a particular place (between the basal lamina 
and the sarcolemma), and it represents an exclusive niche which preserves and 
regulates the survival and behavior of the stem cell [105]. Satellite cells express 
specific markers: Pax7 and Pax3 (paired box transcription factors) [106, 107], 
M-cadherin [108], FoxK (Forkhead box protein K) [109], NCAM (neural cell adhe-
sion molecule) [110] c-Met (tyrosine-protein kinase Met) [111], VCAM-1 [112], 
CD34 [113], Syndecan 3, Syndecan 4 [114], Sox 8 and Sox 15 [115, 116], Integrin α7, 
Integrin β1 [117], caveolin-1 [118], CTR (Calcitonin receptor) [119], Emerin, Lamin 
A/C [120], Hairy [121], and Dystrophin [122].
During post-natal life, satellite cells are responsible for muscle growth and tissue 
regeneration under the action of appropriate stimuli. This role was confirmed 
by a study which analyzed transgenic mice without satellite stem cells. The mice 
revealed a significant deficiency in skeletal muscle mass, lower body weight, and 
smaller myofiber size [106]. An important decrease in the number of cells was 
observed, from 30% at birth to 5% at 2 months old. In the adult life period, the cell 
number remained constant [123]. Even if the implication of satellite cells in muscle 
regeneration has been well documented and described, their role in muscle growth 
during adult life still needs further studies [124].
3.2 Changes in niche composition throughout the time
Discovering the link between stem cells and their niches presents a great interest 
for the biology field. Although previous reports debating the caring relationship 
between stem cells and signaling molecules deployed by niche cells were published, 
the role of extra-cellular matrix (ECM) into the niche is still unclear. Previous stud-
ies highlighted that at activation, satellite cells are responsible for establishing the 
local reshaping of the ECM, and for the accumulation of laminin-α1 and laminin-α5 
right into the basal lamina of the satellite cell niche. Moreover, genetic modification 
of laminin-α1, integrin-α6 signaling, or blocking matrix metalloproteinase activity 
were shown to prevent the cell capacity of expansion and self-renewal. Remodeling 
of the ECM favors dissemination and self-renewal, and could justify the effect of 
laminin-α1 containing supports on stem cells [5].
Stem cells competence decreases with age, and it is associated with chronic 
diseases in mammals. In diseased or aged muscles, myofibers are replaced by fat and 
fibrous tissues, while the remaining myofibers decrease in mass. During aging, not 
only the percent of satellite cells decreases, but also their expression levels of Pax7, 
consequently leading to a decrease in myogenicity and an increase in apoptosis [125].
4. Implications on muscular regeneration and disease
Skeletal muscles possess contractile properties that are crucial for vital functions of 
the body such as breathing, postural support, and movement while also participating 
in the systemic metabolism and thermogenesis due to their endocrine and paracrine 
functions [3]. Following actions that involve contraction and stretch, micro-lesions 
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regards to muscle [91]. Androgens seem to impact the satellite cell nice by stimulat-
ing the stem cell activation and proliferation, while nitric oxide has been shown to 
provide a protective effect against fibrosis [92, 93].
3. Alterations of the skeletal stem cell niche during aging
Satellite cells, known as muscle specific stem cells, take the responsibility of gen-
erating new muscle fibers as a response to injury in the adult human body. However, 
the regenerative abilities of an aged muscle are significantly reduced, while the sus-
ceptibility of developing age-related pathologies is increased [14]. In order to better 
understand the mechanisms that contribute to declining stem cell function with age, 
it is important to firstly identify the cell-extrinsic and cell-intrinsic factors that have 
an influence on stem cell activity. Conditions within the niche are extremely impor-
tant in order to maintain stem cell activity, and they need to be conducive to main-
taining stem cell quiescence in the absence of any external activating cues while also 
promoting proliferation, maturation, and ensuring the self-renewal of the stem cell 
pool. Thus, the niche represents an inherently dynamic environment, which switches 
between the quiescent and the activated niche as a response to local and systemic 
influences. Any perturbation between the cell resident in the immediate vicinity 
and in direct contact with the stem cell is predicted to alter stem cell function [94]. 
Some previous research was focused on describing the characteristics of satellite cells 
residing in aged muscle, thus providing critical information on the transformations 
that occur with the passing of time. One study conducted on old mice revealed that 
the nuclear-cytoplasmic ratio is significantly higher compared to other cytological 
features that are almost identical with the ones identified in younger mice [95]. 
During the aging process, satellite stem cells display a delayed response to activating 
stimuli and also have a reduced proliferative expansion due to the fact that some 
progenitors tend to adopt alternate lineages [80, 82, 96, 97]. Furthermore, satellite 
cells were described to have higher apoptosis rates in the aged muscles [98].
In aging muscles, due to the accumulation of toxic products derived from the 
degradation of connective tissue components, some essential functions of the 
basal lamina are compromised. Necrosis is the result of the cleavaged fibronectin 
and elastin products present in the connective tissue of aging mice [99]. Studies on 
aged muscle sections revealed the presence of extra lamina encroaching into the 
satellite cell-myofiber interspace and mononucleated cells completely enveloped by 
the basal lamina [95]. Although the functional consequences of this less intimate 
association of satellite cells with myofibers in aged muscles are still unknown, it is 
believed that this phenomenon can be correlated to the decreasing percent of satel-
lite cells in the later stages of life [82].
Numerous studies were conducted focusing on the molecular mechanisms that 
underline satellite cell aging. Heterochronic satellite cells were transplanted from old 
mice into young specimens, indicating that the mechanisms that modulate the satel-
lite cell regeneration potential may be cell-extrinsic. Furthermore, various changes 
were observed regarding the availability of Wnt, Notch, FGF, and TGF-β-superfamily 
ligands, and also in cytokine signaling through the JAK-STAT pathway. Moreover, the 
self-renewal defects may be cell-intrinsic, as satellite cell aging was associated with an 
increase in stress-induced p38-MAPK signaling and cellular senescence [100].
3.1 Niche composition and functions at birth and in the early life
Myogenesis is a well-controlled process in which the dermomyotome is formed 
from the dorsolateral side of the somite, and from there, the progenitor cells will 
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differentiate in order to form multinucleated myofibers [24, 101, 102]. Even if it was 
thought to be an interrelation between the existence of multipotent cells and tissue 
development, a group of somatic stem cells was discovered both in mature and early 
post-natal skeletal muscle. These are believed to have important contribution in 
regeneration, homeostasis, and muscle growth [103].
The first remarks about a stem cell population that originate in skeletal muscle 
were made by Mauro and Katz in 1961 [8, 104]. They analyzed the muscle samples 
from frog and rat, and using electron microscopy for identification, they postulated 
that satellite stem cells are located in a particular place (between the basal lamina 
and the sarcolemma), and it represents an exclusive niche which preserves and 
regulates the survival and behavior of the stem cell [105]. Satellite cells express 
specific markers: Pax7 and Pax3 (paired box transcription factors) [106, 107], 
M-cadherin [108], FoxK (Forkhead box protein K) [109], NCAM (neural cell adhe-
sion molecule) [110] c-Met (tyrosine-protein kinase Met) [111], VCAM-1 [112], 
CD34 [113], Syndecan 3, Syndecan 4 [114], Sox 8 and Sox 15 [115, 116], Integrin α7, 
Integrin β1 [117], caveolin-1 [118], CTR (Calcitonin receptor) [119], Emerin, Lamin 
A/C [120], Hairy [121], and Dystrophin [122].
During post-natal life, satellite cells are responsible for muscle growth and tissue 
regeneration under the action of appropriate stimuli. This role was confirmed 
by a study which analyzed transgenic mice without satellite stem cells. The mice 
revealed a significant deficiency in skeletal muscle mass, lower body weight, and 
smaller myofiber size [106]. An important decrease in the number of cells was 
observed, from 30% at birth to 5% at 2 months old. In the adult life period, the cell 
number remained constant [123]. Even if the implication of satellite cells in muscle 
regeneration has been well documented and described, their role in muscle growth 
during adult life still needs further studies [124].
3.2 Changes in niche composition throughout the time
Discovering the link between stem cells and their niches presents a great interest 
for the biology field. Although previous reports debating the caring relationship 
between stem cells and signaling molecules deployed by niche cells were published, 
the role of extra-cellular matrix (ECM) into the niche is still unclear. Previous stud-
ies highlighted that at activation, satellite cells are responsible for establishing the 
local reshaping of the ECM, and for the accumulation of laminin-α1 and laminin-α5 
right into the basal lamina of the satellite cell niche. Moreover, genetic modification 
of laminin-α1, integrin-α6 signaling, or blocking matrix metalloproteinase activity 
were shown to prevent the cell capacity of expansion and self-renewal. Remodeling 
of the ECM favors dissemination and self-renewal, and could justify the effect of 
laminin-α1 containing supports on stem cells [5].
Stem cells competence decreases with age, and it is associated with chronic 
diseases in mammals. In diseased or aged muscles, myofibers are replaced by fat and 
fibrous tissues, while the remaining myofibers decrease in mass. During aging, not 
only the percent of satellite cells decreases, but also their expression levels of Pax7, 
consequently leading to a decrease in myogenicity and an increase in apoptosis [125].
4. Implications on muscular regeneration and disease
Skeletal muscles possess contractile properties that are crucial for vital functions of 
the body such as breathing, postural support, and movement while also participating 
in the systemic metabolism and thermogenesis due to their endocrine and paracrine 
functions [3]. Following actions that involve contraction and stretch, micro-lesions 
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can occur in the plasma membrane of muscular cells or in the T-tubule organization, 
leading to the organization of specific proteins and lipids which form a repair-patch 
and seal the injury. However, during trauma or surgery numerous contusions, strains 
and laceration can occur, and, in these circumstances, myoblasts fuse between them-
selves or with adjacent myofibers and repair the damaged muscle. One important fact 
is that myoblasts can only fuse with non-lethally damaged muscle cells [126–128].
It is widely known that skeletal muscle has a remarkable capacity for regenera-
tion, which places it second after the bone marrow. The main type of stem cells in 
charge of muscle regeneration is represented by satellite cells. Satellite cells are able 
to remain in a non-dividing state in the unharmed muscle and can be recognized 
by their α7 integrin and Pax7 expression. This specific population of cells gets 
triggered when muscle trauma occurs, thus activating the expression of MYF5 and 
MYOD and becoming fusion-competent myoblasts which will further fuse in order 
to give rise to new muscle fibers [8, 129–132]. During muscle injury, there are satel-
lite cells that do not differentiate, with downregulated MYF5 and MYOD expression 
levels, which were described to replace the satellite cell population, ensuring the 
ability to respond to future muscle damages [2, 67, 133, 134].
Studies showed that alongside with satellite cells, there exist various popula-
tions of non-satellite cells, such as side populations, CD133 + cells, pericytes, and 
mesangioblasts (Mabs) that have myogenic abilities, contributing to regenera-
tion and homeostasis maintenance [31, 135–138]. Their involvement in muscle 
regeneration was not firmly demonstrated and future studies are needed. The 
regenerative capacity of this cell category was demonstrated following some 
experiments on mice [135]. Side population cells were transplanted into mice 
suffering from a form of Duchenne muscular dystrophy, leading to an improve-
ment in muscle function and a restoration of dystrophin expression levels [135]. 
Similar results were obtained by intraarterial or intramuscular injecting CD 133+ 
cells into scid/mdx mice [136, 139]. Two other populations of non-satellite cells 
are pericytes and Mabs, the latter were described to derive from pericytes [31]. 
Pericytes are involved in the in situ regeneration and muscle growth in early life 
[140]. Studies revealed that Mabs can take part in muscular regeneration after 
being engrafted or intraarterial injected in dogs and mice [137, 138]. Researchers 
discovered that the behavior of satellite cells could be highly influenced by 
surrounding cells, growth factors such as the vascular endothelial growth factor 
(VEGF), insulin-like growth factor (IGF)-1, fibroblast growth factor (FGF), 
cytokines, and neighboring cellular matrix [141]. For example, one study showed 
that satellite cells which have grown in vitro for a short period of time partially 
lost their myogenic capacity in contrast to freshly isolated satellite cells [129]. In 
order to sustain a faster and more adequate tissue regeneration, a positive feed-
back loop was described between the endothelial cells and satellite cells located 
near small blood vessels. Endothelial cells enable satellite cell proliferation 
through the secretion of growth factors, while differentiated myoblasts stimulate 
angiogenesis [85].
Lately, two studies, both conducted by injecting diphtheria toxin in mouse 
models, speculated that muscle repair is not possible without satellite cells, even 
under normal physiological conditions [142, 143]. During the experiments, 
neither non-satellite cells, nor the innervation and vasculature were altered. One 
of the studies developed mouse models in which only cells expressing Pax7 were 
killed by the toxin, while the second study crossed murine expressing an inducible 
diphtheria toxin with murine expressing under the control of Pax7 tamoxifen-
inducible conditional recombinase [142, 143] . However, further studies are 
needed in order to undoubtably state that muscle restoration can only take place if 
satellite cells are present.
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4.1 The regenerative muscle stem cell niche
In order to analyze the myogenic mechanism of the skeletal muscle, several 
injury models in mice were developed, including chemical injuries such as intra-
muscular injection of snake venoms notexin, cardiotoxin, and barium chloride, 
together with freeze injury and crash [144, 145]. The following regenerative 
response was found to comprise three phases: an inflammatory phase, a prolifera-
tive phase and, lastly, a differentiation phase.
Instantly after muscular damage, necrotic fibers hyper contract inside their basal 
lamina layer [146]. The remnant basal lamina is reconditioned by matrix remodeling 
enzymes and serves as a pattern for the development of new muscle fibers, and also 
guides the growth cones of motor neurons for reinnervation at original synaptic spots 
[147–153]. The necrosis of muscular fibers releases into circulation damage-associated 
molecular patters (DAMPs) that are tracked by both macrophages and mastocytes 
and mobilize neutrophils which deliver trophic factors to call up the satellite cells 
within 2 hours of damage [10, 154–156]. In this early phase of muscle regeneration, 
muscle tissue is cleansed of necrotic fibers through phagocytosis by macrophages and 
lymphocytes during this high inflammatory response phase [1, 147]. The prolifera-
tive stage is characterized by the expansion of stem cell niche and the generation of 
numerous transiently amplifying myoblasts which are waiting to differentiate [1]. 
The structural configuration of skeletal stem cell niche is modified by the accumula-
tion of diverse components of the regenerative matrix. One of the components is 
represented by fibronectin, secreted by fibroblasts, satellite cells, and many other 
cells in the muscular tissue [157, 158]. Attachment to fibronectin is crucial for the pre-
vention of anchorage-dependent cell’s death, the regulation of asymmetric division 
and satellite cells segregation [159, 160]. Another component of the ECM is collagen 
VI secreted by fibroblasts, which is upregulated during the peak of satellite cells 
expansion and has essential mechanical properties in the skeletal muscle stem cell 
niche [161]. The satellite cells show a considerable proliferative ability in day 2 and 3 
after an injury [10, 147]. Following the activation of satellite cells, monocytes convert 
into macrophages. M1 macrophages also exist in the mitogenic niche and secret 
VEGF, TNFα, IL-6, factors that are responsible for the limitation of early differentia-
tion of myoblasts, stimulating the proliferation of stem cells instead [141, 162, 163]. 
When M2 macrophages become predominant to M1 macrophages, the first myoblasts 
start to differentiate [141, 164]. During the differentiation phase, myoblasts fuse to 
form multinucleated muscle cells and resident satellite cells and start to transit into a 
non-dividing state (quiescent state) [1]. At this point in the process of muscle regen-
eration, the blood vessels that irrigate the new muscle fibers become denser and well 
organized; smooth muscles and pericytes are initiated to sustain their structure, while 
immune cells limit the inflammatory reaction and secret anti-inflammatory cytokines 
to sustain tissue repair, resulting in the restoration of muscular architecture within 
nearly 2 weeks [10, 144, 147, 165–167].
4.2 Muscular stem cell niche in disease
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through the secretion of growth factors, while differentiated myoblasts stimulate 
angiogenesis [85].
Lately, two studies, both conducted by injecting diphtheria toxin in mouse 
models, speculated that muscle repair is not possible without satellite cells, even 
under normal physiological conditions [142, 143]. During the experiments, 
neither non-satellite cells, nor the innervation and vasculature were altered. One 
of the studies developed mouse models in which only cells expressing Pax7 were 
killed by the toxin, while the second study crossed murine expressing an inducible 
diphtheria toxin with murine expressing under the control of Pax7 tamoxifen-
inducible conditional recombinase [142, 143] . However, further studies are 
needed in order to undoubtably state that muscle restoration can only take place if 
satellite cells are present.
35
Skeletal Muscle Stem Cell Niche from Birth to Old Age
DOI: http://dx.doi.org/10.5772/intechopen.93502
4.1 The regenerative muscle stem cell niche
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including diaphragm, limb, and heart muscles, in which death occurs in teenage 
years to 20s by cardiorespiratory failure [168]. In Duchenne disorder, the affected 
gene is dystrophin, which has an important structural function in anchoring the 
muscle fibers to the ECM in the muscular stem cell niche [13]. Moreover, dystro-
phin, which is expressed by satellite cells, is situated near the cell membrane and 
coordinates the flow of signaling molecules; therefore, a low level of dystrophin has 
a direct influence on the downstream cell-intrinsic signaling pathways of satellite 
cells, altering their functions [13, 169].
In most of the muscular dystrophies, the structural architecture of muscle cells 
is fragile, and fibers are doomed to get ruptured during repeated contractions; the 
stem cell niche is changing in such a way that the skeletal muscles get infiltrated 
with fat and fibrotic tissue [156, 170, 171]. Muscle ruptures are followed by protein 
leakage that activates inflammatory cells (lymphocytes, neutrophils, natural killer, 
macrophages) [172]. In muscular dystrophies, the inflammatory response is distinct 
than the one in trauma: there are many foci of injury developed in a continuous 
and asynchronous manner and the inflammatory process becomes chronic, and the 
ECM becomes thick and rigid, altering the muscular stem cell niche [173, 174]. In 
the extracellular environment, researchers discovered an accumulation of collagen 
I, III, IV, V, higher levels of various heparan sulfate proteoglycans and, moreover, a 
distinct regulation of the expression levels of MMPs and their endogenous inhibitor 
(TIMPs), together with various serine proteases and their endogenous inhibitors 
(serpins) [175–182]. Furthermore, the increased levels of matricellular proteins like 
fibrinogen, dermatopontin, asporin, and periostin were observed, together with a 
downregulation of fibrillin and nidogen [183–186]. The muscular stem cell niche is 
also enriched in signaling molecules during this inflammatory process, which influ-
ences the myoblast differentiation and fusion [155, 187]. For example, higher levels of 
prostaglandins, cytokines, and chemokines are described in muscular dystrophy, fact 
that supports the regenerative failure of dystrophic fibers [188–193]. This long-term 
inflammatory process changes the satellite cells in such manner that they can no lon-
ger compensate for the fiber degeneration, leading to an altered muscle functionality.
Diabetes mellitus represents a category of metabolic diseases characterized by a 
deficiency in insulin generation and function, leading to hyperglycemia, a condition 
which decreases the antioxidant level and increases the levels of free radical spe-
cies [194, 195]. Muscle renewal is altered in type 1 and 2 of diabetes mellitus, these 
patients having a poor lesion-healing capacity [194, 196–198]. There is a fibrotic dis-
position of collagen and atypical levels of TNFα, TGFβ and ILs in diabetic or obese 
rats and patients due to the high level of M1 macrophages [199–202]. A sustained 
exposure to glucose generates an accumulation of glycated lipids and proteins that 
have an unfavorable impact on myoblasts from both rats and humans [203].
Another dramatic muscular pathology is cachexia. This state occurs as a conse-
quence of various disorders such as AIDS, COPD, cancer, and heart failure and con-
sists in the heavy and accelerated loss of striate muscle mass [204]. Muscular fibers 
from mice with neoplasms or from cachectic patients present abnormalities in the 
architecture of the basal lamina and in the membrane of the muscle cells, rather than 
infiltration of immune cells like in dystrophies or diabetes mellitus [205, 206]. This 
affected niche together with circulating plasma factors contributes to a hyperactiva-
tion of satellite cells and other non-satellite cells including pericytes. Furthermore, 
satellite cells constantly express Pax-7 self-renewal factor, an action that abolishes 
the differentiation process, leading to regenerative failure of muscular fibers [1].
Collectively, the data reviewed above showed the importance of stem cell niche 
behavior in the muscle regenerative process; yet further studies are required to 
fully understand these complex mechanisms involved in the renewal of normal and 
pathological muscle.
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5. Perspectives
Over the last three decades, researchers found that satellite cells are a heterog-
enous population of stem cells and dedicated progenitors for myogenesis in striate 
muscle. With the development of new technologies, like single cell sequencing, 
mass cytometry, or super resolution imaging, the detailed study of satellite cells 
during growth, differentiation, and quiescence state is continuously improving [1]. 
The progress in discovering personalized therapies is slow and full of challenges, 
especially in the field of rare muscle pathologies, yet the stimulation of endogenous 
repair as a prospective therapy for muscle diseases should be one of the key per-
spectives that should be further looked into [207, 208]. The stem cell niche changes 
in behavior and composition during a lifetime, having tree periods: juvenile, adult, 
and old age. It is known that there are difficulties in muscular stem cells isolation 
and preservation due to the fact that they lose their myogenic ability after growing 
in vitro even for a short period of time [129]. A question that is yet to be answered 
is whether the use of juvenile stem cells instead of adult ones would provide for 
more adequate cell cultures, increasing plasticity and improving muscle regenera-
tive therapies. For this purpose, and for a better understanding of skeletal stem cell 
niche, future challenging studies are needed.
6. Conclusion
The muscular stem cell niche is a remarkable structure that enables satellite 
cells and other non-satellite myogenic cells to repair and regenerate skeletal 
muscles when needed. As previously stated, the niche componence is highly 
variable, depending not only on the age of the body, but also on its well-being 
since a multitude of degenerative muscle disorders can alter the stem cell envi-
ronment, leading to a decrease in the regenerative abilities of satellite cells. One 
of the elements of the niche that was proved to change during aging is the basal 
lamina, a key structure that apparently tends to interpose between the myofibers 
and satellite cells in older muscles, thus altering their communication, a fact that 
is believed to be associated to the latter’s decrease in number. Furthermore, it 
was observed that in aged skeletal muscles, myofibers were decreased in mass, in 
contrast to the number of fibroblasts and adipocytes, which tended to increase. 
Satellite cells displayed diminished myogenic abilities and an accelerated apop-
tosis, probably due to lower expression levels of Pax7. Similar changes were 
described in degenerative muscle disorders, one of the most studied and severe 
being Duchenne muscular dystrophy. The chronic inflammation that appears in 
these diseases is believed to thicken the basal lamina and overflow the satellite 
cells with signaling molecules, impairing their capacity to restore muscle fibers. 
Other chronic disorders like diabetes mellitus and cachexia were also associated 
with niche alterations. Research in the field of regenerative medicine promises to 
innovate the therapies in these pathologies; however, there is a long way ahead 
and additional studies are needed.
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Sarcopenia in Older Adults
Eli Carmeli
Abstract
Sarcopenia has become of great interest and focus of many studies since this 
phenomenon affects many people. Moreover, sarcopenia is associated with two 
more pandemic phenomena: frailty and obesity. These health-related conditions are 
increasing in western countries in general and in the older population in particular. 
Each of such health conditions relates to functional decline, yet the combination 
of two or three of them in one person severely affects quality of life and longevity. 
Aged individuals who are less physically active are more likely to develop sarcopenic 
obesity, and those who are obese with muscle weakness and inactive are disposed 
to become frail individuals. Hence, frailty and obesity overlap profoundly with the 
physical manifestations of sarcopenia of aging. These “unhappy” triads encom-
passes a wider range of geriatric decline that also includes cognitive, psychology and 
social deterioration associated with adverse outcomes. Nevertheless, this chapter 
focuses only on sarcopenia and will review the pathophysiological background of 
age-related decline in muscle mass and strength.
Keywords: sarcopenia, elderly, strength, muscle mass, physical performance, 
radicals, cytokines
1. Introduction
1.1 The “unhappy triad”
The end of the last century and the beginning of the first two decades of the 
present century were characterized by the rise of three medical or health pandemic 
phenomena, each of which has a serious impact on public health and especially 
among older people. These three conditions are frailty, sarcopenia, and obesity. 
When sarcopenia or frailty is also accompanied by obesity, a sarcopenic/frail-obese 
phenotype is established [1]. Moreover, the presence of these “unhappy triads” of 
health conditions, in one person, poses a significant threat to one’s quality of life 
and longevity. The prevalence of each of such conditions (i.e., frailty, sarcopenia, 
and obesity) is widely estimated within different countries; however, with no one 
single best outcome measure for these diagnoses, there is highly wide range of 
manifestation and diagnoses in each of these health phenomena [2].
A “cycle of sarcopenia” may be created in which in the presence of one or two 
factors such as frailty and or obesity, sarcopenia status is likely to continue to dete-
riorate unless there is outside intervention. It is extremely difficult to overcome this 
“unhappy triad” when the affected people do not have the resources necessary to 
get out of muscle weakness and fatigue, such as lower cardiac function (myocardial 
infraction, angina, chronic heart failure, metabolic state (hypertension, diabetes, 
and obesity) and arthritis.
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Longevity steadily increased over the past several decades. Life expectancy in 
65 year Western country subjects is ~20 years, and the proportion of people over 
age 60 is increasing faster than any other groups (2). Obesity is also worldwide 
growing [3] and is also accompanied by significant alterations in body composition, 
with a decline in lean body mass and muscle strength and with an increase in fat 
mass. This phenomenon known as sarcopenic obesity [4].
The concept of frailty syndrome is basically a geriatric syndrome, which is 
recently becoming one of the dominant concepts in advanced age. Frailty is a dynamic 
condition with the presence of several components. There are two major operational 
definitions for frailty. The most widely used concept is the Fried physical frailty phe-
notype, which defines frailty based on three or more of the following five symptoms: 
unintentional weight loss, slowness, weakness, exhaustion, and low physical activity 
[5]. Yet, functional decline due to sarcopenia is in the core of frailty syndrome [6].
This chapter focuses on sarcopenia. Aged skeletal muscles can be induced to die 
through different mechanisms mainly via two systems, apoptosis or autophagy; 
both systems can be activated through different molecules such as free radicals, 
inflammatory molecules, hormones, and others [7].
2. Sarcopenia
There are currently over 10,000 articles published in referee journals dealing 
with the phenomenon of Sarcopenia, which was first proposed by Irwin Harold 
Rosenberg in 1989 at the annual conference of the American Society for Clinical 
Nutrition. Sarcopenia is age-related myopenia (decrease of muscle mass) and dyna-
penia (decrease in muscle strength) [8]. More specifically, sarcopenia is a health 
problem of old people characterized by a slow, progressive skeletal muscle disorder 
involving the accelerated loss of muscle mass and strength followed by the func-
tional decline that is associated with falls, obesity, frailty, frequent hospitalization, 
and mortality [9]. Sarcopenia has become of great interest and focus of many studies 
and since this phenomenon affects many people, the number of older population 
with sarcopenia is expected to increase all over the world, and it is becoming one of 
the important and interests, and causes a great deal of financial burden, a private 
and a public concern, from the individual level to the state and various institutions 
that deal with welfare and health [10]. It predisposed by genetic profile and lifestyle 
factors occurring across the life course [11]. The expression of Let-7b and Let-7e 
microRNA precursors (regulating muscle apoptosis) is significantly higher in older 
versus younger subjects. Ingenuity pathway analysis identified that the Let-7 family 
predicted gene targets were related to pathways and biological functions associated 
with macrophages activity.
Therefore, a great deal of knowledge about the nature of the phenomenon 
was accumulated, from a biological and clinical point of view, different means to 
diagnose it, and with particular ways to treat it such as nutritional interventions and 
drugs to augment the beneficial effects of resistance exercise.
2.1 Definition of sarcopenia
Sarcopenia (Greek “sarx” or flesh + “penia” or loss) is a geriatric syndrome 
which is described as a progressive decline in skeletal muscle mass and muscle 
strength from approximately the fifth decade of life.
The European Working Group on Sarcopenia in Older People (EWGSOP) 
defined sarcopenia in 2010 as a quote: “a syndrome characterized by progressive 
and generalized loss of skeletal muscle mass and strength with the risk of adverse 
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outcome such as physical disability, poor quality of life, and death” [12]. The 
EWGSOP proposed that age-related muscle weakness is considered as “primary 
sarcopenia” when no other reason is evident except aging itself. EWGSOP also sug-
gests a concept of three phases of sarcopenia: pre-sarcopenia (there is low muscle 
mass without low muscle strength or decline in physical performance); sarcopenia 
(low muscle mass, accompanying either low muscle strength or low physical perfor-
mance); and severe sarcopenia (when all three criteria are detected).
Another consensus definition of primary sarcopenia done by the International 
Working Group for Sarcopenia (IWGS) as “an individual presents functional and 
mobility decline, history of recurrent falls, recent unwanted body weight loss, 
recent-hospitalization, and chronic metabolic diseases (e.g., diabetes, hypothyroid) 
malnutrition, low protein intake, and cancer” [13].
2.2 Prevalence and epidemiology of sarcopenia
It is well known and extensively documented that as an older person reaches his 
sixth decade of life, there is a progressive decline in muscle mass (~1% per year) 
and strength (~2.5–3% per year) [14]. Sarcopenia is more prevalent in men than in 
women. It is more prevalent in large muscle groups such as tight, more in untrained 
individuals and more in people with poor health background [15]. There is a strong 
association between, muscle strength, age, gender, and disability. In general, there 
is a decrease in muscle mass at an annual rate of 1.5% after about 50 years old, 
reaching to 3% per year in their eight decade [16].
Public health planners, physicians and researchers are needed to come up with 
the consensus of criteria for estimating the prevalence of sarcopenia. Moreover, at 
present time, there are lacking data for developing any consensus on what consti-
tutes poor muscle mass, and what is the optimal, valid, and reliable tool to measure 
and to diagnose sarcopenia.
The prevalence of sarcopenia needs to be investigated in multiethnic population, 
and to explore association with obesity, socioeconomic status, mental and cognitive 
function, morbidity, quality of life, and life style. Previous studies have been dem-
onstrated associations between muscle mass and function, whereas other studies 
have established associations between the following:
a. sarcopenia and physical activity [17],
b. muscle mass and BMI [18];
c. muscle performance and certain minerals [19];
d. muscle mass and strength and depressive symptoms and [20];
e. sarcopenia and cognitive impairment [21];
f. muscle strength and falls [22];
g. muscle mass and osteoporosis [23], thus those with sarcopenia possessed  
approximately 13 times higher risk of having osteoporosis [24], and there is a 
significant association between osteoporosis and deterioration of the skeletal 
microarchitecture [25]. The prevalence of osteosarcopenia increases with aged 
men and women [26]; and
h. sarcopenia and meat intake in male and milk intake in female [27].
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outcome such as physical disability, poor quality of life, and death” [12]. The 
EWGSOP proposed that age-related muscle weakness is considered as “primary 
sarcopenia” when no other reason is evident except aging itself. EWGSOP also sug-
gests a concept of three phases of sarcopenia: pre-sarcopenia (there is low muscle 
mass without low muscle strength or decline in physical performance); sarcopenia 
(low muscle mass, accompanying either low muscle strength or low physical perfor-
mance); and severe sarcopenia (when all three criteria are detected).
Another consensus definition of primary sarcopenia done by the International 
Working Group for Sarcopenia (IWGS) as “an individual presents functional and 
mobility decline, history of recurrent falls, recent unwanted body weight loss, 
recent-hospitalization, and chronic metabolic diseases (e.g., diabetes, hypothyroid) 
malnutrition, low protein intake, and cancer” [13].
2.2 Prevalence and epidemiology of sarcopenia
It is well known and extensively documented that as an older person reaches his 
sixth decade of life, there is a progressive decline in muscle mass (~1% per year) 
and strength (~2.5–3% per year) [14]. Sarcopenia is more prevalent in men than in 
women. It is more prevalent in large muscle groups such as tight, more in untrained 
individuals and more in people with poor health background [15]. There is a strong 
association between, muscle strength, age, gender, and disability. In general, there 
is a decrease in muscle mass at an annual rate of 1.5% after about 50 years old, 
reaching to 3% per year in their eight decade [16].
Public health planners, physicians and researchers are needed to come up with 
the consensus of criteria for estimating the prevalence of sarcopenia. Moreover, at 
present time, there are lacking data for developing any consensus on what consti-
tutes poor muscle mass, and what is the optimal, valid, and reliable tool to measure 
and to diagnose sarcopenia.
The prevalence of sarcopenia needs to be investigated in multiethnic population, 
and to explore association with obesity, socioeconomic status, mental and cognitive 
function, morbidity, quality of life, and life style. Previous studies have been dem-
onstrated associations between muscle mass and function, whereas other studies 
have established associations between the following:
a. sarcopenia and physical activity [17],
b. muscle mass and BMI [18];
c. muscle performance and certain minerals [19];
d. muscle mass and strength and depressive symptoms and [20];
e. sarcopenia and cognitive impairment [21];
f. muscle strength and falls [22];
g. muscle mass and osteoporosis [23], thus those with sarcopenia possessed  
approximately 13 times higher risk of having osteoporosis [24], and there is a 
significant association between osteoporosis and deterioration of the skeletal 
microarchitecture [25]. The prevalence of osteosarcopenia increases with aged 
men and women [26]; and
h. sarcopenia and meat intake in male and milk intake in female [27].
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3.  Biological mechanisms of sarcopenia: from molecular  
to histological level
There are several molecular mechanisms that may be involved, in some degree, 
in the commencement and development of sarcopenia. Although the molecular and 
cellular mechanisms underlying sarcopenia still remain to be clarified, certain com-
mon biological mechanisms have been suggested to be involved in sarcopenia. This 
section will include, in brief, the most common mechanisms related to sarcopenia: 
oxidative stress [reactive oxygen and nitrogen species (ROS and RNS)]; a-without 
clinical symptoms of muscle fiber inflammation (due to presence of myokines/cyto-
kines like TNF-α and IL-6); hormonal regulation impairment (such as testosterone, 
growth hormone, IGF-1, glutathione 4, insulin resistance, and vitamin D); vitamin 
E deficiency; proteolysis pathway [the lack of responsiveness of the ubiquitin-
proteasome system and alterations in the regulation of autophagy and apoptotic 
pathway (Bcl2 signaling and NF-Kb)]; and finally, the role of adult stem (satellite) 
cells. Identifying these mechanisms and their underlying origins is expected to 
facilitate strategy of intervention programs [28].
From a physiology and histology point of view, the skeletal muscle comprises 
several types of fibers. The most prominent types are type I and type II fibers. 
Type II fast twitch muscle fibers characterized by high glycolytic potential, lower 
oxidative capacity, and faster response, are aimed at muscle strength and short-
duration anaerobic activities, whereas type I slow twitch muscle fibers are known 
as fatigue-resistant due to their characteristics such as large density of capillary bed 
and myoglobin and being abundant with mitochondria, to better supply oxygen 
and nutrients to the muscle, thus to improve muscular endurance and aerobic 
activities [29].
Sarcopenia is characterized by more hypotrophy and less fiber activation of 
the lower extremity muscles than upper limbs. Moreover, the lower limb muscles 
of old people are smaller and have significantly more fats and connective tissues 
than lower limb muscles in young individuals. Sarcopenia is characterized by a 
reduction in both the number and size of muscle fibers, mainly of type II, and is to 
some extent caused by a slowly progressive myogenic process, which is stem cells 
dependent. Therefore, these changes affect not only in energy production, poor 
muscle repair, and deprived fiber regeneration, but also practically in decline in 
physical performance and in functional capacity such as walking (stairs), running, 
and early onset of fatigue which all associate with poor quality of life and more 
dependency [30].
Of course there is a connection and interdependence between the various 
factors. Sometimes one of them is a cause or effect, and sometimes it is a result of 
or outcome from. Some of the mechanisms have a positive correlation and oth-
ers have a negative correlation. In general, skeletal muscle can “die” in different 
molecular pathways. Sarcopenia, as a normal physiological process, is associated 
with a significant rise in the levels of inflammatory molecules both in blood serum 
and intra- and extracellular. The aging process induced oxidative stress (OS) and 
degradation of damaged mitochondria promotes the accumulation of lipofuscin, 
which is one histological marker of fiber oxidative damage. The accumulation of 
lipofuscin, is recognized as the hallmark pigment of aging muscle. Lipofuscin is an 
intralysosomal, composed of cross-linked protein residues and lipid per oxidized 
molecules. This intracellular waste material interferes with muscle metabolism and 
muscle contraction [31].
Oxidative stress resulted due to imbalance between the production of reactive 
oxygen/nitrogen species and antioxidants/nitrogen defense molecules. Consequently 
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and practically, a chain response of inflammatory molecules appears within the 
fibers with the release of myokines such as tumor necrosis factor-α (TNF-α), inter-
leukin-6 (IL-6), and interleukin-1 (IL-1) that lead to a predisposition to age-related 
sarcopenia afterward through the activation of the ubiquitin-protease system and 
the activation of myofiber signaling pathway that leads to muscle apoptosis. It is also 
suggested that cytokines also contributes to anabolic resistance through provoking 
the anabolic effect mediated by insulin growth factor-1 (IGF-1), involving in growth 
hormone resistance which limits IGF-I availability. Some other potential factors and 
mechanisms are suggested leading to sarcopenia such as TGF-β-activated kinase 
(TAK)-1; C-reactive protein; a significant reduction of dihydropyridine (DHP)-
sensitive Ca2+ (the decrease of Ca2+ available for mechanical responses in aged 
skeletal muscle is due to DHP receptor (DHPR)-ryanodine receptor (RyR) uncou-
pling); and the stress of sarcoplasmic reticulum due to accumulation of unfolded or 
misfolded proteins like heat shock proteins.
3.1 Oxidative stress and sarcopenia
Sarcopenia is a multifactorial event, thus redox signaling and oxidative stress 
have a key role play, due to an increase in reactive oxygen and nitrogen species 
(ROS/RNS) levels, a decrease in enzymatic antioxidant protection and followed 
by myofiber “quiet” inflammation (i.e., the presence of myokines). Therefore, the 
oxidative stress is more extensively described in the below section of this chapter.
3.1.1  Endogenous sources of reactive oxygen species, reactive nitrogen species,  
and antioxidant systems
Reactive oxygen species (ROS) are mainly and normally produced by the mito-
chondria, and a normal ROS level is indispensable for myofiber functions.
The mitochondrial electron transport chain transfer of a single electron to 
molecular oxygen gives rise to a monovalent reduction of oxygen, which leads to 
the formation of superoxide ions (O2.−). It is the first step in the chain of events 
to create more free radicals such as hydrogen peroxide (H2O2), hydroxyl radical 
(OH.), and hydroxyl ion (OH−) [32]. Another source of ROS in skeletal muscle is 
a large NOX family enzymes (NOX1, NOX2, and NOX4) located in the sarcoplas-
mic reticulum, transverse tubule, and also in the sarcoplasma membrane [33]. 
These enzymes have the capacity to transport electrons across the sarcoplasma 
membrane and generate superoxide and other downstream reactive oxygen 
species (ROS). Since these enzymes play an important role in excitation con-
traction coupling, hyperexpression or overproduction of NOXs inhibits muscle 
contractions. Another mechanism that can explain the crosstalk between NOXs 
and ROS production is the rise of intracellular Ca2+ levels by NOX-derived ROS, 
which, increasing mitochondrial Ca2+ load, induces the ROS production by these 
organelles.
Reactive nitrogen species (RNS) derived from nitric oxide (•NO) and superoxide 
ions is produced via the enzymatic activity of inducible nitric oxide synthase 2 
(NOS2) and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) 
[34]. NOS2 is also expressed after induction of cytokines [26]. In skeletal muscle, 
there are three different isoforms of this isoenzyme: endothelial NOS (eNOS), neu-
ronal NOS (nNOS), and inducible isoform (iNOS). RNS arise from several sources 
and the levels increase with contractile activity. Nitric oxide (NO) is formed from 
L-arginine in a reaction catalyzed by the nitric oxide synthase (NOS) enzyme, and it 
is an important cell signaling molecule [35].
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duration anaerobic activities, whereas type I slow twitch muscle fibers are known 
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Sarcopenia is characterized by more hypotrophy and less fiber activation of 
the lower extremity muscles than upper limbs. Moreover, the lower limb muscles 
of old people are smaller and have significantly more fats and connective tissues 
than lower limb muscles in young individuals. Sarcopenia is characterized by a 
reduction in both the number and size of muscle fibers, mainly of type II, and is to 
some extent caused by a slowly progressive myogenic process, which is stem cells 
dependent. Therefore, these changes affect not only in energy production, poor 
muscle repair, and deprived fiber regeneration, but also practically in decline in 
physical performance and in functional capacity such as walking (stairs), running, 
and early onset of fatigue which all associate with poor quality of life and more 
dependency [30].
Of course there is a connection and interdependence between the various 
factors. Sometimes one of them is a cause or effect, and sometimes it is a result of 
or outcome from. Some of the mechanisms have a positive correlation and oth-
ers have a negative correlation. In general, skeletal muscle can “die” in different 
molecular pathways. Sarcopenia, as a normal physiological process, is associated 
with a significant rise in the levels of inflammatory molecules both in blood serum 
and intra- and extracellular. The aging process induced oxidative stress (OS) and 
degradation of damaged mitochondria promotes the accumulation of lipofuscin, 
which is one histological marker of fiber oxidative damage. The accumulation of 
lipofuscin, is recognized as the hallmark pigment of aging muscle. Lipofuscin is an 
intralysosomal, composed of cross-linked protein residues and lipid per oxidized 
molecules. This intracellular waste material interferes with muscle metabolism and 
muscle contraction [31].
Oxidative stress resulted due to imbalance between the production of reactive 
oxygen/nitrogen species and antioxidants/nitrogen defense molecules. Consequently 
55
Sarcopenia in Older Adults
DOI: http://dx.doi.org/10.5772/intechopen.93418
and practically, a chain response of inflammatory molecules appears within the 
fibers with the release of myokines such as tumor necrosis factor-α (TNF-α), inter-
leukin-6 (IL-6), and interleukin-1 (IL-1) that lead to a predisposition to age-related 
sarcopenia afterward through the activation of the ubiquitin-protease system and 
the activation of myofiber signaling pathway that leads to muscle apoptosis. It is also 
suggested that cytokines also contributes to anabolic resistance through provoking 
the anabolic effect mediated by insulin growth factor-1 (IGF-1), involving in growth 
hormone resistance which limits IGF-I availability. Some other potential factors and 
mechanisms are suggested leading to sarcopenia such as TGF-β-activated kinase 
(TAK)-1; C-reactive protein; a significant reduction of dihydropyridine (DHP)-
sensitive Ca2+ (the decrease of Ca2+ available for mechanical responses in aged 
skeletal muscle is due to DHP receptor (DHPR)-ryanodine receptor (RyR) uncou-
pling); and the stress of sarcoplasmic reticulum due to accumulation of unfolded or 
misfolded proteins like heat shock proteins.
3.1 Oxidative stress and sarcopenia
Sarcopenia is a multifactorial event, thus redox signaling and oxidative stress 
have a key role play, due to an increase in reactive oxygen and nitrogen species 
(ROS/RNS) levels, a decrease in enzymatic antioxidant protection and followed 
by myofiber “quiet” inflammation (i.e., the presence of myokines). Therefore, the 
oxidative stress is more extensively described in the below section of this chapter.
3.1.1  Endogenous sources of reactive oxygen species, reactive nitrogen species,  
and antioxidant systems
Reactive oxygen species (ROS) are mainly and normally produced by the mito-
chondria, and a normal ROS level is indispensable for myofiber functions.
The mitochondrial electron transport chain transfer of a single electron to 
molecular oxygen gives rise to a monovalent reduction of oxygen, which leads to 
the formation of superoxide ions (O2.−). It is the first step in the chain of events 
to create more free radicals such as hydrogen peroxide (H2O2), hydroxyl radical 
(OH.), and hydroxyl ion (OH−) [32]. Another source of ROS in skeletal muscle is 
a large NOX family enzymes (NOX1, NOX2, and NOX4) located in the sarcoplas-
mic reticulum, transverse tubule, and also in the sarcoplasma membrane [33]. 
These enzymes have the capacity to transport electrons across the sarcoplasma 
membrane and generate superoxide and other downstream reactive oxygen 
species (ROS). Since these enzymes play an important role in excitation con-
traction coupling, hyperexpression or overproduction of NOXs inhibits muscle 
contractions. Another mechanism that can explain the crosstalk between NOXs 
and ROS production is the rise of intracellular Ca2+ levels by NOX-derived ROS, 
which, increasing mitochondrial Ca2+ load, induces the ROS production by these 
organelles.
Reactive nitrogen species (RNS) derived from nitric oxide (•NO) and superoxide 
ions is produced via the enzymatic activity of inducible nitric oxide synthase 2 
(NOS2) and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) 
[34]. NOS2 is also expressed after induction of cytokines [26]. In skeletal muscle, 
there are three different isoforms of this isoenzyme: endothelial NOS (eNOS), neu-
ronal NOS (nNOS), and inducible isoform (iNOS). RNS arise from several sources 
and the levels increase with contractile activity. Nitric oxide (NO) is formed from 
L-arginine in a reaction catalyzed by the nitric oxide synthase (NOS) enzyme, and it 
is an important cell signaling molecule [35].
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The intrinsic and extrinsic antioxidant systems inhibit oxidation [36, 37]. The 
intrinsic system includes enzymes such as superoxide dismutase, catalase, peroxi-
dase, and glutathione. Manganese superoxide dismutase (MnSOD) is synthesized by 
a mitochondrion that catalyzes the breakdown of the superoxide anion into oxygen 
and hydrogen peroxide. Catalase catalyzes the conversion of hydrogen peroxide to 
water and oxygen, peroxidase catalyzes the reduction of hydrogen peroxide, and 
glutathione is a very efficient scavenger of hydrogen peroxide, while glutathione 
peroxidase 4 is most active with lipid hydroperoxides. The extrinsic system includes 
dietary supplements such as Ubiquinone-10, coenzyme Q10, creatine, and others, 
and the combination with physical exercise is even better for muscle atrophy preven-
tion and/or treatment of sarcopenia [38].
The levels of ROS and RNS inside the fibers are firmly controlled by the bal-
ance between the rate of endogenous synthesis by ROS/RNS generating systems 
and the rate of removal through the nonenzymatic and enzymatic antioxidant 
systems [39]. In aged muscles, there is an excessive ROS/RNS production or 
diminishing of antioxidant production which interrupts the myofiber metabolism 
and physiological function, both in resting and in force production [40]. There 
is plenty of evidence that sarcopenia is caused by an increase of endogenous ROS 
and/or RNS formation, on the one hand, and decrease in quantity, quality, and 
antioxidant system efficiency, on the other hand [41, 42]. Sarcopenia is also char-
acterized by mitochondrial dysfunction; mitochondrial morphological changes, 
lacking fusion and fission; less mitochondria mobility, leading to the accumula-
tion of damaged mitochondria that induces a catabolic process; muscle loss; and 
fiber inflammation [43, 44].
In conclusion, age-related ROS and RNS overproduction not only generates 
damage of muscle but also plays a role in regulating intracellular signal transduction 
pathways that are directly or indirectly involved in skeletal muscle inflammation 
and apoptosis.
3.1.2 The role of cytokines in sarcopenia
Sarcopenia is definitely associated with inflammatory cytokines/myokines, 
which prompt a serious negative consequence as a loss of muscle mass and strength 
with concomitant increase in fat mass, eventually stimulating protein catabolism 
and muscle degeneration. As such, an excepted catabolic inflammatory process 
is often observed in older adults, and it can enhance and deteriorate the status of 
sarcopenia [45].
Skeletal muscle tissue is an vital source of inflammatory molecules, known as 
“myokines” (e.g., IL-6, IL-1b, TNFα, and IL-1ra) which are overexpressed in aged 
skeletal muscles, related to the slow, non symptomatic, slowly progressed, inflam-
mation process demonstrated in elderly individuals. Myokines are secreted in 
response to muscle contraction or strength training [46]; however, their activation 
as inflammatory signal pathways happen due to aging, which reveals their critical 
impact on sarcopenia [47]. Several inflammatory myokines, especially interleukin-1 
6, and 10 (IL-1, Il-6, IL-10), tumor necrosis factor-alpha (TNF-α), and myostatin 
play crucial roles in the modulation of inflammatory signaling pathway during the 
aging-related loss of skeletal muscle [48, 49].
3.1.2.1 Interleukin
The relationship between sarcopenia and the inflammatory cytokines interleu-
kin-1 and 6 (IL-1, IL-6), and the anti-inflammatory cytokine interleukin-10 (IL-10) 
in an elderly population is well reported [50, 51]. IL-6 within the muscle fibers 
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promotes glucose uptake and fat oxidation via the phosphoinositide 3-kinase (PI3K) 
and AMP-activated protein kinase (AMPK) signaling pathways, respectively, and 
improves insulin sensitivity by blocking the proinflammatory signaling pathways 
in the muscle. High levels of IL-6 (>40 pg./ml) and IL-10 (>4 pg./ml) are associ-
ated with lower physical performance, muscle strength, and muscle mass [52]. 
Hospitalized geriatric patients with inflammation represented significantly weaker 
muscle function, shoulder extension strength, and a worse fatigue resistance [53]. 
Old people living in nursing homes and long-term-assisted living facilities present-
ing high IL-6 levels were associated with the higher prevalence of frailty [54]. The 
significant role of IL-6 levels on depressive symptoms in older women in the year 
after hip fracture may represent a sickness syndrome that is chronic in some indi-
viduals [55]. A recent study in community-dwelling older men suggested that the 
high levels of interleukin-1 (IL-1) is associated with a low grip strength [56]. The 
ratio of proinflammatory cytokine IL-6 to anti-inflammatory cytokine IL-10 (IL-6/
IL-10 ratio) >9.5 pg./ml has been used as a reliable marker for measuring inflamma-
tory status [57].
IL-10 is an anti-inflammatory myokine, mostly produced by macrophages, 
T-helper 2 cells (also known as CD4+ cells), B-lymphocytes, and monocytes. These 
cells either secrete antibodies or suppress and destroy any immune response. IL-10 
is responsible for destroying the proinflammatory response in various tissues, 
including skeletal muscle, by suppressing the activation of phagocytes such as 
macrophages and releasing and activating the inflammatory cytokines such as 
IL-6, TNFα, and IL-1β. Increased IL-10 was associated with poor physical perfor-
mance [58, 59].
In summary, inflammatory and proinflammatory interleukin cytokines have 
both been linked with a number of age-related outcomes, including sarcopenia, 
chronic morbidity, functional decline, and mortality [60].
3.1.2.2 Tumor necrosis factor-α (TNF-α)
The appearance of sarcopenia is accompanied by the increased levels of inflam-
mation factors such as TNF-α. TNF-α inhibits the synthesis of muscle proteins, 
accelerates protein decomposition, and upregulates the expression of muscle 
growth inhibitory factor myostatin and muscle atrophy proteins, F-box-1 Atrogin-1, 
etc., so as to accelerate protein catabolism and promote skeletal muscle consump-
tion. TNF-α and its soluble receptors showed the most consistent associations with 
decline in muscle mass and strength [61]. TNF-α is also reported to suppress the 
Akt/mTOR pathway [62], promoting muscle catabolism, oxidative stress, and nitric 
acid production [63].
3.1.2.3 C-reactive protein (CRP)
Elevated levels of these proteins, reflecting the conditions of chronic inflamma-
tion, have been associated with reduced muscle mass and strength [64], decreased 
physiology capacity, and more difficulties in performing the activities of daily 
living [65]. The levels of CRP are negatively associated with appendicular lean 
body mass [66]. In addition, the increased levels of lipid peroxidation result in the 
breakdown of biological phospholipids in sarcolemma and mitochondrial mem-
brane, thus preventing the mitochondria to break down and converting fatty acid 
molecules (β-oxidation) to acyl-CoA chains in order to produce energy. Damage 
to mitochondria also increases the formation of reactive oxygen species such as 
superoxide anion [O2·−], hydroxyl radical [OH−]), and hydrogen peroxide [H2O2], 
complemented by the increased production and secretion of proinflammatory 
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The intrinsic and extrinsic antioxidant systems inhibit oxidation [36, 37]. The 
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and hydrogen peroxide. Catalase catalyzes the conversion of hydrogen peroxide to 
water and oxygen, peroxidase catalyzes the reduction of hydrogen peroxide, and 
glutathione is a very efficient scavenger of hydrogen peroxide, while glutathione 
peroxidase 4 is most active with lipid hydroperoxides. The extrinsic system includes 
dietary supplements such as Ubiquinone-10, coenzyme Q10, creatine, and others, 
and the combination with physical exercise is even better for muscle atrophy preven-
tion and/or treatment of sarcopenia [38].
The levels of ROS and RNS inside the fibers are firmly controlled by the bal-
ance between the rate of endogenous synthesis by ROS/RNS generating systems 
and the rate of removal through the nonenzymatic and enzymatic antioxidant 
systems [39]. In aged muscles, there is an excessive ROS/RNS production or 
diminishing of antioxidant production which interrupts the myofiber metabolism 
and physiological function, both in resting and in force production [40]. There 
is plenty of evidence that sarcopenia is caused by an increase of endogenous ROS 
and/or RNS formation, on the one hand, and decrease in quantity, quality, and 
antioxidant system efficiency, on the other hand [41, 42]. Sarcopenia is also char-
acterized by mitochondrial dysfunction; mitochondrial morphological changes, 
lacking fusion and fission; less mitochondria mobility, leading to the accumula-
tion of damaged mitochondria that induces a catabolic process; muscle loss; and 
fiber inflammation [43, 44].
In conclusion, age-related ROS and RNS overproduction not only generates 
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3.1.2 The role of cytokines in sarcopenia
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response to muscle contraction or strength training [46]; however, their activation 
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6, and 10 (IL-1, Il-6, IL-10), tumor necrosis factor-alpha (TNF-α), and myostatin 
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aging-related loss of skeletal muscle [48, 49].
3.1.2.1 Interleukin
The relationship between sarcopenia and the inflammatory cytokines interleu-
kin-1 and 6 (IL-1, IL-6), and the anti-inflammatory cytokine interleukin-10 (IL-10) 
in an elderly population is well reported [50, 51]. IL-6 within the muscle fibers 
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significant role of IL-6 levels on depressive symptoms in older women in the year 
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high levels of interleukin-1 (IL-1) is associated with a low grip strength [56]. The 
ratio of proinflammatory cytokine IL-6 to anti-inflammatory cytokine IL-10 (IL-6/
IL-10 ratio) >9.5 pg./ml has been used as a reliable marker for measuring inflamma-
tory status [57].
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IL-6, TNFα, and IL-1β. Increased IL-10 was associated with poor physical perfor-
mance [58, 59].
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growth inhibitory factor myostatin and muscle atrophy proteins, F-box-1 Atrogin-1, 
etc., so as to accelerate protein catabolism and promote skeletal muscle consump-
tion. TNF-α and its soluble receptors showed the most consistent associations with 
decline in muscle mass and strength [61]. TNF-α is also reported to suppress the 
Akt/mTOR pathway [62], promoting muscle catabolism, oxidative stress, and nitric 
acid production [63].
3.1.2.3 C-reactive protein (CRP)
Elevated levels of these proteins, reflecting the conditions of chronic inflamma-
tion, have been associated with reduced muscle mass and strength [64], decreased 
physiology capacity, and more difficulties in performing the activities of daily 
living [65]. The levels of CRP are negatively associated with appendicular lean 
body mass [66]. In addition, the increased levels of lipid peroxidation result in the 
breakdown of biological phospholipids in sarcolemma and mitochondrial mem-
brane, thus preventing the mitochondria to break down and converting fatty acid 
molecules (β-oxidation) to acyl-CoA chains in order to produce energy. Damage 
to mitochondria also increases the formation of reactive oxygen species such as 
superoxide anion [O2·−], hydroxyl radical [OH−]), and hydrogen peroxide [H2O2], 
complemented by the increased production and secretion of proinflammatory 
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cytokines such as tissue necrosis factor (TNF)-α and IL-1, 6, and 8 that trigger a 
cytokine cascade of the inflammatory cytokines that worsen the insulin resistance 
in skeletal muscle, resulting in the decrease of aerobic capacity [67].
3.2 Hormones and sarcopenia
A variety of other hormones appear to play roles in the age-related altera-
tions in muscle mass, strength function, and in the regulation of muscle 
metabolism [68].
Testosterone appears to be the central hormone involved in the development of 
sarcopenia. Testosterone is an important physiologic steroid hormone in muscle 
mass maintenance. Endogenous testosterone which naturally produced within the 
endocrine system in both men and women decline gradually with age, correlating 
with decreased muscle strength it increases both muscle mass and activates adult 
stem cells (i.e., satellite cells) leading to improved muscle function [69].
Normal growth hormone (GH) level is associated with notable protection from 
age-related disease in general, and more specifically against sarcopenia. The levels 
of GH and GH binding proteins declines upon aging. Growth hormone deficiency 
leads to the loss of muscle mass but not muscle strength [69, 70].
Skeletal muscle is the major organ in which the insulin-mediated glucose uptake 
by glucose transporter 4 (GLUT4) takes place. Lack of insulin, or IGF-1, or insulin 
resistance leads to accelerated development of sarcopenia. The muscle IGF-I level 
declines in aged population.
The primary action of insulin in skeletal muscle is to stimulate glucose uptake 
and metabolism. In physiological condition as insulin resistance, there is a gradual 
muscle wasting by several mechanisms such as the following: (a) suppression 
of PI3K/Akt signaling leading to the activation of caspase-3 and the ubiquitin-
proteasome proteolytic pathway causing muscle protein degradation; (b) beta-
adrenergic stimulation increases the lipolysis of the cell membrane, breaking 
down G-proteins that lead to interfering with growth hormone/insulin growth 
factor-1 receptor bind and diminished muscle regeneration; (c) advancement 
of gluconeogenesis metabolic pathway; (d) upregulation of sterol regulatory 
element-binding protein 1c (SREBP-1c); and (e) altering triglyceride and choles-
teryl esters transport in the core of plasma lipoproteins, which causes triglycerides 
to accumulate in skeletal muscle [71, 72]. It has been reported that IGF-I drops 
1.88 ng/ml/year in men and 2.13 ng/ml/year in women [73]. Circulating IGF-I level 
was found to be significantly reduced in sarcopenia patients [74]. mTOR signaling 
is a significant factor in sarcopenia, and mTOR signaling is altered by the change 
of IGF-I level [75].
Various medical problems and health conditions such as muscle weakness 
reduced the muscle mass that is predominantly a type II muscle fiber, bone pain, 
and systematic oxidative stress linked to 1,25-dihydroxyvitamin D [1,25(OH)2D]/
vitamin D deficiency. The vitamin D deficiency expands the sarcomeres space that 
allows the infiltration of irregular connective tissue and fat tissue. As such, the 
vitamin D deficiency resulting in reducing physical performance such as gait speed 
and cognitive performance (such as sustained attention and speed of informa-
tion processing), mental well-being (e.g., depression), falls and leading to bone 
deformities. The vitamin D deficiency is a serious medical condition that drastically 
affects the quality of life of older adults. There are a number of reasons that play 
a role in vitamin D deficiencies in older adults. Since the majority of the time they 
spend indoors, they get minimal exposure to sunlight, lacking resistance exercise 
which is well known to preserve muscle function, and their skin is less exposed to 
the synthesis of vitamin D [76, 77].
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3.3 Vitamin E
Vitamin E, which is a group of eight fat soluble compounds, four tocopherols 
(α, β, γ, and δ) and four tocotrienols (α, β, γ, and δ), is a lipid soluble vitamin, with 
potent antioxidant properties and has a role in the modulation of signaling path-
ways. The vitamin E molecules deficiency, due to malabsorption or malnutrition, 
worsens age-associated skeletal dysfunction and enhances muscle degeneration, 
thus increasing sarcopenia [78, 79].
4. Conclusions
This chapter reviewed the possible mechanisms that are linked to sarcopenia. 
The etiology of sarcopenia is multifactorial, including a wide range of both intra-
muscular and extra muscular factors. This chapter focuses only on the intramus-
cular factors that include oxidative stress, inflammation, lack of vitamins, and 
hormones. Extra muscular factors include adult stem cells, extra cellular matrix 
(e.g., the function of matrix metaloproteinases), capillary bed, and neuronal 
activity.
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The primary action of insulin in skeletal muscle is to stimulate glucose uptake 
and metabolism. In physiological condition as insulin resistance, there is a gradual 
muscle wasting by several mechanisms such as the following: (a) suppression 
of PI3K/Akt signaling leading to the activation of caspase-3 and the ubiquitin-
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to accumulate in skeletal muscle [71, 72]. It has been reported that IGF-I drops 
1.88 ng/ml/year in men and 2.13 ng/ml/year in women [73]. Circulating IGF-I level 
was found to be significantly reduced in sarcopenia patients [74]. mTOR signaling 
is a significant factor in sarcopenia, and mTOR signaling is altered by the change 
of IGF-I level [75].
Various medical problems and health conditions such as muscle weakness 
reduced the muscle mass that is predominantly a type II muscle fiber, bone pain, 
and systematic oxidative stress linked to 1,25-dihydroxyvitamin D [1,25(OH)2D]/
vitamin D deficiency. The vitamin D deficiency expands the sarcomeres space that 
allows the infiltration of irregular connective tissue and fat tissue. As such, the 
vitamin D deficiency resulting in reducing physical performance such as gait speed 
and cognitive performance (such as sustained attention and speed of informa-
tion processing), mental well-being (e.g., depression), falls and leading to bone 
deformities. The vitamin D deficiency is a serious medical condition that drastically 
affects the quality of life of older adults. There are a number of reasons that play 
a role in vitamin D deficiencies in older adults. Since the majority of the time they 
spend indoors, they get minimal exposure to sunlight, lacking resistance exercise 
which is well known to preserve muscle function, and their skin is less exposed to 
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Clinical Relations of Sarcopenia
IGP Suka Aryana
Abstract
Sarcopenia is one of geriatric syndromes, characterized by decreased muscle 
mass accompanied by decreased muscle strength and/or performance. It is more 
prevalent with increase in age, and the prevalence depends on the criteria applied 
and the characteristic of the elderly. Sarcopenia has a higher risk of morbidity and 
mortality in elderly patients. The definition criteria of sarcopenia are still contro-
versial, but diagnostic criteria from the Asian Working Group for Sarcopenia and 
the European Working Group on Sarcopenia in Older People (EWGSOP) are the 
most used criteria for clinical practice. Pathogenesis sarcopenia involved a mul-
tifactorial process and is divided into intrinsic and extrinsic factors. Risk factors 
for sarcopenia include constitutional factors, aging, lifestyle, changes in body 
condition, and chronic diseases. Based on that, sarcopenia is divided into primary 
and secondary sarcopenia. There are three stage of sarcopenia, which are pre-
sarcopenia, sarcopenia, and severe sarcopenia. Nutrition and exercise are the two 
main pillars to manage sarcopenia.
Keywords: sarcopenia, elderly, clinical, muscle, morbidity
1. Introduction
The consequences of sarcopenia due to aging are often not getting noticed. 
Sarcopenia, which is characterized by decreased muscle mass accompanied by 
decreased muscle strength and/or performance, is often regarded as an ordinary 
physiological change due to aging. Muscles that have a mass of nearly 50% of the 
body mass are very important because besides serving as a body movement tool, 
they also are endocrine organs (secrete proteins called myokines that affect the 
metabolism of bodies systematically) and protective organs (counteract the nega-
tive effects of body fat). If muscle mass decreases, then the protective function of 
the body will be disrupted.
As age increases, the prevalence of sarcopenia also increases, where at an age 
of 65–70 years, the prevalence is between 13 and 24%, and at the age of more than 
80 years, it is more than 50% [1]. The prevalence of sarcopenia based on gender at 
the age of 60–69 years is found in 10% of men and 8% of women, while in those 
over 80 years, it is in 40% of men and 18% of women [2]. The prevalence also differs 
based on the health-care setting. In acute care hospitals (age > 65 years), the preva-
lence is 10%. In long-term care facilities (age > 70 years), it is 33%, and in commu-
nity-dwelling elderly (age ≥ 60 years), it is 29% [3]. It is difficult to obtain the typical 
prevalence of sarcopenia because it depends on the definition applied and character-
istics of the elderly, but in the results from large-scale studies involving 1000 or more 
participants, the prevalence rate is estimated to be between 6 and 12% [4].
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Sarcopenia is a risk factor for adverse outcomes in the elderly, including frailty, 
fractures, falls, and mortality. Sarcopenic elderly patients have a higher risk of 
cardiovascular death, especially patients with obesity. In cancer patients, sarcopenia 
reduces the survival rate [4, 5]. Sarcopenia is also associated with a large health 
expenditure which, in the USA (in 2000), is reported to be approximately $18.5 
billion ($10.8 billion for men and $7.7 billion for women) [6].
This chapter will discuss mainly about the clinical relations of sarcopenia as well 
as its definition, pathogenesis, risk factors, diagnosis, stage, and its management.
2. Definition and terminology of sarcopenia
Sarcopenia is a syndrome characterized by progressive, complete loss of mass, 
strength, and/or skeletal muscle performance that is at risk of causing physical 
disability, low quality of life, and death [7]. Based on the Asian Working Group for 
Sarcopenia (AWGS), elderly with low muscle mass coupled with low grip strength 
and/or low walking speed are diagnosed with sarcopenia [8]. The rationalization 
of the use of muscle mass and strength separately on sarcopenia criteria is because 
muscle strength does not depend solely on muscle mass and the relationship 
between strength and muscle mass is not linear. Therefore, defining sarcopenia only 
from muscle mass considered is to be narrow and of limited clinical value [9].
Another opinion states that there is another term for stating muscle assessment, 
dynapenia. Dynapenia can be defined as a syndrome of loss of muscle strength 
related to age but not caused by neurological or muscular disease. In determining 
the mechanism of dynapenia, it is different from the mechanism of sarcopenia. The 
incidence of sarcopenia is determined by multifactorals characterized by a decrease 
in muscle mass, strength, and/or performance, while dynapenia is determined by 
only one factor, namely muscle weakness.
Muscle weakness is one of the factors involved in the etiology of dynapenia 
which causes functional limitations or physical disabilities. The determination of 
dynapenia starts with screening individuals over 60 years of age. For groups with 
high risk, knee extension strength assessment should be carried out to establish the 
diagnosis of dynapenia, while in the low-risk group it is recommended to take grip 
strength assessment measurements to confirm the results of the previous screening. 
Nevertheless, sarcopenia is more widely studied and discussed than dynapenia [10].
3. Pathogenesis of sarcopenia
There are several mechanisms involved in the progression of sarcopenia 
(Figure 1). These mechanisms involve protein synthesis, proteolysis, neuromuscu-
lar integrity, and mobility of nutritional status. In individuals with sarcopenia, vari-
ous mechanisms may be involved and their contribution varies relative to time [7]. 
Walston also believes that there is a multifactorial process that triggers sarcopenia. 
These triggers include chronic illness, fat infiltration, physical inactivity, hormonal 
changes, energy, protein intake, oxidative stress, and inflammatory processes. The 
inflammatory process is recognized as a basic mechanism that results in the stimu-
lation of muscle protein catabolism [11].
When viewed from simpler pathogenesis, sarcopenia is divided into two 
factors, namely intrinsic and extrinsic factors. Intrinsic factors consist of 
accumulation of pro-inflammatory cytokines, oxidative stress, mitochondrial 
dysfunction, insulin resistance, and disorders of motor neuron endplates. While 
extrinsic factors consist of radiation, nutrition, drugs consumed, smoking 
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behavior, infection, social environment, and physical activity. The interaction of 
intrinsic and extrinsic factors occurs in a complex, simultaneous, and dynamic 
manner. Every elderly person who experiences sarcopenia will have specific 
and individual interactions. In the end, the condition occurs as an imbalance 
of protein metabolism between degradation/catabolism and protein synthesis/
anabolism. Sarcopenia occurs due to high protein catabolism accompanied by 
low protein anabolism [12]. High catabolism often results from chronic inflam-
mation in the elderly. The elderly experience an immunosenescence condition 
that causes chronic inflammatory conditions of a low degree. In this condition, 
the body will be exposed to long-term pro-inflammatory cytokine mediators. 
Pro-inflammatory cytokines such as TNF-α will trigger muscle cell apoptosis in 
the elderly [13]. While protein metabolism decreases due to decreased protein 
intake and physical activity as well as decreased IGF-1 and growth hormone due 
to the process.
4. Risk factors for sarcopenia
Sarcopenia is a geriatric syndrome that is influenced by various factors including 
the following [7].
4.1 Constitutional factor
Constitutional factors are factors that are inherently closely related to humans, 
such as age, sex, and genetics. Age affects the occurrence of sarcopenia. The 
prevalence of sarcopenia increases with age, and even more than 45% of people 
over 80 years of age experience sarcopenia [14]. Decreased estrogen levels during 
menopause can cause a decrease in bone density, muscle mass, and muscle strength. 
In this case, the hormonal role of menopause is related to sarcopenia [15]. A study 
of 1971 elderly people in Kashiwa City, Chiba, Japan, showed differences in the 
prevalence of sarcopenia by sex, where in men it was 14.2%, while in women it was 
22.1% [16]. Reverse results can be obtained elsewhere due to the differences in hab-
its, activities, and nutritional intake. Several genes are related to lower limb muscle 
strength such as the growth differentiation factor 8 (GDF8) gene, cyclin-dependent 
kinase inhibitor 1 A (CDKN1A), and myogenic differentiation antigen 1 (MYOD1). 
Besides that, ciliary neurotrophic factor gene variant (CNTF A allele) is associated 
with loss of muscle strength [17].
Figure 1. 
Mechanisms of sarcopenia [7]. Note: Growth hormone (GH); insulin-like growth factor 1 (IGF-1).
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4.2 Aging factor
The consequences of the aging process cause changes in the body system that 
is different for every human being. The aging process causes several changes in 
the human body system associated with sarcopenia, such as loss of neuromus-
cular function, changes in endocrine function, increased production of pro- 
inflammatory cytokines, and mitochondrial dysfunction. The aging process causes 
a decrease in the coordination of muscle work and a decrease in muscle strength 
due to a decrease in the number of alpha motor neurons and motor units. The 
aging process also results in atrophy of type II muscle fibers. Type II muscle fibers 
are found in large muscles that are important for basic activities such as getting 
up, going upstairs, and balance. Also, there is structural damage and decreased 
neuronal function at the motor center to the neuromuscular junction. Good muscle 
contraction requires the optimal functioning of the neuromuscular system because 
muscle tissue and nerve tissue are closely related to form motor neurons [18–20].
4.3 Lifestyle
The current lifestyle affects the incidence of sarcopenia in the elderly. Decreased 
food intake, especially protein, accompanied by less physical activity increases 
the risk of sarcopenia. Physical activity in the elderly experiences setbacks due to 
technological advancements such as elevators, escalators, vehicles, and others. Food 
consumption in the elderly is also changing, which tends to increase the consump-
tion of fast food that is high in calories and fat. Optimal nutrition, especially 
protein, is needed to maintain muscle mass. Geriatric patients require a minimum 
of 1.2–2.0 g of protein/kilogram of body weight per day [21].
4.4 Changes in body condition
Prolonged bed rest increases the risk of sarcopenia. This is due to the lack of 
physical activity and mobility; immobility and underweight increase the risk of 
sarcopenia due to increased protein catabolism.
4.5 Chronic disease
Chronic diseases such as diabetes, advanced organ failure, cognitive impair-
ment, and mood disorders cause chronic inflammation that can cause sarcopenia.
5. Diagnosis of sarcopenia
The diagnosis of sarcopenia is based on various risk factors reinforced by 
muscle weakness, fatigue, low endurance associated with decreased walking speed, 
impaired movement, and inability to perform daily tasks. The problem of diagnosis 
arises due to the variety of these sizes when viewed from age, race, and gender. 
There has not been much great research and precise accuracy to get a normal cutoff 
point. These sizes differ based on race and gender. Some researchers and research 
working groups also issued mixed figures.
Based on the European Working Group on Sarcopenia in Older People 
(EWGSOP), a criterion for sarcopenia is a loss of muscle mass coupled with one 
of the two conditions, namely loss of muscle strength and or loss of performance 
[7, 22]. In 2014, AWGS also issued a consensus with the same criteria with only 
changes in the size of the normal value. The other criteria for defining sarcopenia 
from the international society are listed in Table 1.
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Sarcopenia measurement parameters consist of measurements of muscle mass, 
muscle strength, and function or physical performance (physical performance). 
In clinical practice, diagnosis can follow the algorithm set by AWGS in 2014, as 
shown in Figure 2. The normal threshold check requirements are clearly explained 
in Table 2. Experts often experience differences of opinion for difficulty in getting 
a normal value or cutoff and determining the best inspection technique to get the 
most accurate results.
5.1 Muscle mass
Measurement of muscle mass can be done by using computed tomography 
(CT), magnetic resonance imaging (MRI), and dual energy X-ray absorptiometry 
(DXA). The use of CT and MRI in muscle mass measurement is the measurement 
method that has the best accuracy because the measurement can distinguish fatty 
tissue from other soft tissues, but this measurement requires expensive costs [27]. 
Other measurements using DXA can provide results of body fat composition, bone 
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Table 1. 
Diagnostic criteria for sarcopenia from various international societies.
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mineral, and fat-free body mass. The disadvantages of this technique are that the 
tools used are not portable [28]. While anthropometric measurements are very easy 
to do, it is not recommended to diagnose sarcopenia because it has a very high error 
rate. Anthropometric measurements are performed by measuring the circumfer-
ence of the upper arm (LLA) or the circumference of the calf [27, 29]. Measurement 
of muscle mass is made using bio-impedance analysis (BIA), which is chosen for 
both research and clinical practice. Measurement using BIA has a good correlation 
value with MRI measurement in measuring body fat mass and body fat-free mass. 







Muscle strength Grip strength tests
• Man <26 kg
• Woman <18 kg
Physical performance Walking speed <0.8 m/s
Table 2. 
Measurement of sarcopenia according to the Asian working Group for Sarcopenia [8].
Figure 2. 
Sarcopenia diagnosis algorithm based on the Asian working Group for Sarcopenia [8].
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The most ideal muscle mass calculation for sarcopenia is based on the skeletal mass 
index (SMI), which is formulated by the appendicular skeletal mass (in kg) divided 
by height (in m2). If there is a decrease in two deviations of muscle mass index/skel-
etal mass index (SMI) from the mean SMI population of young men and women, 
then it can be categorized as a decrease in muscle mass [7].
5.2 Muscle strength
Muscle strength can be measured in several ways, namely the grip strength test, 
knee extension test, and peak expiratory flow (PEF). The grip strength test is a 
simple examination so it is both used for clinical practice and research. Studies show 
this examination has a good correlation with inferior limb strength, mobility, and 
daily living activities (ADL). Examination of the knee extension is as good as a grip 
strength test, but this examination requires equipment and training in advance so it 
is not good for clinical practice. In peak expiratory flow (PEF) tests, it is very good 
for measuring respiratory muscle strength but cannot be used to measure the overall 
muscle strength [7]. The criterion for decreasing muscle strength according to the 
AWGS is less than 20 percentile of the mean population of grip strength tests [8].
5.3 Physical performance
An examination of physical performance is an examination of muscle func-
tion by performing physical activity. There are several ways of checking physical 
performance, such as the Short Physical Performance Battery (SPPB), walking 
speed, a 6-min walk test, time up and go test, and the strength of climbing stairs. 
Inspection with Short Physical Performance Battery (SPPB) is a standard inspec-
tion for physical performance. This check is carried out to evaluate balance, path, 
strength, and endurance. SPPB is done by assessing the ability to stand on both legs, 
in semi-tandem and tandem positions, the time needed to walk 8 ft, and the time 
No Component Question Answer
1 S = Strength How difficult it is for the patient to 
lift or carry objects weighing 5 kg?
0 = No difficulties
1 = A little difficult




How difficult is it for sufferers to 




2 = Very difficult, need help, 
or cannot do without help
3 R = Rise from a chair How difficult it is for the sufferer 




2 = Very difficult, need help, 
or cannot do without help




2 = Very difficult or cannot do 
without help
5 F = Falls How many times has the patient 
fallen in the past year?
0 = Not dropped in the past year
1 = Fell 1–3 times in the past year
2 = Fell 4 times in the past year
Table 3. 
Strength, assistance walking, rise from a chair, climb stairs, and falls [34].
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1 S = Strength How difficult it is for the patient to 
lift or carry objects weighing 5 kg?
0 = No difficulties
1 = A little difficult




How difficult is it for sufferers to 




2 = Very difficult, need help, 
or cannot do without help
3 R = Rise from a chair How difficult it is for the sufferer 




2 = Very difficult, need help, 
or cannot do without help




2 = Very difficult or cannot do 
without help
5 F = Falls How many times has the patient 
fallen in the past year?
0 = Not dropped in the past year
1 = Fell 1–3 times in the past year
2 = Fell 4 times in the past year
Table 3. 
Strength, assistance walking, rise from a chair, climb stairs, and falls [34].
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needed to get up from a seat and get back to sitting for as much as five cycles [30]. 
Based on AWGS recommendations, physical performance can be measured by a test 
of running as far as 5 m. Walking speed provides predictive value for the condition 
of disability and predicts the course of the disease [31, 32]. Time to get up and go 
test is a method of measuring physical performance in the elderly by using subjects 
rising from a chair, walking at a close range, returning, and sitting as before [33]. 
Stair climb power test is used as a method for assessing foot impairment. But the 
stair climb power test is only used for research [7].
Currently, there is a questionnaire for Strength, Assistance walking, Rise from a 
chair, Climb stairs, and Falls (SARC-F), which can be used to detect early sarcope-
nia quickly and it has high specifications. This is because the diagnosis of sarcopenia 
using the SARC-F questionnaire does not require certain other measurement tools. 
This criterion is subjective only by conducting careful and thorough interviews. 
The SARC-F questionnaire has a good specificity and sensitivity in identifying the 
presence of sarcopenia. The sarcopenia category is defined if the SARCF score > 4, 
as shown in Table 3 [34].
6. Category and stage sarcopenia
Sarcopenia is a condition with many different causes and outcomes. In some 
individuals, a single cause of sarcopenia can be identified, but in other cases, 
clinicians can fail to identify the cause of sarcopenia. To facilitate clinical practice, 
sarcopenia is categorized into primary and secondary sarcopenia (Table 4). The 
etiology of sarcopenia can be multifactorial in the elderly, so there is a possibility 
that a person belongs to the primary, secondary, or both types of sarcopenia [7].
Sarcopenia stage is divided into three types based on the condition of muscle 




No other cause evident except aging
Secondary sarcopenia
• Activity-related sarcopenia
Can result from bed rest, sedentary lifestyle, deconditioning,  
or zero-gravity conditions
• Disease-related sarcopenia Associated with advanced organ failure (heart, lung, liver, kidney, 
and brain), inflammatory disease, malignancy, or endocrine disease
• Nutrition-related sarcopenia Results from inadequate dietary intake of energy and/or protein, as 
with malabsorption, gastrointestinal disorders, or use of medications 
that cause anorexia
Table 4. 
Category of sarcopenia by cause [7].
Stage Muscle mass Muscle strength Performance
Presarcopenia Decreased
Sarcopenia Decreased Decreased or normal Decreased or normal
Severe sarcopenia Decreased Decreased Decreased
Table 5. 
Stage of sarcopenia [7].
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7. Management of sarcopenia
Sarcopenia is a condition caused by a variety of complex factors. Therefore, a 
Geriatric Patient Full Assessment (P3G) for the management of sarcopenia should 
be carried out interdisciplinary with a focused and comprehensive intervention. 
P3G aims to improve physical and psychological patients, optimize drug admin-
istration to reduce the incidence of hospitalization and the risk of mortality, and 
increase patient satisfaction. P3G is carried out with an interdisciplinary team 
consisting of geriatric doctors, nurses, social workers, pharmacists, and physio-
therapists who make plans for integrated care [17].
Diet control and physical training such as resistance training and stretching have 
a positive impact on sarcopenia associated with chronic diseases such as diabetes 
mellitus, hypertension, and coronary heart disease. Besides, psychological sup-
portive therapy is needed for the management of sarcopenia because psychological 
factors of patients with sarcopenia are important in both prevention and recovery. 
Here are some recommendations for the management of sarcopenia [35]:
a. Multimodal therapy can be carried out with balanced energy and protein 
supplementation for the prevention and recovery of sarcopenia. The recom-
mended total protein intake is 1–1.5 g/kg/day.
b. The recommended protein consumption is of good quality such as the amino 
acid leucine.
c. Creatine supplementation to enhance the physical exercise effects of sarcope-
nia patients.
d. Vitamin D supplementation with doses above 100 nmol/L. A dose of vitamin D 
is given up to 50,000 IU per week.
e. Resistance and aerobic exercise are done for 20–30 min, 3 times a week.
A protein diet is an important key needed to prevent a progressive reduction in 
muscle mass. Its mechanism of action is by preventing a negative nitrogen balance. 
The recommended diet for healthy people is 0.8 g/kg/day (RDA =  recommended 
diet allowance). In the elderly >70 years, 40% of the protein diet is less than the 
RDA. In elderly patients with sarcopenia, the minimum recommended diet is 
according to the RDA (0.8) and will be increased to 1–1.5 g/kg/day by the increase 
in physical activity and comorbidities. Adequate protein intake in the elderly 
over 70 years has a positive effect on the ability to maintain muscle reserves and 
prevent sarcopenia. The positive effect is because the protein diet stimulates 
insulin-like growth factor 1 (IGF-1). Increased levels of IGF-1 as a result of this 
diet have an impact on preventing decreased protein synthesis and decreased 
muscle mass [36].
The use of creatine as a treatment for sarcopenia is still controversial because 
several studies have different results. In one study, the results showed that the 
elderly who took creatine supplements followed by endurance training experienced 
an increased muscle mass and strength. However, other studies show conflict-
ing results, where creatine supplementation does not affect the muscle mass and 
strength [37].
Vitamin D levels can affect the incidence of sarcopenia. Some data show that 
inadequate levels of vitamin D can reduce muscle function and are associated with 
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sarcopenia. Low levels of 25 (OH) D are associated with lower muscle mass, lower 
functional test results and can be used to predict muscle mass loss which will be 
one of the causes of disability. Lack of vitamin D is associated with poorer muscle 
function and loss of muscle mass [17].
Important physical activity becomes a pillar of conventional management that is 
very profitable. Large observational studies such as the British Regional Heart Study 
(BRHS), the Third National Health and Nutrition Examination Survey (NHANES 
III), and the Cardiovascular Health Study (CHS) show an inverse relationship 
between CRP concentration and physical activity in the elderly. The Health Aging 
and Body Composition (Health ABC) Study also found a linear tendency to 
decrease TNF with increased physical activity [9]. Therefore, physical activity is 
very necessary for the management of sarcopenia. The management of sarcopenia 
through physical activity must be designed with specific guidelines so that it gradu-
ally burdens muscles and makes positive adaptations. This should also be noted in 
physiology related to age and aging to avoid injury. Physical exercise in sarcopenia 
patients is focused on dynamic movements that target the major or major muscle 
groups such as knee and hip extensors through intrinsic and eccentric movements. 
The period of heating and cooling in the elderly is sought to last 15–20 min when 
heating and 10–15 min when cooling [38].
Management of other sarcopenia is still under studies, such as the therapeutic 
approach of using testosterone, estrogen, dehydroepiandrosterone (DHEA), and 
angiotensin-converting enzyme inhibitors (ACE inhibitors) [17].
8. Conclusions
Sarcopenia is more prevalent in older patients, especially men, and is defined 
by decreased muscle mass with decreased muscle strength and/or performance. 
Sarcopenia can cause multiple morbidities in the elderly, including frailty, fractures, 
falls, and even death. There are multifactorial factors (divided into intrinsic and 
extrinsic factors) that trigger sarcopenia, but the inflammatory process is recog-
nized as a basic mechanism. Constitutional factors, aging, lifestyle, changes in body 
condition, and chronic diseases are considered as risk factors for sarcopenia in the 
elderly. Diagnostic criteria for sarcopenia are still under controversy since there 
is a variety of the component because it differs based on race and gender. Criteria 
from EWGSOP and AWGS are the most widely used. Currently, SARC-F question-
naires can detect early sarcopenia and have high specifications. In clinical practice, 
sarcopenia is categorized into primary and secondary sarcopenia and is divided 
into three stadiums, which are pre-sarcopenia, sarcopenia, and severe sarcopenia. 
Management of sarcopenia should be interdisciplinary with a focused and com-
prehensive intervention. Nutrition and physical training are the most important 
therapies for sarcopenia in the elderly.
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Abstract
Muscle mass is maintained through an interplay between anabolic and catabolic 
pathways. The ubiquitin-proteasome system plays an important role in the proteoly-
sis progress during skeletal muscle atrophy which can be blocked by some protea-
some inhibitors. But few studies have demonstrated the ability of these inhibitors 
to preserve muscle mass and architecture under catabolic condition in vivo. The 
insulin-like growth factor-1/phosphatidylinositide 3-kinases/protein kinase B/
mammalian target of rapamycin (IGF-1/PI3K/Akt/mTOR) pathway was associ-
ated with anabolic pathways. The activation of IGF-1 causes muscle hypertrophy; 
however, it cannot be used as a drug target. Myostatin pathway maintains activation 
that can induce skeletal muscle atrophy involved with various transcriptional and 
genetic factors. Skeletal muscle atrophy is a debilitating consequence of multiple 
chronic diseases and conditions that involve starvation. It reduces treatment options 
and positive clinical outcomes as well as compromising quality of life and increasing 
morbidity and mortality. Though considerable research has been undertaken to find 
the drug target and the molecular mechanisms that improve skeletal muscle atro-
phy, no drug was approved to treat skeletal muscle atrophy. However, these years, 
the signaling pathways involved in muscle atrophy were clarified and some effective 
treatments were currently available to prevent, attenuate, or reverse muscle atrophy 
for experiment research.
Keywords: muscle atrophy, sarcopenia, cachexia, anabolic, catabolic
1. Introduction
The pathophysiology of skeletal muscle atrophy is multifactorial, with cancer, 
sepsis, renal and cardiac failure, acquired immune deficiency syndrome (AIDS) and 
chronic obstructive pulmonary disease (COPD) as well as inactivity or during aging 
[1–3]. These factors gradually lead to muscle wasting and weakness by decreasing 
protein synthesis and accelerating protein degradation, which are characterized 
by substantial decrease in myonuclear number, muscle fiber cross-sectional area, 
muscle strength and protein content while increasing in fatigability and resistance 
to insulin [4, 5]. Muscle atrophy is recognized as an independent predictor of 
mortality and is associated with functional impairment and poor quality of life [6].
Studies have revealed that different types of molecular mediators/catabolic 
players such as pro-inflammatory cytokines i.e. tumor necrosis factor-α (TNF-
α), interleukin-6 (IL-6), interleukin-1 (IL-1), interferon gamma (IFN-γ) and 
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TNF-like weak inducer of apoptosis (TWEAK), eicosanoids and transforming 
growth factor-β (TGF-β) family effectors (such as activin A and myostatin) are 
involved in skeletal muscle atrophy under above mentioned clinical settings [7–9]. 
These cytokines binding to their respective receptor results in activation of several 
catabolic pathways including nuclear factor-kappa B (NF-κB), Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) pathways and small mothers 
against decapentaplegic homolog 2/3 (SMAD2/3). In addition to cytokines, growth 
factors such as insulin-like growth factor-1 (IGF-1) signal through anabolic pathway 
(phosphatidylinositide 3-kinases/protein kinase B/mammalian target of rapamycin; 
PI3K/Akt/mTOR) to mediate functional repression of the transcription factors fork-
head box protein O1 (FoxO1) or FoxO3 by inhibiting their nuclear translocation and 
overall levels, which together inhibit the transcription of muscle atrophy genes [10].
In spite of many promising therapeutic targets for improving skeletal muscle 
atrophy, no treatment has been successful to date. In this chapter, we classify the 
potential drugs currently in laboratory/preclinical research into four categories and 
then discuss their mechanism of action.
2. Anabolic medications
2.1 Androgen/androgen receptor modulators
Testosterone treatments increase muscle protein synthesis and fat free mass, and 
its effects on muscle are modulated by nutrition and exercise [11]. Several studies 
have shown the beneficial effects of testosterone supplementation on sarcopenia 
characteristics such as decreases in the muscle mass [12] and grip strength [13]. A 
study recently demonstrated that testosterone administration for 3 years in older 
men (over 60 years old) significantly improved stair-climbing power, muscle 
mass and power [14, 15]. Similarly, lower doses of testosterone supplementation 
in women with hysterectomy or chronic heart failure significantly increases lean 
body mass, 6-m walk time, chest press power and maximal voluntary contraction 
[16]. Evident showed that the effect of testosterone in improving skeletal muscle 
atrophy is related to the positive regulation of IGF-1 [12], wnt [17] and myostatin 
[18]. Although testosterone and its analogs can induce muscle growth and increase 
muscle strength [19], its clinical use is substantially limited by severe side effects 
including the increased risk of developing prostate hypertrophy, cancer, sleep apnea, 
 masculinization, thrombosis complication and behavioral abnormalities [20, 21].
Compared with testosterone, the selective androgen receptor modulator 
(SARM) binds to androgen receptors with differing levels of sensitivity [22], 
showed androgenic effects in some tissues (such as muscle and bone), and has no 
effect on other organs (such as prostate or skin), thereby limiting adverse reactions 
such as prostate hypertrophy or androgen production. Enobosarm (GTx-024), an 
orally bioavailable nonsteroidal SARM, has been shown to increase lean body mass 
in phase I and II clinical trials of cancer cachexia patients [23, 24]. Moreover, the 
stimulation of reproductive organs with enobosarm seems to be less pronounced 
compared to testosterone administration. However, the phase III clinical trial 
of enobosarm failed to meet its common primary endpoint of preserving lean 
body mass and physical function [25]. Phase I clinical trials using another SARM 
non-steroidal oral preparation LGD-4033/VK5211 also showed increased muscle 
mass, but there was no effect on fat mass [26]. The 4-aza steroidal drug MK0773 
(TFM-4AS-1) is a dual SARM and an inhibitor of 5α-reductase. Studies have 
shown that it can improve IGF-1 levels and muscle function in women, however, 
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the trial was terminated due to increased cardiovascular risk [27]. GSK2881078, 
which is assessed for its impact on muscle growth and strength, has completed its 
phase I trial [28] and phase II trial for the treatment of weakness caused by COPD 
(NCT03359473). The development of SARM drugs still requires long-term follow-
up and/or more effective and selective SARM trials to prove the safety and efficacy 
of SARM in improving physical function and health outcomes.
2.2 Ghrelin and its receptor agonist
Ghrelin is a growth hormone (GH)-releasing polypeptide that binds to the 
GH secretagogue receptor (GHSR-1α) and stimulates appetite by activating the 
neuropeptide Y (NY) in the hypothalamus and helps in regulation of body weight 
[29, 30]. Studies have shown that ghrelin can reduce dexamethasone, fasting, dener-
vation, cancer and cisplatin-induced muscle atrophy [31, 32]. In cachexia induced 
by lung adenocarcinoma, ghrelin treatment can reduce the expression of TNF-α, 
IL-1β, IL-6 and C-reactive protein, and inhibit skeletal muscle atrophy by restoring 
the expressions of the p-Akt and p-FoxO1, and reducing the expressions of p-p38 
mitogen-activated protein kinase and p-NF-κB in skeletal muscle of tumor-bearing 
mice [33]. A three-week clinical study of ghrelin therapy in cachexia patients with 
nausea, COPD and chronic heart failure (CHF) showed an increase in lean body 
mass and muscle strength [29, 34]. Although ghrelin plays a key role in stimulating 
appetite, gaining body weight and preventing muscle catabolism, its clinical efficacy 
is limited due to its half-life (0.5 h) and route of administration (intravenous) [35].
Ghrelin agonists (such as anamorelin) have the advantage of oral activity. 
Compared with ghrelin (0.5 h), it has a better half-life (7–12 h) [36]. A randomized, 
double-blind, placebo-controlled phase I clinical study showed that anamorelin 
gained body weight after 6 days of treatment [37]. In two phase II anamorelin trials 
in cachectic patients with advanced or incurable cancer [38] and two multinational 
phase III trials (ROMANA 1 and 2 trials) in cachectic patients with unresectable 
non-small cell lung cancer (NSCLC) [39], significant gains were recorded in lean 
body mass and body weight over 12 weeks, but there was no improvement in 
physical functions and hand-grip strength. Similarly, a multicenter, open-label, 
single-arm study investigated the efficacy and safety of anamorelin in advanced 
gastrointestinal cancer patients with cancer cachexia, and this study showed a posi-
tive effect of anamorelin on lean body mass, body weight, anorexia and patients’ 
nutritional status [40]. Furthermore, anamorelin treatment was well tolerated over 
12 weeks. Finally, two meta-analyses also strongly supported the positive effect of 
anamorelin on lean body mass and body weight [41, 42]. Recently, a single-center 
study on healthy young adults showed anamorelin elicited modest increases in 
hunger and achieved significant increases in hunger and caloric intake [43]. The 
findings are consistent with multi-center findings in cachectic cancer patients and 
expand the evidence supporting anamorelin as a potential intervention.
2.3 β-Adrenoceptor agonists
Muscle growth can also be stimulated by activation of G-protein coupled 
β2-adrenoreceptor (β2-AR), which causes protein kinase A activation [44] and 
thereby stimulating PI3K/Akt/mTOR signaling [45]. Formoterol is a β2-AR agonist, 
the administration of formoterol significantly increased the levels of follistatin 
and decreased the levels of myostatin and its receptors (activin receptor IIB, 
ActRIIB) in tumor-bearing rats, thereby regulating muscle mass loss [46, 47]. In 
addition to skeletal muscle, formoterol also shows a strong protective effect on the 
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β2-adrenoreceptor (β2-AR), which causes protein kinase A activation [44] and 
thereby stimulating PI3K/Akt/mTOR signaling [45]. Formoterol is a β2-AR agonist, 
the administration of formoterol significantly increased the levels of follistatin 
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ActRIIB) in tumor-bearing rats, thereby regulating muscle mass loss [46, 47]. In 
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heart muscle [48]. Clinical studies have also shown that formoterol treatment can 
increase the content of PGC-1α and mtDNA in skeletal muscle of COPD patients to 
enhance the oxidation process of skeletal muscle and improve exercise ability [49]. 
Clenbuterol is another β2-AR agonist and can improve skeletal muscle atrophy in 
a variety of muscle atrophy models dominated by denervation [50], immobiliza-
tion [51] and spinal cord injury [52]. However, due to concerns about potential 
cardiovascular side effects [44, 53], such as cardiac arrhythmia, there has been little 
interest in the clinical applications of β2-AR agonists for muscle atrophy treatment. 
Among them, espindolol may be a potentially attractive compound. It is a β1 recep-
tor antagonist, a partial β2 receptor agonist and also has 5-HT1a receptor activities. 
In old rats, espindolol has been shown to significantly increase muscle mass, while 
reducing fat mass without negatively affecting heart function [54]. In addition, it 
has also shown very promising results in phase IIa cancer cachexia studies leading to 
increased muscle mass and grip strength [55, 56].
3. Enzyme inhibitors
3.1 Cox2 inhibitors
Cox2 is a bifunctional enzyme with cyclooxygenase and peroxidase activities. 
Cyclooxygenase activity is responsible for the synthesis of prostaglandins (PGE2) 
from arachidonic acid, while peroxidase activity can produce adjacent carcinogens. 
Both Cox2 and PGE2 are downstream effectors of cytokine activity and medi-
ate cachexia [57]. A placebo-controlled study of celecoxib (Cox2 inhibitor) on 
cachectic patients with either head and neck or gastrointestinal cancer showed a 
significant increase of body mass and the quality of life [58]. In addition, a phase 
II non-randomized trial examined the efficacy and safety of celecoxib on cancer 
cachexia. Celecoxib administered at 300 mg/day for 4 months induced a significant 
increase of lean body mass, a decrease of serum TNF-α levels, and a trend toward a 
reduction of fatigue symptom [59]. Moreover, side effects such as grade 1/2 anemia, 
neuropathy and epigastralgia have been observed in only a few patients, and no 
grade 3/4 adverse events have been observed. Recently, a randomized double-blind 
clinical trial of combined treatment with megestrol acetate plus celecoxib versus 
megestrol acetate alone in cachexia-anorexia syndrome induced by gastrointestinal 
cancers was performed, however, this study failed to show that adding celecoxib 
(200 mg/day) to megestrol (320 mg/day) could enhance anti-cachexic effects of 
megestrol [60]. Meloxicam is another Cox2 inhibitor, and can suppress the expres-
sion of Cox2, Atrogin-1 and MuRF1 induced by lipopolysaccharide (LPS), and 
regulate the loss of muscle mass in rats by attenuating protein degradation [61]. In 
addition to cachexia, the administration of meloxicam can also inhibit the up-
regulation of Atrogin-1 and MuRF1 in the muscles of arthritis rats and improve the 
loss of muscle mass [62].
3.2 Histone deacetylase inhibitors
Trichostatin A (TSA) is a well-known class I and II histone deacetylase inhibi-
tor. Published data indicate that TSA regulates atrogenes level and controls muscle 
mass by reducing HDAC4 activity and myogenin expression, and increasing Dach2 
level under denervation condition (neuromuscular disorders) [63]. TSA treatment 
can improve body weight, myofiber cross-sectional area and myofiber number 
[64]. Recent report shows that TSA inactivates FoxO by inhibiting HDAC activity, 
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which leads to atrophy of skeletal muscle atrophy and contractile dysfunction [65]. 
In addition, under nutrition-deprived atrophy on C2C12 myotubes, TSA treatment 
leads to the suppression of FoxO target genes, including Lc3 (autophagy marker), 
MuRF1 and Atrogin-1 [66]. Similarly, TSA treatment can regulate muscle depletion 
by inhibiting the levels of Atrogin-1 and MuRF1 in dexamethasone-induced atro-
phic mice [63]. However, study shows that TSA treatment increased the expression 
level of follistatin (a negative regulator of skeletal muscle development), without 
retaining or increasing muscle mass in tumor-bearing mice [67]. Recent studies 
have shown that TSA can inhibit skeletal muscle atrophy and histomorphological 
alterations induced by unloading [68] and cigarette smoke (the main risk factor 
for COPD) [69]. Due to the contradictory findings, further research is needed to 
confirm the use of HDAC blockers to regulate atrophy.
3.3 PDE inhibitors
Torbafylline (HWA 448) is a xanthine derivative which acts as a phosphodi-
esterase (PDE) inhibitor [70]. Torbafylline treatment down-regulates the mRNA 
expression of cathepsin L, calpain and E3 ligases, and regulates the proteolytic 
pathway in burn-induced injury. In addition, the anti-atrophic effects of torbafyl-
line have been demonstrated in casting, denervation or cancer induced cachexia 
models [70–72]. Torbafylline inhibits PDE activity leading to stimulation of the 
anti-proteolytic effect in PDE4/cAMP/Epac/PI3K/Akt pathway-mediated muscle 
atrophy [73]. Pentoxifylline (PTX) is another xanthine derivative that is non-
selective in inhibiting PDE. Published data indicate that the administration of PTX 
under various pathological conditions in animal models (diabetes, tumors, sepsis) 
can stimulate the formation of cAMP, and by down-regulating calpain, cathepsin 
L and proteasome proteolytic system activity [74–76]. Other selective inhibitors 
of PDE, including rolipram and cilomilast have also been shown to reduce muscle 
atrophy in denervation and casting animal models [77, 78].
3.4 Angiotensin-converting enzyme inhibitors
ANGII induces muscle atrophy through several mechanisms including sup-
presses protein anabolism by reducing IGF-1 level and appetite, and promotes 
protein catabolism by increasing reactive oxygen species (ROS) and intermedi-
ate molecules (TNF-α, IL-6, glucocorticoids) in skeletal muscle [79]. In ACE-Is, 
enalapril treatment can reduce the risk of weight loss by>19% and delay the 
occurrence of cachexia by about 8 months [80]. Studies conducted in an old rat 
model show that the administration of enalapril can increase muscle strength and 
has a protective effect on age-related muscle degeneration [81]. Perindopril (an 
ACE inhibitor) has shown especially in a double-blind randomized controlled 
trial, which evaluated the effect of perindopril on the elderly 6-minute walking 
distance, thereby improving physical function, especially the 6-minute walk 
distance and reduced the incidence of hip fractures [82]. In subjects with dysfunc-
tion, perindopril improved exercise capacity to the extent reported after 6 months 
of exercise training [83]. However, the use of the perindopril in cachectic mice 
bearing colon-26 tumors to inhibit this pathway does not reduce muscle atrophy, 
nor does it increase the production of maximum muscle strength. Nonetheless, 
treatment with ACE inhibitors did enhance physical function and reduce fatigue 
of respiratory muscles. These effects appear to be due to a shift to a more oxidized 
muscle phenotype, as evident from increased oxidative enzyme capacity in the 
muscle cross-section [84].
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Thalidomide is a glutamic acid derivative with various pharmacological activities, 
such as anti-inflammatory, immunomodulatory, anti-angiogenic, anti-emetic and 
sedative effects. Report shows that thalidomide and its derivatives can inhibit Cox2 
and PGE2 synthesis induced by LPS in murine macrophages [85], and control systemic 
inflammation. In addition, evidence shows that thalidomide can reduce serum IL-6 
and CRP levels in patients with cancer cachexia [86, 87]. Another study showed that 
thalidomide can maintain the fast-twitch type myofibers by reducing the expression of 
TNF-α and TGF-β1 in soleus muscle of cholangiocarcinoma rats [88]. Down-regulation 
of NF-κB/iNOS pathway by chronic thalidomide treatment improves hepatopulmo-
nary syndrome and skeletal muscle atrophy in rats with biliary cirrhosis [89]. In addi-
tion to anti-inflammatory and anti-cachectic activity, thalidomide treatment (Phase 
II trial) also showed an effect on appetite in 64% of patients with advanced stage of 
cancer [87]. Studies reported that thalidomide (100 mg/day and 200 mg/day) treat-
ment showed a significant improvement in body weight and skeletal muscle atrophy 
in AIDS associated cachexia patients [90]. Similarly, another research team worked 
with pancreatic cachexia patients and observed a significant increase in body weight 
of patients treated with thalidomide [91]. The lack of benefits was mainly due to the 
drug toxicity of thalidomide including peripheral neuropathy, dizziness, constipation 
and rash, considering that 47% of patients receiving active treatment were unable to 
continue taking thalidomide due to side effects and disease-related morbidity [92].
4.2 Anti-IL-6/STAT3
Evidence has shown that antibodies against IL-6 or its receptor can effectively 
reduce skeletal muscle atrophy and cachexia in mouse models [93, 94]. Preliminary 
results of a phase II double-blind trial in patients with advanced NSCLC have 
shown that ALD518 (humanized IL-6 monoclonal antibody) can reverse fatigue 
and prevent muscle loss [95]. Tocilizumab is an IL-6 receptor (IL-6R) neutralizing 
antibody approved by the FDA for rheumatoid arthritis. It can destroy the binding 
of IL-6/IL-6R to GP130, and cause the decrease of JAK/STAT3 pathway activity, 
reduce B cell hyperactivity and lead to a dramatic normalization of the acute phase 
reactions [96, 97]. Pharmacologic inhibition of the IL-6R using tocilizumab anten-
nas skeletal muscle atrophy and function loss during infection [98]. Recently, a case 
of 65-year-old man who underwent percutaneous coronary intervention for acute 
myocardial infarction received tocilizumab led to prompt remission of Takayasu 
arteritis activity and improvement of left ventricular function and skeletal muscle 
atrophy [99]. Ruxolitinib, a JAK1/2 inhibitor, may protect muscle through on-target 
effects because it significantly reduces IL-6-induced STAT3 activation and myotube 
atrophy in vitro [100]. However, due to the inability to recruit qualified patients, 
the clinical trial of cancer patient study (NCT02072057) that investigating whether 
blocking downstream signaling of IL-6 by ruxolitinib improves muscle atrophy were 
terminated. In addition, there is evidence that C188-9 (a small molecule of STAT3 
inhibitor) can reduce skeletal muscle atrophy in tumor-bearing mice [101, 102], but 
there are no relevant clinical studies.
4.3 Anti-TNF-α
Studies have shown that the administration of anti-murine TNF IgG in rats 
bearing Yoshida AH-130 ascites hepatoma can reduce circulating TNF-α and 
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inhibit muscle protein degradation [103]. Similarly, injecting soluble TNF receptors 
(sTNFR1, a specific inhibitor of TNF-α) prevents the interaction of TNF-α with its 
receptor and attenuates ubiquitin transcription, reduce the waste of skeletal muscle 
and preserve body weight in cardiac cachexia [76]. A study reported the opposite 
effect of sTNFR1 on arthritic rat that it did not alter muscle mass and MuRF1 and 
Atrogin-1 gene expression [104]. Infliximab is a chimeric monoclonal antibody 
that blocks TNF-α action, thereby preventing its binding to cellular receptors and 
downstream immunological effects. A phase II study of the combined chemother-
apy drugs gemcitabine and infliximab did not show the benefit of maintaining lean 
body mass or survival in pancreatic cancer cachexia patients [105]. Interestingly, in 
clinical trials of Crohn’s disease patients with skeletal muscle atrophy or sarcopenia 
arising from chronic inflammation, significant gains were recorded in muscle 
volume and strength over 25 weeks of infliximab treatment [106, 107]. Etanercept 
is a recombinant fusion protein that acts as a decoy receptor to neutralize TNF-α, 
and has been used to treat inflammatory diseases including rheumatoid arthritis. In 
another study, significant weight gain was observed in rheumatoid arthritis patients 
who received etanercept twice a week for 12 consecutive months [108]. A phase I/II 
study compared the efficacy of etanercept with gemcitabine and gemcitabine alone 
for the treatment of advanced pancreatic cancer cachexia patients, and the results 
were also disappointing because the addition of etanercept did not improve symp-
toms of cancer cachexia [109].
4.4 Anti-IL-1α
MABp1 is a human antibody against IL-1α (a chronic inflammatory mediator) 
and has anti-tumor activity. Intravenous MABp1 treatment for 8 weeks in adults 
with metastatic solid cancer showed increased lean body mass and improved quality 
of life (fatigue, pain, and loss of appetite), and has no toxic; however, there was no 
control group in this study [110]. A randomized, double-blind, placebo-controlled 
phase III clinical study showed that MABp1 improved the lean body mass, anorexia, 
fatigue and pain scores in advanced colorectal cancer patients [111]. Another phase 
I dose-escalation study evaluating the IL-1α-targeted monoclonal antibody xilonix 
in patients with NSCLC showed increased lean body mass and improved symptoms, 
suggesting a clinically important response [112]. In view of this, a phase III placebo-
controlled study of human antibodies against IL-1α has been conducted in patients 
with advanced colorectal cancer to assess the remission rate of the disease, muscle 
mass and appetite. Xilonix was very well tolerated by NSCLC patients, with the 
clinically significant reductions in pain, fatigue and improved lean body mass and 
appetite [113]. However, the primary limitation of this report is the small number 
of patients which made any comparisons statistically difficult.
4.5 TWEAK/Fn14 inhibition
The inflammatory cytokine TNF-like weak inducer of apoptosis (TWEAK) 
and its related receptor fibroblast growth factor-inducible 14 (Fn14) play multiple 
roles in proliferation, inflammation and wound repair. TWEAK/Fn14 signaling also 
negatively regulates muscle growth and function [8]. Report showed that TWEAK 
activates noncanonical NF-κB pathway and promotes myoblast fusion at low con-
centrations (10 or 100 ng/ml), and activates canonical NF-κB signaling to inhibit 
differentiation at high concentrations (500 ng/ml). Thus, TWEAK can maintain 
myoblast differentiation at physiological conditions; however, under pathological 
conditions (such as denervation and disuse), TWEAK/Fn14 system becomes acti-
vated and causes muscle atrophy [8]. Blocking antibodies against TWEAK antibody 
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can improve muscle function in mice caused by myotonic dystrophy and amyo-
trophic lateral sclerosis (ALS) [114, 115]. Consistent with these findings, colon-26 
tumor-bearing mice treated with anti-Fn14 antibodies showed increased weight and 
muscle mass, improved muscle fatigue, and increased survival [116]. These results 
indicate that neutralizing antibodies against TWEAK and Fn14 should be further 
explored in various muscle atrophy models and clinical trials.
5. Other investigational drugs
5.1 Myostatin inhibition
Existing evidence indicates that members of the TGF-β superfamily, such as 
myostatin and activin A, are powerful catabolic stimuli that can inhibit muscle 
growth and promote muscle protein loss in various disease states [117]. It is reported 
that myostatin can improve the dystrophy phenotype of mdx mouse models, sarco-
penia in aging mouse models and muscle atrophy in tumor-bearing mice [118, 119], 
which can significantly inhibit systemic inflammation and prolong the survival of 
tumor-bearing mice without affecting tumor growth [117]. There are currently two 
main strategies for targeting myostatin signals: First, neutralize myostatin directly 
by using humanized myostatin antibody (LY2495655), and second, block ActRII 
by using soluble ActRIIB (ACE-031) or ActRII antibody (bimagrumab/BMY338). 
LY2495655 treatment had mixed results in elderly subjects: the appendicular lean 
body mass and gait speed were slightly improved, and despite increased muscle 
mass, grip strength was not affected [120]. However, a randomized, phase II trial in 
patients with pancreatic cancer, LY2495655 treatment have no significant improve-
ment in muscle volume or functional. Additionally, among possibly drug-related 
adverse events, fatigue, diarrhea, and anorexia were more common in LY2495655-
treated than in placebo-treated patients [121]. Soluble recombinant ActRIIB and 
other “ligand trap” interventions can generally inhibit TGF-β signaling and affect 
other tissues and processes, including reproduction and angiogenesis, with some 
causing severe off-target effects. Therefore, new strategies that target myostatin 
receptors and thereby reduce the activity of other ligands seem more promising. For 
example, after ACE-031 treatment, a group of 48 postmenopausal women gained 
weight and increased lean body mass [122]. However, in the phase II clinical trial 
conducted by ACE031 with Duchenne muscular dystrophy (DMD) patients and 
healthy volunteers, some participants experienced bleeding gums, nosebleeds, and 
skin vasodilation, which led to the interruption of the trial [123]. Blocking ActRII 
by administering BMY338 can greatly increase muscle mass and prevent dexameth-
asone-induced muscle atrophy in mice [124], and significantly improve patient’s 
lean body mass, muscle mass, and 6-minute walking test in patients with myositis 
after 8 weeks of treatment. However, no significant differences were observed after 
24 weeks of treatment [125]. In addition, there are no beneficial effects on these 
treatments were reported in cancer patients, while in COPD patients, muscle vol-
ume increases without affecting functional indicators, which is similar to the effect 
of BMY338 in sarcopenia patients [126, 127]. Therefore, these treatments seem to 
improve muscle mass and have less effect on muscle strength and other functional 
parameters [128].
5.2 Appetite stimulants
The FDA approved megestrol acetate (MA) as the treatment of cachexia caused 
by cancer and AIDS in 1993. More than 15 clinical trials have shown that this drug 
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can significantly improve appetite and lean body mass at a dose of 160–1600 mg/
day. MA can be used alone or as a supplement along with meloxicam in patients 
with cancer cachexia, showing a positive effect in controlling weight loss [129]. 
Although the mechanism of appetite stimulation/weight gain is unclear, studies 
have shown that it is related to the involvement of neuropeptide Y and the inhibi-
tion of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α [130, 131]. 
However, a newer meta-analysis started in 2015, which studied the use of non-
cancer cachexia (HIV, COPD, renal failure and geriatric cachexia) and concluded 
that progesterone therapy (MA or medroxyprogesterone acetate) has a negligible 
effect on weight gain when treat of non-cancer cachexia [132]. MA treatment can 
also cause serious side effects such as thromboembolism, peripheral edema, hyper-
glycemia, hypertension, adrenal suppression and adrenal insufficiency [132].
Previous studies have shown that cannabinoids have the potential to improve 
appetite, body weight and fat mass, as well as amelioration of quality of life in 
several chronic diseases including cancer [133]. The results of a pilot study con-
ducted in adult patients with advanced solid tumors showed that patients receiving 
delta-9-tetrahydrocannabinol (THC) treatment had a marked increase in appetite 
[134]. However, the study did not record changes in participants’ body weight and 
lean body mass, and a larger trial was needed to study the effect of cannabinoids 
on skeletal muscle atrophy. A pilot study in patients with advanced NSCLC showed 
food intake and quality of life in patients treated with nabilone (a tetrahydrocan-
nabinol) have improved significantly [135]. However, another randomized, double-
blind placebo-controlled trial showed that nabilone did not improve the symptoms 
of nausea during radiotherapy in head and neck cancer patients, nor did it have 
significant benefits for the appetite and body weight [136].
5.3 Natural compounds
Recently, growing evidence has shown that natural products play a key role in the 
prevention and treatment of skeletal muscle atrophy. Numerous studies conducted 
in vitro and in vivo confirmed that resveratrol treatment can prevent proteolysis-
inducing factor (PIF), angiotensin I and II, phorbol ester, 12-O-tetradecanoylphorbol 
13-acetate (TPA), and dexamethasone-induced protein degradation [137]. In addi-
tion, resveratrol has been shown to protect muscle atrophy under various catabolic 
conditions, including cachexia and disuse [138, 139]. Salidroside is one of the main 
phenylpropane glycosides found in Rhodiola rosea. Research shows that salidroside 
treatment can effectively maintain body weight, reduce fat and gastrocnemius 
muscle loss in CT26 and LLC models. Additionally, in combination chemotherapy, 
salidroside can synergistically enhance the anti-tumor activity of cisplatin, especially 
reduce or eliminate cachexia caused by chemotherapy. Further analysis showed that 
salidroside can significantly increase the expression of p-mTOR and MyHC in the 
gastrocnemius muscle [140]. Matrine improves skeletal muscle atrophy in CT26 
induced cachexia via inhibiting the production of TNF-α and IL-6 and activating 
the Akt/mTOR/FoxO3α signaling pathway [141]. Other natural medicines reported 
to improve skeletal muscle atrophy include imperatorin [142], parthenolide [143], 
ursolic acid [144] and cryptotanshinone [145], but more research is still needed to 
prove the anti-muscular atrophy effect of these compounds.
6. Conclusions
Up-regulation of muscle protein catabolic is a sign of atrophy, so most potential 
drugs target the proteolytic system to cure or prevent skeletal muscle atrophy. 
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Due to the multifactorial pathogenesis of muscle atrophy, combining new drugs 
with multimodal transport interventions including exercise methods and nutri-
tional interventions may be the most promising approach; however, few clinical 
trials have investigated this approach. In this light, a better understanding of the 
contributing factors and underlying mechanisms of muscle atrophy is essential for 
the development of targeted therapies, and new methods of combination therapy 
for muscle atrophy treatment are needed.
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Muscle atrophy occurs under a number of different conditions, including 
disuse and aging accompanied by the onset of sarcopenia. Although muscle mass is 
reduced by decreased protein synthesis and/or increased protein degradation, the 
mechanisms of disuse muscle atrophy and sarcopenia differ. Therefore, nutrition 
strategies need to be customized for each type of muscle atrophy. Difficulties are 
associated with assessing the efficacy of nutrients for preventing sarcopenia due to 
uncontrolled factors in human studies. We herein (a) summarize nutritional epide-
miology evidence related to sarcopenia from recent systematic reviews, (b) review 
nutrient supplementation for attenuating sarcopenia through dietary control, and 
(c) provide evidence for the efficacy of nutrient supplementation for treating disuse 
muscle atrophy under dietary control. Epidemiological studies have indicated that 
diets with a sufficient intake of beneficial foods are useful for preventing sarcope-
nia. Supplementation with vitamin D and leucine-enriched whey protein have been 
suggested to help attenuate sarcopenia in geriatric patients, particularly those who 
are unable to exercise. Further studies are needed to clarify the effects of protein 
and amino acid supplementation on muscle mass and strength. High-quality studies 
with controlled diets and physical activities are required to clarify the effects of 
nutritional interventions on both types of muscle atrophy.
Keywords: diet quality, muscle atrophy, disuse, sarcopenia, epidemiology
1. Introduction
Muscle mass and strength have been linked to overall health and mortality [1, 2], 
and improvements in skeletal muscle properties and the prevention of muscle wast-
ing with disuse/atrophy are essential for all individuals, particularly inactive older 
adults [3]. Sarcopenia is characterized by the loss of skeletal muscle mass and physi-
cal function (muscle strength or physical performance) with advancing age [4–6]. 
It is associated with physical disability, poor quality of life, and increased mortality 
in older adults [5]. Although the loss of muscle mass and physical function is associ-
ated with aging, rates of decline vary across the population [7]. Therefore, modifi-
able behavioral factors, such as diet, may influence the development of sarcopenia. 
Since a poor diet and nutritional status are common among the elderly [8–10], 
improvements in these factors may contribute to the prevention and treatment of 
sarcopenia, thereby promoting better health in later life for this population [11].
The term diet quality describes how well an individual’s diet conforms to dietary 
recommendations using a principal component or factor analysis [12, 13]. In older 
adults, a higher quality diet leads to several positive health outcomes, including a 
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Muscle atrophy occurs under a number of different conditions, including 
disuse and aging accompanied by the onset of sarcopenia. Although muscle mass is 
reduced by decreased protein synthesis and/or increased protein degradation, the 
mechanisms of disuse muscle atrophy and sarcopenia differ. Therefore, nutrition 
strategies need to be customized for each type of muscle atrophy. Difficulties are 
associated with assessing the efficacy of nutrients for preventing sarcopenia due to 
uncontrolled factors in human studies. We herein (a) summarize nutritional epide-
miology evidence related to sarcopenia from recent systematic reviews, (b) review 
nutrient supplementation for attenuating sarcopenia through dietary control, and 
(c) provide evidence for the efficacy of nutrient supplementation for treating disuse 
muscle atrophy under dietary control. Epidemiological studies have indicated that 
diets with a sufficient intake of beneficial foods are useful for preventing sarcope-
nia. Supplementation with vitamin D and leucine-enriched whey protein have been 
suggested to help attenuate sarcopenia in geriatric patients, particularly those who 
are unable to exercise. Further studies are needed to clarify the effects of protein 
and amino acid supplementation on muscle mass and strength. High-quality studies 
with controlled diets and physical activities are required to clarify the effects of 
nutritional interventions on both types of muscle atrophy.
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1. Introduction
Muscle mass and strength have been linked to overall health and mortality [1, 2], 
and improvements in skeletal muscle properties and the prevention of muscle wast-
ing with disuse/atrophy are essential for all individuals, particularly inactive older 
adults [3]. Sarcopenia is characterized by the loss of skeletal muscle mass and physi-
cal function (muscle strength or physical performance) with advancing age [4–6]. 
It is associated with physical disability, poor quality of life, and increased mortality 
in older adults [5]. Although the loss of muscle mass and physical function is associ-
ated with aging, rates of decline vary across the population [7]. Therefore, modifi-
able behavioral factors, such as diet, may influence the development of sarcopenia. 
Since a poor diet and nutritional status are common among the elderly [8–10], 
improvements in these factors may contribute to the prevention and treatment of 
sarcopenia, thereby promoting better health in later life for this population [11].
The term diet quality describes how well an individual’s diet conforms to dietary 
recommendations using a principal component or factor analysis [12, 13]. In older 
adults, a higher quality diet leads to several positive health outcomes, including a 
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reduced risk of common age-related diseases and greater longevity. For example, a 
high quality diet is associated with a significantly reduced risk of all-cause mortal-
ity, cardiovascular disease, cancer, type 2 diabetes, and neurodegenerative disease, 
as well as reduced mortality in cancer survivors [14–17].
While there is growing evidence linking healthier diets with greater muscle 
strength and better physical performance outcomes in older adults, limited infor-
mation is currently available on how diet quality influences sarcopenia in older 
adults [11, 18]. A recent systematic review concluded that the number of longitudi-
nal studies was too small to reach concrete conclusions; however, there is growing 
evidence for the benefits of adhering to a Mediterranean diet [19–21]. The next 
section summarizes current epidemiological evidence for the relationship between 
diet quality and sarcopenia in older adults.
2. Nutritional approaches for attenuating muscle atrophy
2.1 Nutritional epidemiology evidence related to sarcopenia
The world’s population is getting older [22]. Based on a 2017 report, the number 
of adults aged 60 years and older will increase worldwide, from 962 million (or 
one in eight individuals) in 2017 to 2.1 billion (one in five) by the middle of the 21st 
century [23]. Several environmental and lifestyle factors may modify the aging 
process [24], including physical activity [25, 26] and diet [27–29].
A large number of observational and intervention studies have used a single-
nutrient approach to investigate the relationship between diet and muscle health 
in aging. However, difficulties are associated with isolating the influence of one 
dietary component on health outcomes from other components as well as obtaining 
a clearer understanding of how dietary components interact within a whole diet to 
affect health outcomes. Previous studies using a whole-diet approach were con-
ducted to clarify the role diet quality plays in muscle health with aging [30–33].
Two main methods of defining diet quality—a priori (hypothesis-driven) 
and a posteriori (data driven)—have been used to investigate the relationships 
between diet quality and muscle health in epidemiological studies on muscle 
aging. The a priori method defines diet quality as adherence to predefined dietary 
scores or indices based on current knowledge on what constitutes a healthy diet 
for a particular health condition (e.g., cardiovascular disease or diabetes). In this 
method, higher scores reflect the greater consumption of beneficial foods (e.g., 
fruits, vegetables, lean meat, fish, nuts, and low-fat foods) and lower consump-
tion of nutrient-poor foods (e.g., sweets, processed meat, refined grains, and 
trans-fats) [34–36]. In contrast, the a posteriori method is exploratory, using all 
available dietary data to define diet quality. This method may be used to describe 
a population’s normal diet, which may or may not be related to particular health 
outcomes. In this method, multivariate statistical tools (e.g., a factor principal 
component analysis [PCA] and cluster analysis) may be used to assess diet 
quality. While these two tools follow markedly different procedures, they may 
be used in tandem to improve the interpretability of the data obtained from each 
method [37].
We reviewed nutritional epidemiology studies on the role of diet quality in 
muscle health and function in older adults (Table 1). Only eight studies reported 
a relationship between diet quality (i.e., the amount of nutrients consumed and/or 
the uptake of specific nutrients from foods) and sarcopenia components [38–45]. 
Five of these studies were cross-sectional, while three were longitudinal. Study 
sample sizes ranged between 156 and 2983 participants. The majority of studies 
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reduced risk of common age-related diseases and greater longevity. For example, a 
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trans-fats) [34–36]. In contrast, the a posteriori method is exploratory, using all 
available dietary data to define diet quality. This method may be used to describe 
a population’s normal diet, which may or may not be related to particular health 
outcomes. In this method, multivariate statistical tools (e.g., a factor principal 
component analysis [PCA] and cluster analysis) may be used to assess diet 
quality. While these two tools follow markedly different procedures, they may 
be used in tandem to improve the interpretability of the data obtained from each 
method [37].
We reviewed nutritional epidemiology studies on the role of diet quality in 
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were conducted in a community setting (e.g., a nursing home or care facility) and 
with participants whose mean age ranged between 65 and 75 years.
Robinson et al. examined the relationship between diet quality and grip strength 
in older men and women [38]. A food frequency questionnaire (FFQ ) based on 
the European Prospective Investigation of Cancer (EPIC) questionnaire was used 
to assess the subject’s diet. They used the FFQ that contained 129 foods and food 
groups and assessed the average frequency of the consumption of the listed foods 
over the three months preceding the interview. Nutrient intake for each food item 
consumed was calculated by multiplying the nutrient content listed in the UK 
national food composition database or manufacturer composition data. The 129 
foods listed in the FFQ were divided into 54 food groups based on similarity and 
nutrient compositions. The PCA of the reported weekly consumption frequencies 
of these food groups was used to define diet patterns. The prudent diet was charac-
terized by the high consumption of fruit, vegetables, whole grain cereals, and fatty 
fish and by the low consumption of white bread, chips, sugar, and full-fat dairy 
products. Participants with higher prudent diet scores had stronger grip strengths. 
In addition, an increase was observed in grip strength of 0.43 kg in men and 0.48 kg 
in women for each additional fatty fish portion consumed per week.
Martin et al. investigated the relationship between diet and physical perfor-
mance (measured using a short physical performance battery) in a group of men 
and women living in West Hertfordshire who were part of the Hertfordshire Cohort 
Study [39]. Nutrient intake for each food item consumed was calculated by multi-
plying the nutrient content listed in the UK national food composition database or 
manufacturer composition data. Higher prudent diet scores were related to shorter 
three-meter walk times and shorter chair-rise times in women. Additionally, inverse 
relationships were observed between physical function and the consumption of 
vegetables, whitefish, shellfish, and oily fish. These findings indicate that a rela-
tionship exists between diet variations in community-dwelling older women and 
differences in physical performance. However, further studies are needed to clarify 
the role of diet variations in physical performance, particularly in men.
Bollwein et al. examined whether the risk of frailty was significantly reduced in 
participants who scored in the highest quartile for Mediterranean diet consumption 
(MED) [40]. This scoring is an alternative to the MED scoring used by Fung et al. 
[46], who adapted the original MED score used by Trichopoulou et al. [47] for a 
non-Mediterranean population. They combined FFQ foods into nine nutritional 
characteristics, classified as either beneficial (vegetables, legumes, fruits, unre-
fined cereals, nuts, fish, high monounsaturated fatty acid [MUFA]/saturated fatty 
acid [SFA] foods, and moderate alcohol consumption) or detrimental (red and 
processed meats) to health, to calculate the score, and found an inverse correla-
tion between a low walking speed and MED scores. Moreover, a relationship was 
observed between high diet quality (high MED score) and slow walking speed in 
older men and women.
Rahi et al. investigated the relationship between diet quality and muscle strength 
changes over three years in diabetic participants aged 67 to 84 years [41]. Diet qual-
ity was evaluated at recruitment using the validated Diet Quality Index-Canada and 
nine-item Canadian Healthy Eating Index (C-HEI) [48]. Diet quality was calculated 
using data from the mean of three, non-consecutive, 24-hour dietary recalls col-
lected using the five-step, multiple-pass method [49]. The C-HEI has nine compo-
nents. The first four components evaluate the extent to which respondents meet age 
and gender-based recommendations for the number of portions eaten from each of 
the four groups of Canada’s Food Guide (grain products, vegetables and fruits, milk 
and alternatives, and meat and alternatives). The next four items reflect Canadian 
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were conducted in a community setting (e.g., a nursing home or care facility) and 
with participants whose mean age ranged between 65 and 75 years.
Robinson et al. examined the relationship between diet quality and grip strength 
in older men and women [38]. A food frequency questionnaire (FFQ ) based on 
the European Prospective Investigation of Cancer (EPIC) questionnaire was used 
to assess the subject’s diet. They used the FFQ that contained 129 foods and food 
groups and assessed the average frequency of the consumption of the listed foods 
over the three months preceding the interview. Nutrient intake for each food item 
consumed was calculated by multiplying the nutrient content listed in the UK 
national food composition database or manufacturer composition data. The 129 
foods listed in the FFQ were divided into 54 food groups based on similarity and 
nutrient compositions. The PCA of the reported weekly consumption frequencies 
of these food groups was used to define diet patterns. The prudent diet was charac-
terized by the high consumption of fruit, vegetables, whole grain cereals, and fatty 
fish and by the low consumption of white bread, chips, sugar, and full-fat dairy 
products. Participants with higher prudent diet scores had stronger grip strengths. 
In addition, an increase was observed in grip strength of 0.43 kg in men and 0.48 kg 
in women for each additional fatty fish portion consumed per week.
Martin et al. investigated the relationship between diet and physical perfor-
mance (measured using a short physical performance battery) in a group of men 
and women living in West Hertfordshire who were part of the Hertfordshire Cohort 
Study [39]. Nutrient intake for each food item consumed was calculated by multi-
plying the nutrient content listed in the UK national food composition database or 
manufacturer composition data. Higher prudent diet scores were related to shorter 
three-meter walk times and shorter chair-rise times in women. Additionally, inverse 
relationships were observed between physical function and the consumption of 
vegetables, whitefish, shellfish, and oily fish. These findings indicate that a rela-
tionship exists between diet variations in community-dwelling older women and 
differences in physical performance. However, further studies are needed to clarify 
the role of diet variations in physical performance, particularly in men.
Bollwein et al. examined whether the risk of frailty was significantly reduced in 
participants who scored in the highest quartile for Mediterranean diet consumption 
(MED) [40]. This scoring is an alternative to the MED scoring used by Fung et al. 
[46], who adapted the original MED score used by Trichopoulou et al. [47] for a 
non-Mediterranean population. They combined FFQ foods into nine nutritional 
characteristics, classified as either beneficial (vegetables, legumes, fruits, unre-
fined cereals, nuts, fish, high monounsaturated fatty acid [MUFA]/saturated fatty 
acid [SFA] foods, and moderate alcohol consumption) or detrimental (red and 
processed meats) to health, to calculate the score, and found an inverse correla-
tion between a low walking speed and MED scores. Moreover, a relationship was 
observed between high diet quality (high MED score) and slow walking speed in 
older men and women.
Rahi et al. investigated the relationship between diet quality and muscle strength 
changes over three years in diabetic participants aged 67 to 84 years [41]. Diet qual-
ity was evaluated at recruitment using the validated Diet Quality Index-Canada and 
nine-item Canadian Healthy Eating Index (C-HEI) [48]. Diet quality was calculated 
using data from the mean of three, non-consecutive, 24-hour dietary recalls col-
lected using the five-step, multiple-pass method [49]. The C-HEI has nine compo-
nents. The first four components evaluate the extent to which respondents meet age 
and gender-based recommendations for the number of portions eaten from each of 
the four groups of Canada’s Food Guide (grain products, vegetables and fruits, milk 
and alternatives, and meat and alternatives). The next four items reflect Canadian 
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nutritional recommendations for moderation: the daily percentage of energy from 
total fat, the daily percentage of energy from saturated fat, cholesterol intake (mg), 
and sodium intake (mg). The final component, dietary variety (adapted from the 
Dietary Diversity Score), was assessed as the daily consumption of at least one 
food from each food group. The findings obtained indicated that the combination 
of a high diet quality with stable or increased physical activity minimized muscle 
strength losses in diabetic older males over the three-year follow-up period.
Hashemi et al. investigated whether adherence to a particular dietary pattern 
was associated with sarcopenia among elderly adults in a district of Teheran, 
Iran [42]. A semiquantitative FFQ was used to survey the dietary intake of 300 
randomly-selected older men and women. They evaluated the dietary patterns of 
participants using PCA. Participants in the highest tertile of the Mediterranean 
dietary pattern had a lower odds ratio for developing sarcopenia than those in the 
lowest tertile. In contrast, adherence to the Western dietary pattern (characterized 
by the high consumption of sugar, soy, and fast foods) and mixed dietary pattern 
(characterized by the high consumption of animal proteins, potatoes, and refined 
grains) did not affect the odds of developing sarcopenia. These findings suggested 
that Mediterranean diet adherence was associated with a lower odds ratio for the 
development of sarcopenia among older Iranian individuals.
Granic et al. examined the relationship between previously established dietary 
patterns and declines in muscle strength and physical performance among older 
adults [43]. In total, 791 participants were followed for five years to detect changes 
in grip strength and timed up and go test (TUG) scores. Trained research nurses 
kept a detailed record of food intake on the previous day for each participant on 
two different days of the week, at least one week apart. Each food had a unique 
food code (>2000), and intakes were entered into a Microsoft Access-based dietary 
data system, then further grouped into 118 food groups based on McCance and 
Widdowson’s composition of foods [50, 51]. These 118 groups were combined into 
33 food groups based on food/nutrient composition similarities and then classi-
fied as either absent or present in each participant’s food intake. Participants were 
divided into three groups: dietary pattern 1 (DP1; high red meat); dietary pattern 2 
(DP2; low meat); and dietary pattern 3 (DP3; high butter). The findings obtained 
showed that men in DP1 had worse overall grip strength, whereas those in DP3 
had steeper grip strength declines than those in DP2. Additionally, TUG scores 
were significantly longer for men in DP1 and women in DP3 than those in DP2. 
Therefore, diets high in red meats, potatoes, gravy, and butter appear to adversely 
affect muscle strength and physical performance in later life.
Perälä et al. researched whether the consumption of a healthy Nordic diet for 
10 years was associated with improved physical performance measures [44]. After 
the diets of 1072 participants (mean age 67 years) had been examined using a 
validated 128-item FFQ, the a priori Nordic diet score was calculated. The diet items 
checked included Nordic fruits and berries, vegetables, cereals, low-fat milk, fish, 
red and processed meat, alcohol, polyunsaturated omega-3 fatty acids (PUFA)/
SFA and trans-fatty acids ratios, and total fat. Since participants had a mean age of 
71 years, their physical performance was measured using the Senior Fitness Test 
(SFT), and an overall SFT score was calculated. The findings obtained revealed that 
women with the highest diet scores had 17% better in that of walk, 16% better in 
that of arm curl, and 20% better in that of chair-stand than women with the lowest 
diet scores. These findings indicated that women who consumed a healthy Nordic 
diet had better physical performance (i.e., better aerobic endurance and upper and 
lower body strength) 10 years later.
Suthutvoravut et al. investigated the relationship between dietary patterns and 
sarcopenia in a sample of older community-dwelling Japanese adults [45]. The 
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sample included 1241 older adults aged 65 years and older who were not eligible for 
long-term care. Dietary intake by participants was assessed using the brief self-
administered diet history questionnaire. Dietary patterns were identified using both 
PCA and Japanese diet scores (soybeans and soybean products, fish, vegetables, 
pickles, mushrooms, seaweeds, and fruits). Participants were classified into three 
groups: dietary pattern 1 (DP1; high factor loading for the consumption of fish, 
tofu, vegetables, and fruits found in typical Japanese side dishes); dietary pattern 
2 (DP2; high factor loading for fish, rice, and miso soup found in typical Japanese 
main dishes); and dietary pattern 3 (DP3; high factor loading for noodles). The 
findings obtained showed that men with the lowest tertile DP1 score had a higher 
likelihood of being sarcopenic, while women with the lowest tertile DP2 score had 
a moderate likelihood of being sarcopenic. Additionally, low adherence to Japanese 
dietary patterns increased with the prevalence of sarcopenia in both genders.
Many traditional regional diets may have similar benefits to those described 
here. We then focused on diets with demonstrated effects on muscle mass, reported 
by randomized controlled trials that investigated diet quality using precise param-
eters. For example, the traditional diets of Korea and China may be beneficial for 
preventing sarcopenia in the populations of these countries. Healthier diets are 
higher in plant-based food and lower in animal-based foods than Western diets. 
Further epidemiological studies are needed to investigate the relationship between 
healthy diets and development of sarcopenia throughout the world, particularly in 
developing countries.
2.2 Nutrient supplementation for attenuating sarcopenia
Skeletal muscle is a dynamic, plastic tissue with a mass that is regulated by the 
balance between the rates of muscle protein synthesis and breakdown. Adopting an 
appropriate dietary strategy is crucial for facilitating an anabolic response that may 
prevent muscle wasting with atrophy by suppressing the breakdown of muscle pro-
tein. An adequate nutrient intake is essential for maintaining and improving muscle 
properties. Many supplements have been proposed to enhance muscle mass and 
strength. More than 50% of adults in the United States take some form of dietary 
supplement to improve their health or well-being [52]. However, there is no scien-
tific evidence for the effectiveness of many of these supplements. In some cases, 
their use has been linked to serious adverse side effects. This section summarizes the 
effects of several popular nutritional supplements when administered under strict 
dietary controls, either alone or in combination with other supplements.
In a randomized study, Tieland et al. examined the effects of 24 weeks of dietary 
protein supplementation on muscle mass, strength, and physical performance in a 
sample of frail older adults [53]. This study included 65 frail participants who were 
allocated to either the daily protein supplementation group (15 g protein consumed 
at breakfast and lunch) or placebo group (0 g protein at breakfast and lunch). 
Participants recorded their food intake for three days with the help of trained 
dieticians. Dietary intake data were coded (the type of food, time of intake, and 
amount), and energy and macronutrient intakes were calculated using a food-
calculation system from the 2006 Dutch food composition database. The findings 
obtained indicated that skeletal muscle mass did not change in either the protein or 
placebo group following the 24-week intervention. However, leg extension strength 
increased more in the protein group than in the placebo group. Furthermore, physi-
cal performance significantly improved (from 8.9 to 10.0 points) in the protein 
group, but not in the placebo group. Therefore, while dietary protein supplemen-
tation appeared to improve physical performance in frail older adults, it did not 
increase their skeletal muscle mass.
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were significantly longer for men in DP1 and women in DP3 than those in DP2. 
Therefore, diets high in red meats, potatoes, gravy, and butter appear to adversely 
affect muscle strength and physical performance in later life.
Perälä et al. researched whether the consumption of a healthy Nordic diet for 
10 years was associated with improved physical performance measures [44]. After 
the diets of 1072 participants (mean age 67 years) had been examined using a 
validated 128-item FFQ, the a priori Nordic diet score was calculated. The diet items 
checked included Nordic fruits and berries, vegetables, cereals, low-fat milk, fish, 
red and processed meat, alcohol, polyunsaturated omega-3 fatty acids (PUFA)/
SFA and trans-fatty acids ratios, and total fat. Since participants had a mean age of 
71 years, their physical performance was measured using the Senior Fitness Test 
(SFT), and an overall SFT score was calculated. The findings obtained revealed that 
women with the highest diet scores had 17% better in that of walk, 16% better in 
that of arm curl, and 20% better in that of chair-stand than women with the lowest 
diet scores. These findings indicated that women who consumed a healthy Nordic 
diet had better physical performance (i.e., better aerobic endurance and upper and 
lower body strength) 10 years later.
Suthutvoravut et al. investigated the relationship between dietary patterns and 
sarcopenia in a sample of older community-dwelling Japanese adults [45]. The 
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sample included 1241 older adults aged 65 years and older who were not eligible for 
long-term care. Dietary intake by participants was assessed using the brief self-
administered diet history questionnaire. Dietary patterns were identified using both 
PCA and Japanese diet scores (soybeans and soybean products, fish, vegetables, 
pickles, mushrooms, seaweeds, and fruits). Participants were classified into three 
groups: dietary pattern 1 (DP1; high factor loading for the consumption of fish, 
tofu, vegetables, and fruits found in typical Japanese side dishes); dietary pattern 
2 (DP2; high factor loading for fish, rice, and miso soup found in typical Japanese 
main dishes); and dietary pattern 3 (DP3; high factor loading for noodles). The 
findings obtained showed that men with the lowest tertile DP1 score had a higher 
likelihood of being sarcopenic, while women with the lowest tertile DP2 score had 
a moderate likelihood of being sarcopenic. Additionally, low adherence to Japanese 
dietary patterns increased with the prevalence of sarcopenia in both genders.
Many traditional regional diets may have similar benefits to those described 
here. We then focused on diets with demonstrated effects on muscle mass, reported 
by randomized controlled trials that investigated diet quality using precise param-
eters. For example, the traditional diets of Korea and China may be beneficial for 
preventing sarcopenia in the populations of these countries. Healthier diets are 
higher in plant-based food and lower in animal-based foods than Western diets. 
Further epidemiological studies are needed to investigate the relationship between 
healthy diets and development of sarcopenia throughout the world, particularly in 
developing countries.
2.2 Nutrient supplementation for attenuating sarcopenia
Skeletal muscle is a dynamic, plastic tissue with a mass that is regulated by the 
balance between the rates of muscle protein synthesis and breakdown. Adopting an 
appropriate dietary strategy is crucial for facilitating an anabolic response that may 
prevent muscle wasting with atrophy by suppressing the breakdown of muscle pro-
tein. An adequate nutrient intake is essential for maintaining and improving muscle 
properties. Many supplements have been proposed to enhance muscle mass and 
strength. More than 50% of adults in the United States take some form of dietary 
supplement to improve their health or well-being [52]. However, there is no scien-
tific evidence for the effectiveness of many of these supplements. In some cases, 
their use has been linked to serious adverse side effects. This section summarizes the 
effects of several popular nutritional supplements when administered under strict 
dietary controls, either alone or in combination with other supplements.
In a randomized study, Tieland et al. examined the effects of 24 weeks of dietary 
protein supplementation on muscle mass, strength, and physical performance in a 
sample of frail older adults [53]. This study included 65 frail participants who were 
allocated to either the daily protein supplementation group (15 g protein consumed 
at breakfast and lunch) or placebo group (0 g protein at breakfast and lunch). 
Participants recorded their food intake for three days with the help of trained 
dieticians. Dietary intake data were coded (the type of food, time of intake, and 
amount), and energy and macronutrient intakes were calculated using a food-
calculation system from the 2006 Dutch food composition database. The findings 
obtained indicated that skeletal muscle mass did not change in either the protein or 
placebo group following the 24-week intervention. However, leg extension strength 
increased more in the protein group than in the placebo group. Furthermore, physi-
cal performance significantly improved (from 8.9 to 10.0 points) in the protein 
group, but not in the placebo group. Therefore, while dietary protein supplemen-
tation appeared to improve physical performance in frail older adults, it did not 
increase their skeletal muscle mass.
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Kim et al. investigated whether protein-energy supplementation prevented 
functional declines in frail older adults with a low socioeconomic status [54]. In that 
study, 84 frail elderly participants were assigned to either an intervention or control 
group. The intervention group received two 200-ml cans of commercial liquid 
formula (an additional 400 kcal of energy, 25 g of protein, 9.4 g of essential amino 
acids, and 400 ml of water) each day for 12 weeks, while the control group did not. 
Dietary intake was assessed in three, non-consecutive 24-hour recall sessions (one 
face-to-face and two by telephone; weekday and weekend ratio of 2:1) to show the 
nutritional status. The same research dietitian coded dietary data, and a nutrient 
analysis was performed using CAN-Pro 3.0. No significant changes were observed in 
grip strength in either group; however, physical functioning, usual gait speed, and 
TUG scores were significantly better in the protein group than in the control group. 
Therefore, protein-energy supplementation administered to frail older adults with a 
low socioeconomic status appeared to reduce the progression of functional decline.
Veronese et al. investigated whether 12 weeks of oral magnesium supplementa-
tion improved physical performance in healthy older women [55]. In that study, 124 
participants were grouped into either a treatment group (300 mg of magnesium/
day) or control group (no treatment). A dietary assessment was examined by a 
modified method including an estimated three-day record and a questionnaire about 
the frequency that participants generally ate certain foods. They used the data from 
the previous month as a reference and calculated the macronutrients and micro-
nutrients of usual food intake by a national food composition table. After 12 weeks 
of supplementation with magnesium, the treatment group had significantly higher 
total short physical performance battery scores, chair-stand times, and four-minute 
walking speeds than the control group. These findings indicated that magnesium 
supplementation prevented or delayed age-related physical performance declines.
Roma et al. examined the effects of PUFA supplementation on the parameters of 
body composition, muscle strength, and physical performance in the elderly [56]. 
Fifty participants were randomly assigned to a PUFA-treated group (receiving 1.3 g 
of PUFA and 10 mg of vitamin E) or control group (receiving 11 mg of vitamin E). 
Participants were assessed using the mini nutritional assessment (composed of six 
questions related to decreased food intake in the three months before the test) and 
a 12-question survey on diet (number of meals consumed and consumption of pro-
tein, fruits, vegetables, and liquids) and the ability to feed themselves. No significant 
between-group differences were observed in muscle mass, grip strength, or TUG 
scores. Therefore, the 12-week PUFA supplementation did not appear to affect the 
parameters evaluated in elderly individuals with a decreased muscle mass.
Bauer et al. sought to test the hypothesis that a specific oral nutritional supple-
ment may improve selected sarcopenia measures [57]. The active group (n = 184) 
consumed a vitamin D and leucine-enriched whey protein nutritional supplement 
twice daily for 13 weeks. The control group (n = 196) consumed an iso-caloric con-
trol product twice daily for 13 weeks. A dietary assessment was completed at baseline 
and week 13 using three-day prospective diet records for two weekdays and one 
weekend day. Additional energy and protein intakes from both supplements were 
added to habitual three-day intakes to assess total intake. The active group gained 
more appendicular muscle mass and performed better in the chair-stand test than 
the control group. These findings demonstrated that specific nutritional supplemen-
tation alone may benefit geriatric patients, particularly those unable to exercise.
Porter et al. investigated whether participants following an enhanced protein 
regimen have greater functional status improvements and better lean muscle mass 
preservation than control group participants [58]. In that study, 67 obese older adults 
were randomly assigned to either a traditional weight loss regimen (control group) 
or one with a higher protein intake at each meal (protein group). Control group 
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participants were prescribed a 500-kcal deficit diet (15% protein, 30% fat, and 55% 
carbohydrate), which met the recommended dietary allowance (RDA) for protein 
intake (0.8 g/kg of body weight). Protein group participants were also prescribed 
a 500-kcal deficit, but with a macronutrient distribution of 30% protein, 30% fat, 
and 40% carbohydrate, for a total prescribed protein intake of 1.2 g/kg. Both groups 
exhibited significant weight loss at the six-month endpoint. However, while both 
groups had improved muscle function, the Short Physical Performance Battery 
response was greater in the protein group than in the control group. These findings 
indicated that functionally limited obese adults undergoing a six-month weight loss 
intervention that included a meal-based protein enhancement lost similar amounts 
of weight, but had better functional improvements than the control group.
Only one of the studies used an iso-caloric control supplement to investigate the 
efficacy of a vitamin D and leucine-enriched whey protein nutritional supplement 
(not combined with exercise) for attenuating sarcopenia. To produce the most 
useful data, future studies that investigate whether a simple nutrient supplement 
contributes to the prevention of sarcopenia will need to use dietary control in a 
sample of more than 100 elderly participants. Evidence from two in vivo studies 
showed that calorie restriction or fasting may help to prevent reductions in muscle 
mass or strength [59, 60]. Future human studies need to focus on the effects of the 
removal of some nutrients from the diet, instead of solely assessing the effects of 
their addition, in order to obtain more useful data (Table 2).
2.3  Nutrient supplementation effects on muscle mass and strength during 
muscle disuse
A number of conditions, such as recovery from injury or illness or space flight, 
require prolonged periods of muscle disuse (i.e., unloading) in otherwise healthy 
individuals, resulting in the progressive loss of skeletal muscle mass that impairs 
functional strength, reduces the basal metabolic rate, and increases body fat mass. 
Therefore, prolonged muscle disuse is a significant health concern, particularly in 
aging populations. While nutrition is an important factor regulating muscle mass, 
the development of effective nutritional strategies that attenuate muscle loss during 
periods of muscle disuse warrants further efforts. Table 3 shows an overview of 
studies that have assessed the efficacy of nutritional interventions for attenuating 
muscle disuse atrophy under controlled diet quality.
Paddon-Jones et al. examined whether supplementation with essential amino 
acids and carbohydrates offset the catabolic response to 28 days of bed rest [61]. 
Thirteen healthy male participants were randomly assigned to either the experi-
mental or control groups. The control group consumed nutritionally mixed meals 
three times a day. The experimental group consumed the same meals plus 30 g of 
carbohydrate and 16.5 g of essential amino acids three times a day. The Harris-
Benedict equation was used to estimate daily caloric requirements, according to 
the following formula: daily energy requirement (kcal) = [66 + (13.7 × kg) + (5 × 
cm) – (6.8 × yr)] × 1.3 (activity factor for bed rest). Participants were placed on a 
three-day rotating diet with daily nutrient intake evenly distributed between the 
three meals. The findings obtained revealed that the experimental group main-
tained lean leg mass throughout bed rest (+0.2 kg), whereas the control group lost 
mass (−0.4 kg). In addition, strength loss was more pronounced in the control 
group (exp group, −8.8 kg; cont group, −17.8 kg). Therefore, supplementation 
with essential amino acids and carbohydrates during bed rest appeared to provide 
an anabolic stimulus that ameliorated lean muscle mass loss in an otherwise 
catabolic environment. However, it currently remains unclear whether additional 
energy intake contributed to these findings.
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a 500-kcal deficit, but with a macronutrient distribution of 30% protein, 30% fat, 
and 40% carbohydrate, for a total prescribed protein intake of 1.2 g/kg. Both groups 
exhibited significant weight loss at the six-month endpoint. However, while both 
groups had improved muscle function, the Short Physical Performance Battery 
response was greater in the protein group than in the control group. These findings 
indicated that functionally limited obese adults undergoing a six-month weight loss 
intervention that included a meal-based protein enhancement lost similar amounts 
of weight, but had better functional improvements than the control group.
Only one of the studies used an iso-caloric control supplement to investigate the 
efficacy of a vitamin D and leucine-enriched whey protein nutritional supplement 
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useful data, future studies that investigate whether a simple nutrient supplement 
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their addition, in order to obtain more useful data (Table 2).
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functional strength, reduces the basal metabolic rate, and increases body fat mass. 
Therefore, prolonged muscle disuse is a significant health concern, particularly in 
aging populations. While nutrition is an important factor regulating muscle mass, 
the development of effective nutritional strategies that attenuate muscle loss during 
periods of muscle disuse warrants further efforts. Table 3 shows an overview of 
studies that have assessed the efficacy of nutritional interventions for attenuating 
muscle disuse atrophy under controlled diet quality.
Paddon-Jones et al. examined whether supplementation with essential amino 
acids and carbohydrates offset the catabolic response to 28 days of bed rest [61]. 
Thirteen healthy male participants were randomly assigned to either the experi-
mental or control groups. The control group consumed nutritionally mixed meals 
three times a day. The experimental group consumed the same meals plus 30 g of 
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Trappe et al. investigated whether nutritional countermeasures, consisting 
of additional protein and free leucine, reduced volume and strength losses in 
lower-limb skeletal muscle during 60 days of simulated weightlessness [62]. Young 
women were assigned to either the bed rest group (control) or the bedrest plus a 
nutrition countermeasure group (intervention). Dietary staff prepared all meals 
for both groups. These meals contained controlled amounts of total energy and 
macronutrients. The findings obtained demonstrated that thigh muscle (quadriceps 
femoris) volume decreased in both the control (−21%) and intervention groups 
(−24%). Moreover, both groups exhibited similar large decreases in isometric and 
dynamic (centric force, eccentric force, power, and work) muscle strength for the 
supine squat (−19% to −33%). Therefore, the nutrition countermeasure did not 
appear to be effective at offsetting volume or strength losses in lower-limb muscles. 
Furthermore, exercise countermeasures may need to be modified to protect the calf 
muscles of participants.
Ferrando et al. examined the effects of an increasing protein intake (through 
essential amino acid supplementation) in older individuals subjected to 10 days of 
bed rest on their lean body mass and muscle function [63]. Participants received 
either a placebo or 15 g of essential amino acids, three times a day throughout 
10 days of bed rest. The placebo was a non-caloric diet soda. During diet stabiliza-
tion and bed rest, subjects consumed a lacto-ovo vegetarian diet providing the 
RDA for protein (0.8 g/kg of protein per day). The diet consisted of a three-day 
rotation based on the Harris-Benedict equation designed to maintain body weight 
throughout the study. An activity factor of 1.3 was used to estimate daily energy 
requirements during bed rest. The findings obtained indicated that essential amino 
acids did not affect the maintenance of total or leg lean muscle mass. However, 
stair ascent power and standing plantar flexion appeared to be maintained with 
essential amino acid supplementation. Therefore, increasing protein intake above 
the RDA may preserve muscle function in elderly individuals during compulsory 
inactivity. However, this protocol may need to be operated under iso-caloric 
nutritional interventions.
Deutz et al. attempted to clarify whether beta-hydroxy-beta-methylbutyrate 
(HMB), a leucine metabolite, was capable of attenuating muscle decline in 
healthy older adults during 10 days of bed rest [64]. Healthy older adults were 
randomly assigned to a control group or HMB group (Ca-HMB, 1.5 g twice daily, 
total 3 g/day). Participants were fed a metabolically controlled diet for diet stabi-
lization, providing the RDA for protein intake (0.8 g protein/kg of body weight 
per day). Total calorie needs were estimated using the Harris–Benedict equation 
for resting energy expenditure. An activity factor of 1.35 was used to estimate 
daily energy requirements during bedrest. The study protocol significantly 
decreased total lean body mass in the control group. In contrast, the treatment 
with HMB prevented these declines in all but one participant in the HMB group. 
However, differences in functional parameters were not observed between the 
two groups. These findings indicated that HMB supplementation contributed 
to the preservation of muscle mass during 10 days of bed rest. Further studies 
using larger samples and iso-calorie conditions for nutritional interventions 
are needed to clarify the preventative effects of HMB on the acute decline in 
muscle mass.
Dirks et al. investigated whether protein supplementation preserved muscle 
mass during a short period of limb immobilization [65]. Healthy older men were 
subjected to five days of one-legged knee immobilization using a full-leg cast with 
or without the twice-daily administration of a dietary protein supplement (20.7 g 
of protein, 9.3 g of carbohydrate, and 3.0 g of fat). Weighted dietary intake records 
were completed by participants for the five-day immobilization period and on a 
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separate consecutive five-day occasion, either before or after the immobilization 
period. Immobilization decreased the quadricep cross-sectional area by 1.5 and 
2.0%, and muscle strength by 8.3 and 9.3% in the control and protein groups, 
respectively. These findings indicated that dietary protein supplementation (~20 g 
twice daily) did not attenuate muscle loss during short-term muscle disuse in 
healthy older men.
English et al. investigated whether leucine protects skeletal muscle health 
during bed rest [66]. In that study, a group of middle-aged adults were randomly 
assigned to a leucine group (4.5 g leucine × 3 times/day) or alanine group (4.5 g 
alanine × 3 times/day). Participants were fed controlled isoenergetic diets with 
protein intake evenly distributed across three daily meals for diet stabilization. 
Daily energy requirements were estimated using the Harris-Benedict equation. An 
activity factor of 1.3 was used during the bedrest period. The findings obtained 
indicated that while leg lean mass significantly decreased in both groups, leucine 
supplementation protected knee extensor peak torque more than in the alanine 
group. Therefore, leucine supplementation appeared to protect muscle health 
during relatively brief periods of physical inactivity. The parameters of this study 
allowed for the strict control of diets and nutritional supplementation under 
energy-matched conditions; therefore, leucine supplementation may help protect 
muscle function in muscle disuse atrophy.
Holloway et al. examined the safety, tolerability, and atrophy-mitigating effects 
of a novel amino acid composition (containing essential amino acids and arginine, 
glutamine, and N-acetylcysteine) during single-limb immobilization [67]. Twenty 
young men were randomly assigned to receive either the amino acid mixture or an 
energy-matched, non-amino acid-containing placebo three times a day (two hours 
after breakfast, lunch, and dinner) for consecutive days. Diets were designed to 
achieve an energy balance, and meal plans included protein derived from dairy 
sources held constant at 1.0 g/kg/day. The reduction in the cross-sectional area of 
the quadriceps muscle was significantly lower in the amino acid group than in the 
placebo group. However, immobilization resulted in similar relative declines in peak 
torque in both groups. These findings indicated that the daily consumption of an 
amino acid mixture (three times a day for 28 days) attenuated muscle atrophy, and 
are bolstered by the use of well-controlled diets and nutritional supplementation 
with energy-matched conditions.
A number of human studies examined the effects of nutritional interventions on 
muscle mass and strength during a period of muscle disuse [68, 69]. Due to insuf-
ficient dietary control, these studies were not sufficient to clarify the nutritional 
value of such supplements. Despite these deficits, many studies have reported the 
efficacy of nutritional supplementation for preventing the loss of muscle mass and 
strength during a period of muscle disuse in vivo [70–72]. Future studies are needed 
to clarify whether these candidates for nutritional supplementation preserve muscle 
mass during disuse. These studies must control diet quality and modify the nutri-
tional intervention period (e.g., expand the duration of nutritional administration 
before muscle disuse) to provide sufficient evidence.
3. Conclusions
In this chapter, we (a) summarized nutritional epidemiology evidence related to 
sarcopenia from recent systematic reviews; (b) reviewed the role nutrient supple-
mentation plays in attenuating sarcopenia through dietary control; (c) provided 
evidence for the efficacy of nutrient supplementation for treating disuse muscle 
atrophy under controlled diet quality conditions.
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10 days of bed rest. The placebo was a non-caloric diet soda. During diet stabiliza-
tion and bed rest, subjects consumed a lacto-ovo vegetarian diet providing the 
RDA for protein (0.8 g/kg of protein per day). The diet consisted of a three-day 
rotation based on the Harris-Benedict equation designed to maintain body weight 
throughout the study. An activity factor of 1.3 was used to estimate daily energy 
requirements during bed rest. The findings obtained indicated that essential amino 
acids did not affect the maintenance of total or leg lean muscle mass. However, 
stair ascent power and standing plantar flexion appeared to be maintained with 
essential amino acid supplementation. Therefore, increasing protein intake above 
the RDA may preserve muscle function in elderly individuals during compulsory 
inactivity. However, this protocol may need to be operated under iso-caloric 
nutritional interventions.
Deutz et al. attempted to clarify whether beta-hydroxy-beta-methylbutyrate 
(HMB), a leucine metabolite, was capable of attenuating muscle decline in 
healthy older adults during 10 days of bed rest [64]. Healthy older adults were 
randomly assigned to a control group or HMB group (Ca-HMB, 1.5 g twice daily, 
total 3 g/day). Participants were fed a metabolically controlled diet for diet stabi-
lization, providing the RDA for protein intake (0.8 g protein/kg of body weight 
per day). Total calorie needs were estimated using the Harris–Benedict equation 
for resting energy expenditure. An activity factor of 1.35 was used to estimate 
daily energy requirements during bedrest. The study protocol significantly 
decreased total lean body mass in the control group. In contrast, the treatment 
with HMB prevented these declines in all but one participant in the HMB group. 
However, differences in functional parameters were not observed between the 
two groups. These findings indicated that HMB supplementation contributed 
to the preservation of muscle mass during 10 days of bed rest. Further studies 
using larger samples and iso-calorie conditions for nutritional interventions 
are needed to clarify the preventative effects of HMB on the acute decline in 
muscle mass.
Dirks et al. investigated whether protein supplementation preserved muscle 
mass during a short period of limb immobilization [65]. Healthy older men were 
subjected to five days of one-legged knee immobilization using a full-leg cast with 
or without the twice-daily administration of a dietary protein supplement (20.7 g 
of protein, 9.3 g of carbohydrate, and 3.0 g of fat). Weighted dietary intake records 
were completed by participants for the five-day immobilization period and on a 
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separate consecutive five-day occasion, either before or after the immobilization 
period. Immobilization decreased the quadricep cross-sectional area by 1.5 and 
2.0%, and muscle strength by 8.3 and 9.3% in the control and protein groups, 
respectively. These findings indicated that dietary protein supplementation (~20 g 
twice daily) did not attenuate muscle loss during short-term muscle disuse in 
healthy older men.
English et al. investigated whether leucine protects skeletal muscle health 
during bed rest [66]. In that study, a group of middle-aged adults were randomly 
assigned to a leucine group (4.5 g leucine × 3 times/day) or alanine group (4.5 g 
alanine × 3 times/day). Participants were fed controlled isoenergetic diets with 
protein intake evenly distributed across three daily meals for diet stabilization. 
Daily energy requirements were estimated using the Harris-Benedict equation. An 
activity factor of 1.3 was used during the bedrest period. The findings obtained 
indicated that while leg lean mass significantly decreased in both groups, leucine 
supplementation protected knee extensor peak torque more than in the alanine 
group. Therefore, leucine supplementation appeared to protect muscle health 
during relatively brief periods of physical inactivity. The parameters of this study 
allowed for the strict control of diets and nutritional supplementation under 
energy-matched conditions; therefore, leucine supplementation may help protect 
muscle function in muscle disuse atrophy.
Holloway et al. examined the safety, tolerability, and atrophy-mitigating effects 
of a novel amino acid composition (containing essential amino acids and arginine, 
glutamine, and N-acetylcysteine) during single-limb immobilization [67]. Twenty 
young men were randomly assigned to receive either the amino acid mixture or an 
energy-matched, non-amino acid-containing placebo three times a day (two hours 
after breakfast, lunch, and dinner) for consecutive days. Diets were designed to 
achieve an energy balance, and meal plans included protein derived from dairy 
sources held constant at 1.0 g/kg/day. The reduction in the cross-sectional area of 
the quadriceps muscle was significantly lower in the amino acid group than in the 
placebo group. However, immobilization resulted in similar relative declines in peak 
torque in both groups. These findings indicated that the daily consumption of an 
amino acid mixture (three times a day for 28 days) attenuated muscle atrophy, and 
are bolstered by the use of well-controlled diets and nutritional supplementation 
with energy-matched conditions.
A number of human studies examined the effects of nutritional interventions on 
muscle mass and strength during a period of muscle disuse [68, 69]. Due to insuf-
ficient dietary control, these studies were not sufficient to clarify the nutritional 
value of such supplements. Despite these deficits, many studies have reported the 
efficacy of nutritional supplementation for preventing the loss of muscle mass and 
strength during a period of muscle disuse in vivo [70–72]. Future studies are needed 
to clarify whether these candidates for nutritional supplementation preserve muscle 
mass during disuse. These studies must control diet quality and modify the nutri-
tional intervention period (e.g., expand the duration of nutritional administration 
before muscle disuse) to provide sufficient evidence.
3. Conclusions
In this chapter, we (a) summarized nutritional epidemiology evidence related to 
sarcopenia from recent systematic reviews; (b) reviewed the role nutrient supple-
mentation plays in attenuating sarcopenia through dietary control; (c) provided 
evidence for the efficacy of nutrient supplementation for treating disuse muscle 
atrophy under controlled diet quality conditions.
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Chapter 7
Effects of Physiotherapy 
Interventions on the Function of 
the Locomotor System in Elder 
Age: View of Theory and Practice
Boglárka Debity and Julianna Cseri
Abstract
The aim of this chapter is to give an overview about the aging processes 
in the neural and muscuo-skeletal system at cellular and tissue level to highlight 
the demand for physiotherapy interventions. Searching the relevant literature 
published in the last decade, it was found that the loss of muscle mass (myofiber 
atrophy and decrease in the number of myofibers) is associated with decreased 
regeneration capacity of the skeletal muscle, deterioration of the neural control and 
bone remodeling as well as the impaired microcirculation leading to insufficient 
adaptation to the physical exercises. In the management of the aging-related dete-
rioration of the skeletal muscle (sarcopenia), the first tool is the resistance train-
ing that improves the muscle mass and power as well as the functional outcomes 
regarding the mobility and physical performance. The endurance (aerobic) training 
improves the cardiovascular and respiratory status providing better blood supply 
to the skeletal muscle and exerts some effects directly to the skeletal muscle and 
bone (increases the mitochondrial functions, improves the bone remodeling). The 
combination of aerobic and resistance training seems to be more effective against 
the sarcopenia and osteopenia. The balance training gives additional benefits, so 
(together with increased muscle power and performance) improves the quality 
of life.
Keywords: skeletal muscle, skeleto-neuro-muscular system, aging, physiotherapy 
practice, physiotherapy and aging
1. Introduction
The homeostasis of the neuromuscular system requires preserved muscle 
structure and functionality with normal regeneration capacity as well as the intact 
motor control including peripheral innervation and upper control mechanisms. For 
the normal locomotion the healthy bone structure and function provide stable basis 
for muscle function and the proper blood supply is inevitable. All components may 
be influenced by aging and diseases to some extent causing dysfunction of motor 
activity.
The skeletal muscle fibers are multinucleated huge cells containing contrac-
tile proteins (actin and myosin) organized into sarcomeres. In the fetal life the 
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embryonal myoblasts fuse into long multinucleated structures. It is relevant to our 
topic that the skeletal muscle fibers are categorized basically into slow type (Type I) 
and fast type (Type II) twitch fibers based on the kinetics of contraction-relaxation 
cycle and metabolic properties. Recently, this simple model has become more 
complex and the diversity of muscle fibers has revealed [1].
The skeletal muscle fibers do not show spontaneous activity without innerva-
tion. The somatic motor nerves form neuromuscular junction NMJ) with the 
endplate of the muscle fibers. The NMJ serves as the site of communication between 
the two structure. One motor neuron commonly innervates more than one muscle 
fibers constructing a motor unit in which the muscle fibers work together. The 
motor neurons and the muscle fibers influence the activity of each other, i.e. the 
motor neuron activates the myofibers, and the muscle fibers release cytokines 
that act on the motor neuron. The third component of the communication is the 
perisynaptic Schwann cell (PSC) population. The PSCs play stabilizer and trophic 
role in the NMJ. Recently, a new component, kranocyte has discovered that is a 
fibroblast-like cell covering the NMJ. The kranocytes may play role in the post-
injury nerve regeneration [2].
The muscle stem cells (satellite cells) are responsible for the muscle repair after 
a cell damage caused by micro- or macro-traumatization. The satellite cells are 
located along the multinucleated muscle fibers between the muscle fiber and the 
basal lamina. On the adequate stimulation they can proliferate, fuse and form a 
new muscle fiber or – undergoing an asymmetric cell division – can regenerate the 
pool of the satellite cells [3]. Our knowledge about the factors regulating the normal 
function of the stem cells and the pathomechanism of impaired muscle repair in 
different conditions is ever-increasing and reported in many publications. Recently, 
Feige et al. [4] has reviewed the factors affecting the self-renewal capacity and 
repairing function of satellite cells in diseases and aging.
The healthy bone is a fundamental organ in the skeletomuscular system. There is 
an interesting concept to explore the crosstalk between the muscles and the bones. 
It means that the skeletal muscles and bones interact with each other and keep the 
homeostasis in normal stage [5]. The bone is a very dynamic structure with con-
tinuous bone resorption and counteracting bone formation. This process is called 
bone remodeling that plays important role in the bone homeostasis. The resident 
cells of the bone tissue are osteoblasts, osteocytes, osteoclasts and the bone lining 
cells originated from the mesenchymal stem cells located in the bone marrow. The 
osteoblasts are responsible for the bone formation characterized by intensive pro-
tein synthesis and release of proteins into the bone matrix. The osteocytes located in 
the lacunae surrounded with the mineralized bone matrix serve as mechanosensors 
coordinating the function of osteoblasts and osteoclasts. Osteoclasts are multinucle-
ated cells with bone resorptive ability. Recently, information about their cytokine 
releasing activity and effects on other bone cells has emerged. Bone lining cells are 
quiescent osteoblasts covering the bone surfaces. Their role in the bone remodeling 
is poorly understood, but more and more data about their secretory activity and 
effects on the other bone cells has been published [6–8].
The microcirculation comprises terminal arteriole, arteriovenous capillary, 
metarteriole, capillary bed and postcapillary venule. The microcirculation sup-
plies the tissues with oxygen and nutrients, delivers carbon-dioxide and metabolic 
products and provides optimal milieu for cellular functions. Hendrickse and 
Degens reviewed the morphology and function of microvasculature including the 
role of these elements in the plasticity of skeletal muscle microcirculation. The 
adaptation of microcirculation to functional demand is an essential requirement 
for proper functioning of the muscle. The parallel change in the myofiber diameter 
and capillary density has been reported in many articles. The endothelial cells are 
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very important in vascular homeostasis and vascular adaptation. Nitric oxide (NO) 
promotes the release of the vascular endothelial growth factor (VEGF) that serves 
as the main angiogenetic molecule [9].
Another review article provides an overview on the systemic and local control 
of blood flow in the skeletal muscle microvasculature. The metabolic and endo-
thelial regulations must be emphasized in relation to the topic of this chapter. The 
endothelium-derived relaxing (NO, endothelium-derived relaxing  factor – EDRF, 
prostacyclin) or contracting (endothelin) substances play substantial role in the 
functional adaptation of microcirculation in normal and pathological states. 
Differences of microcirculation in oxidative and glycolytic muscles are also 
reviewed that worth to be considered in training protocols [10].
It is generally accepted that the physiotherapy (including various types of 
exercises) is a key factor in the management of sarcopenia. Basically, the physical 
exercises can be categorized into endurance (aerobic) and resistance type exercises. 
The endurance (aerobic) training works with large muscle groups, being sustained 
and rhythmic, e.g. swimming, burst walking, dancing, cycling, jogging, long distance 
running, etc. The most prominent functional outcome of this type of exercises is the 
improvement of the cardiorespiratory functions. The resistance training includes 
series of movements performed against static or dynamic resistances (e.g. weight, 
elastic band) that impacts also the major muscle groups and several joints. Usually 
it is repeated 2 or 3 times per week with increasing dosage. The primary aim of the 
resistance training is to improve the muscle power as functional outcome [11].
The aim of this chapter is to offer an overview about the aging processes in dif-
ferent elements of the locomotor system, to summarize the current results related 
to the physiotherapeutic interventions, and to give an insight into the undergoing 
processes influenced by exercises.
2. Aging-related alteration of the neural and musculo-skeletal system
In the past decade numerous evidences have been accumulated about the 
structural and functional changes during the aging process in muscle homeostasis 
including the loss of muscle mass and/or strength, the impaired repair mechanism 
and the disturbed adaptation of microvasculature to the metabolic demand. The 
loss of muscle muss and strength (sarcopenia) as well as the decrease in the bone 
mass (osteopenia, osteoporosis) together with the alteration of cardiovascular and 
respiratory system and disturbed metabolism cause the frailty syndrome [5, 12]. 
The regulation of muscle metabolism, its adaptation to nutrition and short-term 
or chronic physical exercise in young versus elder age have been overviewed in a 
recent review [13]. Further reviews also provide complex approach to aging process 
regarding the elements of muscle homeostasis (muscle fibers, motor unit, regenera-
tive capacity, metabolic background) [14, 15].
To interpret the data, it is worth to distinguish the primary and secondary aging. 
The primary aging of skeleto-neuro-muscular system is manifested in a progressive 
deterioration in the structure and disturbed function. The secondary aging refers 
to the additional structural and functional changes caused by diseases and lifestyle 
factors. The aim of the therapeutic interventions can be to make slower the aging by 
limiting the secondary aging process [16].
2.1 Aging of skeletal muscle fibers and the whole motor units
Sarcopenia is the progressive loss of muscle mass and/or strength with conse-
quent decline in functional outcome and activity of daily living (ADL) functions. 
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embryonal myoblasts fuse into long multinucleated structures. It is relevant to our 
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plies the tissues with oxygen and nutrients, delivers carbon-dioxide and metabolic 
products and provides optimal milieu for cellular functions. Hendrickse and 
Degens reviewed the morphology and function of microvasculature including the 
role of these elements in the plasticity of skeletal muscle microcirculation. The 
adaptation of microcirculation to functional demand is an essential requirement 
for proper functioning of the muscle. The parallel change in the myofiber diameter 
and capillary density has been reported in many articles. The endothelial cells are 
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or chronic physical exercise in young versus elder age have been overviewed in a 
recent review [13]. Further reviews also provide complex approach to aging process 
regarding the elements of muscle homeostasis (muscle fibers, motor unit, regenera-
tive capacity, metabolic background) [14, 15].
To interpret the data, it is worth to distinguish the primary and secondary aging. 
The primary aging of skeleto-neuro-muscular system is manifested in a progressive 
deterioration in the structure and disturbed function. The secondary aging refers 
to the additional structural and functional changes caused by diseases and lifestyle 
factors. The aim of the therapeutic interventions can be to make slower the aging by 
limiting the secondary aging process [16].
2.1 Aging of skeletal muscle fibers and the whole motor units
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quent decline in functional outcome and activity of daily living (ADL) functions. 
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Among others, Wilkinson et al. [17] reviewed the characteristic changes in the skel-
etal muscle in elder age. It was revealed that the decline in the muscle mass derives 
from the muscle fiber atrophy and the decrease in the number of muscle fibers. 
The imbalance between the protein anabolism and catabolism was detected with 
conclusion that the protein turnover is mainly affected by the protein intake and 
the physical activity. The aged muscles seem to be resistant to the anabolic stimula-
tion (e.g. insulin resistance) that causes loss of muscle proteins, i.e. atrophy. The 
sedentary lifestyle and the chronic, partial immobilization due to physical inactivity 
facilitate the loss of muscle mass [13, 17].
The impaired mitochondrial functions, mitochondrial dynamics and  
mitochondrial autophagy with consequent decrease in oxidative capacity of 
muscles are also associated with the aging-related sarcopenia, especially in the 
fast type myofibers [18].
A new approach is the investigation of the aging-related changes in the whole 
motor unit (motor neuron, NMJ and the innervated muscle fibers) together. We 
have found two review articles reported in the last decade that are closely related 
to our topic and give an excellent basis for interpretation of the effects of physical 
exercise on the neuromuscular functions [19, 20].
The loss of motor neurons, formation of very large motor units during reinner-
vation together with the decrease in the number and diameter of the muscle fibers 
(sarcopenia) impact negatively the mechanical performance and the fine motor 
control of the muscles. In the peripheral nervous system, the loss of motor neurons 
with high diameter is prominent, to large extent in the lumbar region. The effect of 
aging is muscle specific, i.e. the muscles in the lower limb are more affected than in 
the upper limb, the muscles being fast (type II) are more impaired than the muscles 
containing mainly slow fibers (type I). The upper motor control is also impaired by 
aging due to decreased excitability of corticospinal pathways [19].
The reorganization of the motor units, the decreased number of motor neurons 
and the increased number of myofibers innervated by an individual motor neuron 
seems to be the first step in the aging process. At cellular level, decrease in the rate 
of axoplasmic transport, the velocity of impulse propagation, and the speed of 
nerve regeneration were detected together with the fragmentation of the NMJ and 
impaired signal transduction [20].
The impaired neuromuscular function is manifested in the decreased maximum 
strength, power, and RFD (rate of force rise: DF/Dt) and in the attenuated func-
tional capacity in daily living [19].
2.2 Aging-related decrease in the regeneration capacity of the skeletal muscle
It is widely accepted in the literature that the number of satellite cells with 
proliferative ability becomes progressively decreased in elder age resulting in the 
attenuated hypertrophy during exercise and the muscle regeneration after a muscle 
injury. The impaired self-renewal capacity has also been described in elder age lead-
ing to decreased number of satellite cells being in quiescence and become activated 
under stimulation. The imbalance between the symmetric and asymmetric cell divi-
sion (resulting in proliferating cells and satellite cells returning to quiescent state) 
seems to be the key factor in the aging process of the muscle regeneration [3, 4].
The regeneration capacity can be influenced by the intrinsic and extrinsic 
factors determining the proliferation and differentiation of the satellite cells and 
the renewal of the quiescent satellite cell pool [21]. The extrinsic factors have been 
intensively studied [see ref. 4], but the intrinsic mechanisms occurring inside the 
muscle cells have been rather unknown. Blau et al. reviewed genetic experiments 
oriented to discover the intrinsic changes in satellite cells associated with aging [22]. 
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In another review the aging-associated genetic changes are also reported. The stem 
cells become fragile with increasing chance of damage and death. The number of 
senescent cells (alive, metabolically active cells without cell division) increases that 
release pro-inflammatory cytokines with consequent inflammation. Replacing the 
lost myofibers, fibrosis and accumulation of adipose tissue is also characteristic in 
aging [23].
The first step in the muscle regeneration is the local inflammation when macro-
phages (M1 and M2) infiltrate the surroundings and eliminate the cell fragments. 
In elder age, the balance between the M1 and M2 macrophages is impaired leading 
to improper satellite cell activation. The extracellular matrix is also affected leading 
not proper milieu for satellite cells [24].
2.3 Aging and bone
The aging process of the bone is manifested in osteopenia and decreased min-
eralization of the bone (osteoporosis), in a disease with high prevalence and risk of 
pathologic fractures. The aging of bone (osteopenia) is frequently associated with 
sarcopenia therefore the physiotherapy interventions must be focused on treatment 
of sarcopenia and the osteoporosis parallel.
It has been reported recently that the dysfunction of osteogenic mesenchymal 
stem cells (MSCs) is the one sign of the aging process. The differentiation of MSCs 
is shifted towards adipogenesis instead of osteogenesis. The details of pathomecha-
nism at cellular and molecular level has been reviewed by Infante and Rodríguez in 
2018 [25].
The aging alters the number and function of osteoblasts (bone-forming cells) 
and causes impaired mineralization. In the background, the impaired organization 
of the cytoskeletal structure of the osteoblasts is supposed. The accumulation of the 
free oxygen radicals may be the reason of consequent series of altered processes [26].
In elder age, the adaptation of bone macro- and microstructure to the mechani-
cal load is substantially impaired, mainly due to the inadequate control of osteo-
blasts and osteoclasts activity by the osteocytes as mechanosensors. Osteocytes are 
responsible for the balance between the activity of osteoblasts and osteoclasts (bone 
formation and bone resorption). In the elder age, the osteoclast activity exceeds the 
osteoblast activity mainly due to the impaired coordinator function of osteocytes. 
The current literature is heterogenous related to the changes in the density and 
morphology of osteocytes, the shape of lacunae and canaliculi network. Differences 
may derive from species and sex differences as well as from different techniques 
used for measuring and analyzing the data. The type of bone (trabecular or com-
pact) also may modify the changes and reactions of cellular elements [27].
2.4 Aging-related changes in the microcirculation
Evidences for the microcirculatory theory of aging has recently been reviewed. 
Decreased capillary density with reduced blood flow and insufficient tissue perfu-
sion has been reported by several authors. Although, the experimental data are 
somehow conflicting according to the basal flow and post-exercise hyperemia in 
human leg; some evidences exist showing that the blood flow and reactivity of the 
vessels to exercise decline in elder age [9, 28]. It is suggested that the decrease in the 
capillary density precedes the sarcopenia [9]. Other data are not in agreement with 
this statement since neither capillarization nor arrangement of microvasculature 
seems to be affected by aging, but there are evidences for impaired endothelial 
functions including decreased NO and prostacyclin production and insufficient 
spread of vasodilation alone the microvasculature [10].
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Among others, Wilkinson et al. [17] reviewed the characteristic changes in the skel-
etal muscle in elder age. It was revealed that the decline in the muscle mass derives 
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tional capacity in daily living [19].
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injury. The impaired self-renewal capacity has also been described in elder age lead-
ing to decreased number of satellite cells being in quiescence and become activated 
under stimulation. The imbalance between the symmetric and asymmetric cell divi-
sion (resulting in proliferating cells and satellite cells returning to quiescent state) 
seems to be the key factor in the aging process of the muscle regeneration [3, 4].
The regeneration capacity can be influenced by the intrinsic and extrinsic 
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intensively studied [see ref. 4], but the intrinsic mechanisms occurring inside the 
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not proper milieu for satellite cells [24].
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of sarcopenia and the osteoporosis parallel.
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stem cells (MSCs) is the one sign of the aging process. The differentiation of MSCs 
is shifted towards adipogenesis instead of osteogenesis. The details of pathomecha-
nism at cellular and molecular level has been reviewed by Infante and Rodríguez in 
2018 [25].
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and causes impaired mineralization. In the background, the impaired organization 
of the cytoskeletal structure of the osteoblasts is supposed. The accumulation of the 
free oxygen radicals may be the reason of consequent series of altered processes [26].
In elder age, the adaptation of bone macro- and microstructure to the mechani-
cal load is substantially impaired, mainly due to the inadequate control of osteo-
blasts and osteoclasts activity by the osteocytes as mechanosensors. Osteocytes are 
responsible for the balance between the activity of osteoblasts and osteoclasts (bone 
formation and bone resorption). In the elder age, the osteoclast activity exceeds the 
osteoblast activity mainly due to the impaired coordinator function of osteocytes. 
The current literature is heterogenous related to the changes in the density and 
morphology of osteocytes, the shape of lacunae and canaliculi network. Differences 
may derive from species and sex differences as well as from different techniques 
used for measuring and analyzing the data. The type of bone (trabecular or com-
pact) also may modify the changes and reactions of cellular elements [27].
2.4 Aging-related changes in the microcirculation
Evidences for the microcirculatory theory of aging has recently been reviewed. 
Decreased capillary density with reduced blood flow and insufficient tissue perfu-
sion has been reported by several authors. Although, the experimental data are 
somehow conflicting according to the basal flow and post-exercise hyperemia in 
human leg; some evidences exist showing that the blood flow and reactivity of the 
vessels to exercise decline in elder age [9, 28]. It is suggested that the decrease in the 
capillary density precedes the sarcopenia [9]. Other data are not in agreement with 
this statement since neither capillarization nor arrangement of microvasculature 
seems to be affected by aging, but there are evidences for impaired endothelial 
functions including decreased NO and prostacyclin production and insufficient 
spread of vasodilation alone the microvasculature [10].
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It is widely accepted that the function of microvasculature is altered by aging 
itself and due to the accompanying diseases being frequently present in elder peo-
ple. However, the possibility for in vivo investigation of microvasculature is limited 
by technical difficulties. A new promising tool is the contrast-enhanced ultrasound 
(CEUS) method that provides a relatively non-invasive imaging technique for clini-
cal and research application [29]. By using this technique, impaired micro- vascular 
reaction to isometric exercise and attenuated, delayed post-exercise hyperemia were 
found in middle-aged subjects in comparison to young people without significant 
differences in vascular morphology and total leg perfusion [30].
Regarding the blood supply, the capillary:fiber (C:F) ratio is a determining 
parameter. The C:F ratio is lower in the patients with sarcopenia than in the patients 
at similar age without sarcopenia. The C:F ratio is mainly affected by aging in the 
skeletal muscle type II (fast) while is not changed in the muscles type I (slow). On 
the other hand, the increase in the fiber size (hypertrophy) is not associated to the 
increased capillarization [9].
It is also interesting that the capillary endothelium and the satellite cells act on 
each other, i.e. the vascular endothelium-derived growth factor (VEGF) stimulates 
the proliferation of the satellite cells and the angiogenesis is facilitated by the 
satellite cells. It is reported that the VEGF production is decreased in advanced age 
leading to loss of capillaries. Furthermore, the distance between the capillaries and 
satellite cells increases resulting in impaired regeneration of muscle fibers [9].
3. Physiotherapy on functional outcomes
It is widely accepted in the literature that the level of daily physical activity and 
the structured exercises contribute to the preservation of skeletal muscle structure 
and function and attenuates the aging-related decline acting directly on the neuro-
muscular or indirectly on the other system of organs, especially on the cardiorespi-
ratory system [31].
The endurance (aerobic) exercises provide good basis for intervention against 
the decrease in muscle loss, while resistance exercises directly increase the muscle 
mass and performance. The combined training programs including resistance and 
aerobic exercises, completed with balance training provide the effective interven-
tions in prevention of fall and improving the every-day functionality [9].
3.1 Effects of resistance training
The aging causes severe limitation in the every-day physical activity (walking, 
climbing stairs, rising from a chair etc.), predominantly in the lower extremities. 
To increase the physical performance, the improvement of the muscle power (the 
product of muscle force and contraction velocity) is the most important requirement. 
The widely used traditional resistance training (consisting heavy weights moved 
at a slow/moderate velocity) increases the power and functional performance but 
improves the contraction velocity to less extent than the power training (where the 
concentric movements are performed at high velocities). The power training with rat-
ing of perceived exertion is recommended to reach the best functional outcome [31].
The complex effects of strength (resistance) training has also been reviewed 
including improvement of muscle strength, reduction of sarcopenia and bone 
loss, as well as decrease in the risk of fall and injury by using different training 
parameters. Higher intensity of strength training results in more benefits even in 
old people. Significant improvement of functional and clinical outcomes was found 
also in patients suffering with different diseases [32]. The relationships between the 
131
Effects of Physiotherapy Interventions on the Function of the Locomotor System in Elder Age…
DOI: http://dx.doi.org/10.5772/intechopen.94239
sarcopenia and physical activity were analyzed in a systematic review and meta-
analysis where the resistance training was emphasized as a potent intervention 
against sarcopenia [33].
In a recent review, the controlled resistance training has been designated as the 
most powerful and fundamental tool for improvement of muscle strength, power 
and functional outcomes as gait speed, Timed Up and Go test (TUG), sit-to-stand 
test, Short Physical Performance Battery (SPPB) scores leading to a decrease in the 
risk of falls even in the frail persons [9].
Decline in the muscle power begins in the 4th–5th decades, so it is very 
important to start the progressive resistance training in middle age focusing on 
the muscles in lower extremity (gluteal muscles, quadriceps, and hamstrings) to 
prevent the further deterioration and progressive limitations in mobility. The leg 
press and knee extensor training resulted in similar improvement in the muscle 
power and functional outcomes. The exercise intensity seems not to be a significant 
moderator of the efficacy of resistance training improving the muscle force. It is 
suggested that the higher training intensity results in increase in the absolute force 
while the training at lower intensity increases the contraction velocity. The train-
ing volume (product of sets and repetition) has been in negative correlation with 
muscle power (the less volume resulted in higher power). The effect of variation in 
intensity and volume requires further meta-analysis [34].
Another systemic review and meta-analysis revealed that the most effective 
resistance training regarding the muscle strength was done with 2–3 session/week 
with 2–3 sets/exercise and 7–9 repletion at 70–79% of the 1RM for 50–53 weeks [35].
The multiple benefits of resistance training were reviewed including the facilita-
tion of the physical functions and increasing the bone mineralization [36].
A follow-up study carried out in 6th and 18 months after a 12-week resistance 
training with 149 participants explored that the maintenance of benefits gained 
during a supervised resistance training was sustained only for a short period. 66% 
of participants self-reported doing the recommended level of physical activity 
(≥30 min/d) including walking, swimming, gymnastics and gardening, but only 
less than half of the participants continued the resistance exercises. The muscle 
strength of quadriceps decreased in comparison to the value at the end of the 
supervised training but remained higher than before the training program. In 
general, neither the leisure time physical activity nor the uncontrolled exercise 
training could completely prevent the decline in the muscle strength, only could 
limit the negative tendency. In contrast, the result of timed up and go test improved 
by exercise training was unchanged during the follow-up [37].
Recent review focused on the effect of physical activity in the prefrail or 
frail persons. Definition of frailty syndrome can be seen in a review article [12]. 
Although the intervention protocols were heterogenous, the most authors applied 
resistance training aiming to increase the muscle strength in frailty syndrome. It 
was generally reported that the physical activity reduced the frailty, improved the 
physical performance and caused a slight increase in the muscle strength [38].
Comparison of machine-based RT (M-SRT) on stable surface and RT on 
unstable surface (URT) either in machine-based (M-URT) or free-weight URT 
(F-URT) form resulted in similarly significant improvement in the muscle strength 
and power of lower extremities and balance in the groups of old participants (65 to 
80 years). The lower extremity muscle strength was increased to highest extent in 
machine based URT, but the degree of muscle power improvement was indepen-
dent on the form of exercises. The gait analysis revealed also important impact on 
parameters independently of the form of training. It has clinical relevance that the 
maximal training load of the squat-movement was significantly lower in F-URT in 
comparison to two other types of exercises [39].
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sarcopenia and physical activity were analyzed in a systematic review and meta-
analysis where the resistance training was emphasized as a potent intervention 
against sarcopenia [33].
In a recent review, the controlled resistance training has been designated as the 
most powerful and fundamental tool for improvement of muscle strength, power 
and functional outcomes as gait speed, Timed Up and Go test (TUG), sit-to-stand 
test, Short Physical Performance Battery (SPPB) scores leading to a decrease in the 
risk of falls even in the frail persons [9].
Decline in the muscle power begins in the 4th–5th decades, so it is very 
important to start the progressive resistance training in middle age focusing on 
the muscles in lower extremity (gluteal muscles, quadriceps, and hamstrings) to 
prevent the further deterioration and progressive limitations in mobility. The leg 
press and knee extensor training resulted in similar improvement in the muscle 
power and functional outcomes. The exercise intensity seems not to be a significant 
moderator of the efficacy of resistance training improving the muscle force. It is 
suggested that the higher training intensity results in increase in the absolute force 
while the training at lower intensity increases the contraction velocity. The train-
ing volume (product of sets and repetition) has been in negative correlation with 
muscle power (the less volume resulted in higher power). The effect of variation in 
intensity and volume requires further meta-analysis [34].
Another systemic review and meta-analysis revealed that the most effective 
resistance training regarding the muscle strength was done with 2–3 session/week 
with 2–3 sets/exercise and 7–9 repletion at 70–79% of the 1RM for 50–53 weeks [35].
The multiple benefits of resistance training were reviewed including the facilita-
tion of the physical functions and increasing the bone mineralization [36].
A follow-up study carried out in 6th and 18 months after a 12-week resistance 
training with 149 participants explored that the maintenance of benefits gained 
during a supervised resistance training was sustained only for a short period. 66% 
of participants self-reported doing the recommended level of physical activity 
(≥30 min/d) including walking, swimming, gymnastics and gardening, but only 
less than half of the participants continued the resistance exercises. The muscle 
strength of quadriceps decreased in comparison to the value at the end of the 
supervised training but remained higher than before the training program. In 
general, neither the leisure time physical activity nor the uncontrolled exercise 
training could completely prevent the decline in the muscle strength, only could 
limit the negative tendency. In contrast, the result of timed up and go test improved 
by exercise training was unchanged during the follow-up [37].
Recent review focused on the effect of physical activity in the prefrail or 
frail persons. Definition of frailty syndrome can be seen in a review article [12]. 
Although the intervention protocols were heterogenous, the most authors applied 
resistance training aiming to increase the muscle strength in frailty syndrome. It 
was generally reported that the physical activity reduced the frailty, improved the 
physical performance and caused a slight increase in the muscle strength [38].
Comparison of machine-based RT (M-SRT) on stable surface and RT on 
unstable surface (URT) either in machine-based (M-URT) or free-weight URT 
(F-URT) form resulted in similarly significant improvement in the muscle strength 
and power of lower extremities and balance in the groups of old participants (65 to 
80 years). The lower extremity muscle strength was increased to highest extent in 
machine based URT, but the degree of muscle power improvement was indepen-
dent on the form of exercises. The gait analysis revealed also important impact on 
parameters independently of the form of training. It has clinical relevance that the 
maximal training load of the squat-movement was significantly lower in F-URT in 
comparison to two other types of exercises [39].
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3.2 Effects of endurance training
The numerous benefits of endurance (aerobic) training in old age are evidenced 
in several publications. Regarding the locomotor system, the increased aerobic 
capacity must be emphasized, but there are evidences for increased muscle strength 
on the effect of a long-term aerobic training [18].
The impact of endurance training on sarcopenia has been revealed less than 
of resistance training because the improvement of muscle mass and strength by 
resistance training is in the focus of investigators [13].
The primary aim of the endurance (aerobic) training is the improvement of cardio-
vascular functions. Beside the impact on the cardiovascular health the aerobic physical 
activity influences the metabolism, increases the glucose tolerance, positively acts on 
body composition, and is an important factor in maintenance of the bone density [40].
3.3 Effects of combined training
There are a lot of publications regarding the effects of combined (multimodal) 
exercises on general fitness and especially the improvement of sarcopenia in old 
age. We summarize here the most relevant data gained from supervised, controlled 
exercise training programs consisting of aerobic (AT) and resistance training (RT) 
or RT and balance training. The functional outcomes are highlighted beside the fea-
sibility and safety of the programs in old population without sever comorbidities.
Combined AT (2 times/week) and RT (2 times/week) were applied in a 6-week 
high-volume, moderate-intensity exercise program where the measurement of the 
functional outcomes (TUG test and the SPPB) was completed with the explora-
tion of feasibility and safety of the training program for old untrained persons. 
The results showed unchanged TUG but significantly improved SPPB scores. The 
positive feedback about the subjective experiences during the follow-up in the semi-
structured interviews and adherence to enter a longer program indicate that this 
exercise protocol is promising for the future and worth to consider these findings in 
planning the exercise interventions [40].
The functional outcomes (gained from the TUG test, the functional reach test, 
30-second chair stand test and the 6-minute walk test) were analyzed compar-
ing to the control on the effect of a 32-week aerobic training alone (3 times per 
week) or combined with resistance training (1 session of RT + 2 session of AT) in a 
randomized controlled trial carried out in a group of old (˃65ys) men (n = 22 in each 
group). It was found that the AT alone caused significant decrease in the time mea-
sured by TUG test and increase in the value of functional reach test and distance in 
the 6-minute walk test at the 24th weeks of the program and later. The combined 
training evoked greater improvement in parameters mentioned above with earlier 
manifestation (the walking distance became significantly higher as in the control 
group already at the 8th week). It was suggested by the authors that the improved 
functional outcomes might decrease the risk of fall [41].
The frequency (2 or 3 times per week) of combined (resistance and aerobic) 
training did not influence the functional outcomes in old men [42].
It was found in a randomized clinical trial (LIFE study) that the risk of fall in 
elder age cannot be attenuated by using resistance and balance training together 
with long-term structured physical activity (walking, strength and balance train-
ing) in the very old age (70–89 yeas) in sedentary people with functional limita-
tions, but can reduce the rate of fall with consequent fracture and hospitalization, 
especially in men. The training program lasted for 24–42 months, partly in a 
supervised form (2 sessions/week with 63% attendance) and partly in the form of 
home-based activity (3–4 sessions/week) [43].
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The effect of combined, high level balance and moderate intensity resistance 
training in long-term residential age care was also reported focused on the preven-
tion of fall. Significant decrease in the rate of falls and increase in physical perfor-
mance were found after a 25-week intervention period with progressive dosage 
followed by a maintenance program with low dosage up to 12 months [44].
4. Theoretical interpretation of practical experiences
It is interesting to see the theoretical findings regarding the effects of physical 
exercises on the structure and function at cellular and tissue level. These data 
may prove evidences for practical experiences and can help to design the training 
protocols.
4.1 Effect of physical exercise on the muscle itself and the whole motor unit
It is evidenced that the aerobic exercise improves the mitochondrial functions, 
the synthesis of insulin receptor and the myosin heavy chain protein even in the 
advanced age [13–15]. Impairment of the mitochondrial structure and function 
seems to be the consequence of decreased physical activity in older persons rather 
than the aging itself [14]. Not only the structured physical exercises, but the regular 
physical activity in the daily life promotes the mitochondrial protein synthesis [45].
It is generally accepted, that the resistance training increases the muscle mass 
and strength, although, some data show controversary results or the variability of 
the degree of improvement. The contractile properties of a single muscle fiber seem 
to be increased by both resistance and endurance training [14]. It is worth to men-
tion that the skeletal muscle reacts to the resistance training in elder age less than 
younger age, due to the impaired protein synthesis [19].
The studies revealed differences in the remodeling of the muscle fibers on the 
effect of concentric (CON RET) vs. eccentric resistance training (ECC RET) at the 
80% of one-repetition maximum for 4 weeks. Both type of training evoked hyper-
trophy and increased protein content of the muscles, while the CON RET increased 
the pennation angle and the ECC RET increased the myofiber length. It is suggested 
that the new sarcomeres are coupled in parallel to the old ones after a CON RET 
training but in series by using an ECC RET [46].
It is interesting, that not only the high-load but the low-load resistance exercise 
can stimulate the mitochondrial biogenesis and function besides the positive effects 
on the contractile machinery [47].
The electrical stimulation increases the size of the fast type muscle fibers parallel 
to the decrease in the diameter of the slow type myofibers, similarly to the resis-
tance training in a 70y old population [48].
Although, the aging-related loss of motor neurons seems to be inevitable but 
physical exercise, especially the strength training can evoke adaptive changes in 
the motor units that compensate the decrease in the number of motor neurons. The 
reinnervation of deinnervated muscle fibers by the collateral axons can be pro-
moted, but other data contradict to these findings [19].
Similar findings have recently been reported showing that the muscle cross-
sectional area (CSA) in vastus lateralis has decreased by aging independently of dif-
ferent trainings. The number of motor units has been larger in young power training 
group compared to young controls but in elder age neither the power nor the endur-
ance training have impacted this parameter The size of motor units has increased 
by age without significant effect of power or endurance training. In conclusion, the 
benefit of regular training may be the improvement in motor unit remodeling [49].
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The power training (concentric contractions at high velocity) evokes earlier acti-
vation and higher firing rate in the motor unit [31]. Overview of the spinal motor 
neuron plasticity, i.e. its adaptation to different exercises has recently been pub-
lished. In human investigations, indirect approach has been used to get information 
about the motor neuron behavior analyzing the response of the motor unit by using 
surface or intramuscular electromyography. The heterogenous training protocols 
make difficult to explore and interpret the association between the exercise features 
and the motor neuron response, so this field is open for further investigations [50].
4.2  Effect of physical exercise on the regeneration capacity of the skeletal 
muscles
Both the short- and long-term resistance training downregulate the M1 type and 
upregulate the M2 type macrophage expression. This shift facilitates the phago-
cytosis and satellite cell activation after an injury of muscle fibers improving the 
regeneration capacity of the skeletal muscle. The electric stimulation increases the 
number of Pax7 and neural cell adhesion molecule (NCAM) positive satellite cells 
(myogenic cells committed to differentiation) [48].
It is worth to consider that the mode of contraction used in a resistance training 
affects the muscle cell damage and regeneration at different way and to differ-
ent extent. The eccentric muscle contractions (ECC) resulted in higher degree of 
damage than the concentric ones. The inflammatory cytokine concentration was 
increased due to the eccentric, but not the concentric exercises. The number of 
satellite cells increased in ECC group but remained unchanged after the concentric 
exercises [51]. The eccentric contractions stimulate the production of collage type I, 
III and IV so restoring the extracellular matrix around the satellite cells. The fibrosis 
and adipogenesis seems to be attenuated [52].
It has been reported that the number of type I specific Pax7+ satellite cells has 
increased 96 h after resistance training alone or combined with endurance training 
but the number of type I specific MyoD+ (activated) cells have increased only after 
the resistance training. The number of type II specific satellite cells (Pax7+ and 
MyoD+) have not changed in any type of exercise in vastus lateralis of the middle-
aged, overweight/obes, sedentary patients [53].
4.3 Effect of physical exercise on the bone
The loss of muscle mass and strength (sarcopenia) is frequently associated with 
the impaired structure (osteoporosis) and function of the bone (osteopenia).
Due to the technical difficulties in human (lack of non-invasive technique to 
measure the mechanical strain in the bone) there are no direct data about the effect 
of various types of physical exercises on bone cells. The indirect data derive from 
the measuring the markers for bone formation and bone resorption. The weight-
bearing exercises (jumping, aerobics and running) and low impact exercises (as 
walking) are recommended in several authors and authorities for the prevention 
of bone loss. However, the effectiveness and feasibility of different trainings seems 
to be age dependent. In old age the concomitant diseases (joint and cardiovascular 
problems) make limitation in the choice of training type [54].
A recent publication has revealed a close correlation between the effect 
of a 3-month combined resistance and weight-bearing training on the bone 
remodeling and the muscle power in post-menopausal women. The number of 
circulating osteogenic cells has increased parallel to the bone-formation marker 
with significant correlation to the one-repetition maxim in the lower and upper 
 extremities [55].
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The osteoblast activity showed marked (but not significant) increase on 
the effect of a 10-week progressive aerobic training in women suffering from 
 postmenopausal osteoporosis [56].
4.4 Effect of physical exercise on the skeletal muscle microcirculation
In advanced age, the reactivity of microcirculation to various factors, especially 
the endothelium derived relaxing and contracting factors as well as the sympatho-
lytic mechanisms during exercise are impaired. The vasodilation is reduced, and the 
vasoconstriction is higher than in younger people leading to lower blood flow and 
decreased tolerance to aerobic exercises [57].
According to the microcirculation theory of aging [28], the impairment of 
the microvasculature structure and reactivity in old age plays important role in 
deterioration of the neuromuscular homeostasis and can be an important target for 
physiotherapy interventions.
Endurance exercises stimulate the angiogenesis and oxidative metabolism in the 
muscle fibers, so it is recommended to precede the muscle mass increasing resistance 
exercises [9]. The better capillarization as a result of the long-term aerobic exercises 
or chronic electric stimulation usually precedes the increased activity of oxidative 
enzymes. Heavy resistance training does not stimulate the  capillarization [10].
5. Recommendations to practitioners
The types of physical activity being feasible even in hospitalized and physically 
frail patient have been reviewed recently. Resistance exercises alone or in combination 
with other types of physical activity even done in bed at low to moderate intensity 
evoke positive changes in the physical performance. High speed, dynamic resistance 
exercise with concentric contractions are preferable in this situation. Resistance exer-
cises performed by using elastic bands result in significant improvement in muscle 
power and functional outcome even in a short-term training program. Aerobic exer-
cises with progressive duration (e.g. cycle-ergometer, treadmill or so simple exercises 
as steps-up, stationary cycling, walking) are strongly recommended [58].
The recently published position statement from the National Strength and 
Conditioning Association gives an excellent guideline for practitioners engaged 
in care of old people. Regarding the resistance training protocols directed to old 
people 2–3 sets of exercises acting on the large muscle groups and many joints with 
frequency of 2–3 sessions/week at 70–85% of 1RM and inclusion of power exercise 
with concentric movement at high velocity but moderate intensity (40–60% of 
1RM) are recommended. There is a need to adapt the training program to neuro-
muscular disorders, limitation in movement, the comorbidities and frailty. The 
completion of resistance training with endurance and balance training is recom-
mended to reach as benefits as possible [59].
The international practice guideline for sarcopenia elaborated by the participants 
in International Conference on Sarcopenia and Frailty Research strongly recommends 
the resistance training program for old persons based on evidences. It is noted that 
the individually tailored training program can be better than the group training but 
there is some cost limitation for this type of training program. The authors note that 
increase in physical activity in the leisure time is also  advantageous [60].
The combination of aerobic and resistance training is also preferred by other 
authors to reach the possible maximal functional outcomes [5, 18, 53]. The best 
effects can be supposed if the aerobic training precedes the resistance training 
 supporting the metabolic adaptation of neuromuscular system [9].
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people 2–3 sets of exercises acting on the large muscle groups and many joints with 
frequency of 2–3 sessions/week at 70–85% of 1RM and inclusion of power exercise 
with concentric movement at high velocity but moderate intensity (40–60% of 
1RM) are recommended. There is a need to adapt the training program to neuro-
muscular disorders, limitation in movement, the comorbidities and frailty. The 
completion of resistance training with endurance and balance training is recom-
mended to reach as benefits as possible [59].
The international practice guideline for sarcopenia elaborated by the participants 
in International Conference on Sarcopenia and Frailty Research strongly recommends 
the resistance training program for old persons based on evidences. It is noted that 
the individually tailored training program can be better than the group training but 
there is some cost limitation for this type of training program. The authors note that 
increase in physical activity in the leisure time is also  advantageous [60].
The combination of aerobic and resistance training is also preferred by other 
authors to reach the possible maximal functional outcomes [5, 18, 53]. The best 
effects can be supposed if the aerobic training precedes the resistance training 
 supporting the metabolic adaptation of neuromuscular system [9].
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6. Conclusions
The main characteristics of the aging of skeleto-neuro-muscular system at 
cellular and tissue level is overviewed in a holistic approach with the aim of giving a 
theoretical basis for physiotherapeutic interventions. The muscle fiber atrophy and 
numeric decline in the muscle fibers are associated with the fundamental alteration 
of the motor neurons and NMJ accompanied by the remodeling of motor units. The 
regeneration capacity of the muscle fibers is attenuated due to the intrinsic aging of 
the satellite cells and the self-renewal ability of stem cell pool. The aging of neu-
romuscular system (sarcopenia) is frequently associated with the aging processes 
in the bone (osteopenia). The blood supply to the skeletal muscle is also affected 
by the aging of microvasculature leading to decreased vasodilation and increased 
vasoconstriction responses.
The implementation and functional outputs of resistance and endurance train-
ing is overview in the mirror of current literature. It is generally accepted that the 
resistance training is the most important interventions in the elder age with taking 
into consideration the aging-dependent limitations. Feasibility and safety relations 
are also cited. The endurance training alone improves the cardiovascular fitness 
with lower (but not zero) direct impact on muscle power and performance. The 
combined training (AT+RT) completed with the elements of balance training seems 
to be the more effective in old people. The data about the effects of the physical 
exercises at cellular and tissue level offer good background to interpretation of the 
practical experiences.
Based on the current literature, we recommend the combined exercise trading, 
fundamentally based on resistance training but completed with the endurance and 
balance training elements.
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Muscular atrophy is one of disease by the loss of skeletal muscle mass. So, by the loss 
in muscle often causes rapid muscle atrophy and the occurs during injury and illness its 
causes immobilization in spinal muscle mass. Usually, the impact factor of the nervous 
system in musculoskeletal is caused by aging, immobility, malnutrition, medication 
and even the range of injuries disease impact by the nervous system. To meet the needs 
needed by the loss of skeletal, we need high total antioxidant from herbal medicine as 
multifunctional potentially prevention of muscular atrophy condition. Antioxidants 
are agents that can slow down or prevent oxidation process and protect cells system 
from the damage of cell by the loss skeletal in muscle mass. One of herbal medicine is 
Abelmoschus manihot L. Medik From Palu of central Sulawesi as a possible multifunc-
tional prevention of Muscular Atrophy, where the total antioxidant value is 3,45 mg/mL.
Keywords: total antioxidant, herbal medicine, multifunctional prevention,  
muscular atrophy
1. Introduction
Muscular atrophy is one of disease by the loss of skeletal in muscle mass. The 
muscular atrophy recessive autosomal in neuromuscular with characterized of 
alpha motor neuron in the spinal cord [1]. The neuromuscular disorders are one 
factor genetic of infant mortality [2]. The spinal muscular atrophy deletion or 
mutation the Survival motor neuron 1 (SMN 1 gene), reduction of levels functional 
survival motor neuron 1 (SMN 1 gene) and also resulting selective death of spinal 
motor neurons system in a pathway, it’s depends by the age of onset, symptoms 
and maximum function achieved [3]. By the age at the onset it causes at birth: 
Neuromuscular disease, congenital myotonic dystrophy and spinal muscular atro-
phy, other causes are systematic septicemia-induced disease, lung damage, intracra-
nial pathologies, infection of the central nervous system, disorders of the peripheral 
nerves, disease of the neuromuscular junction, Prader-Willi syndrome and drug 
intoxication during pregnancy or delivery system and after 6 months of age were 
the neuromuscular disease: spinal muscular atrophy types II and III, polyneuropa-
thies, childhood myasthenia gravis, muscular dystrophies and metabolic myopathy 
and besides that in other causes were congenital heart disease, malnutrition, rickets, 
metabolic diseases, nephropathies and lung diseases [4, 5]. The clinical prognosis of 
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spinal muscular atrophy is variable and depends on types of spinal muscular atro-
phy continuous spectrum with the age of death by infancy to normal life expectancy 
condition system on cell pathway system [6]. The Muscular atrophy its described 
with characterized generalized muscle and atrophy in the proximal limb muscle and 
phenotype by four grades of severity, where the spinal Muscular Atrophy I, spinal 
Muscular Atrophy II, spinal Muscular Atrophy III and spinal Muscular Atrophy IV, 
it’s all depended by onset and motor spinal function [7, 8]. The muscular atrophy 
disease by the control mutation in the homozygous of survival motor neuron α 
(SMN 1) gene. The skeletal of muscular atrophy it’s adverse consequences and the 
mechanism such as wasting or decrease of injury time. Lack of use in the spinal 
muscular atrophy and event disease category of spinal muscular atrophy. The spinal 
muscular atrophy it’s usually considered by chronic diseases such as poliomyelitis, 
Diabetes mellitus, cancer, renal failure or pulmonary obstruction [1].
To activation of spinal muscular atrophy, we need the process to activation of the 
distinct pathway (ATP) in proteolysis pathway. The condition of spinal muscular 
atrophy it’s depends on the level of muscle protein nutrition system. To reduce the 
fiber muscle we need synthesis protein to innervate proximal hindlimb muscles and 
medical motor neurons axial muscles [9]. Mitochondrial is important in skeletal 
muscle to activation of function and subpopulation involved in cellular functions. 
Mitochondria play in role key on muscle fibers to the regulation of myonuclear 
apoptosis and serving uptake the calcium [10]. Mitochondria also continuously 
produce superoxide radicals and dismutated into hydrogen peroxide (H2O2), where 
H2O2 is a relatively and diffuse freely with cytosol, it’s very important as signaling to 
the molecule on cell, to affecting multiple control of the cell cycle, uptake to cellular 
stress response, activation energy metabolism and also to the expression of numer-
ous redox-sensitive genes in spinal muscular atrophy disease [9].
2. Prevalence, incidence and carrier frequency of muscular atrophy
According to the worldwide about a study into the prevalence and incidence 
of spinal muscular atrophy, where approximately 1–2 per 100.000 people and 
incidence around 1 in 10.000 live births have been estimated with the spinal 
muscular atrophy type I accounting for around 60% of all cases and estimation of 
the incidence of all types of spinal muscular atrophy of around 10 in 100.000 (1 in 
10.000) live birth is cited [11]. Every incidence is a factor from a number of new 
cases of the disease in a particular time period. The evaluation of the incidence of 
all type SMA combined it’s around 8 per 100.000 live births. The incidence of spinal 
muscular atrophy type I is around 4–6 in 100.000 and for the type II and III it’s a 
high incidence combined 10,6 per 100.000 and for the gender, it’s a nearly even split 
male and female [12]. The indicated difference of spinal muscular atrophy types is 
the between ethnicities and differences in health system clinically diagnosed. The 
prevalence in Indonesia of neuromuscular in RSCM hospital from January –  
December 2017 is 2,6% of all patients who come to the neurology outpatient ward. 
The five most who have neuromuscular disorders are neuropathy peripheral, 
Duchenne muscular dystrophy, spinal muscular atrophy, Guillain barre syndrome 
and chronic inflammatory demyelinating polyneuropathy [13].
3. Genetics of spinal muscular atrophy
Spinal muscular atrophy is a defect in survival motor neuron 1 (SMN 1) and it’s 
gene localized to 5q11.2-q13.3). SMN gene (SMN 1 and SMN 2) on chromosome 
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5q13 and the homozygous deletion of the SMN 1 gene result in Spinal muscular 
atrophy. Besides that, the SMN 2 gene it produces mostly a shortened, unstable the 
survival motor neuron mRNA and also to alternative splicing, a small amount of 
full – length on functional SMN mRNA. The SMN 2 gene is a good prognostic of 
the spinal muscular atrophy in clinical severity. The clinical severity management 
of spinal muscular atrophy disease is supportive to increase the survival motor 
neuron expression levels in motor neurons cells system. So, the management of 
spinal muscular atrophy depends on increase SMN expression levels in motor 
neurons [3].
The survival motor neuron 1 gene it should be sequenced mutations if both 
full SMN 1 present of diagnosis on spinal muscular atrophy is highly, but the SMN 
1 gene should be sequenced if the striking typical phenotype, where if sequenc-
ing indicates and intact SMN 1 gene of phenotype suggestive of spinal muscular 
atrophy neurogenic. The survival motor neuron 2 gene should be routinely assessed 
and it’s important to factor system influencing the severity of the spinal muscular 
atrophy phenotype [1].
4. Molecular oxidative stress factor of muscular atrophy
Factor oxidative stress of muscle atrophy it’s important to maintenance and 
quality to the rehabilitation of disease. The skeletal of muscle atrophy need continu-
ously produce oxidants like as a reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) to an imbalance of skeletal muscle mechanism process. The soluble 
atrophy it’s produced different oxidative stress state species such as O2−, H2O2 and 
OH−. Where, it also needs antioxidant species state such as catalase, glutathione 
peroxidase (GPx) and superoxide dismutase (SOD) and the last to imbalance 
denominated of oxidative stress, it’s can produce oxidative damage in lipids, 
Deoxyribonucleic acid (DNA) and protein to impairing functional protein factor of 
cellular system [14].
Generation of ROS could uptake of oxygen, activation of NADPH oxidase and to 
production of the superoxide anion radical, see the reaction:
 
oxidase
2 22O NADPH 2O NADP H
− + +
+ → + +  (1)
Where O2− is converted to H2O2 (Eq. (2) by SOD
 2 2 2 22O 2H H O O
SOD
+
+ → +  (2)
The skeletal of muscle atrophy could inactivity increase of mitochondrial reac-
tive oxygen species (ROS) production on the ways. The mitochondrial could uptake 
of calcium and increase mitochondrial levels state of fatty acid hydroperoxides and 
the last depressed protein could transport into the mitochondria system. So, if the 
mechanism responsible, it’s could increase mitochondrial fission [9].
The observation of muscle mass-specific overexpression of Peroxisome 
proliferator-activated receptor-y-coactivator-1α (PGC-1α) and the master regula-
tor of mitochondria biogenesis could prevent activation of catabolic system and 
disuse of muscle atrophy system. The Peroxisome proliferator-activated receptor-
y-coactivator-1α (PGC-1α) is mediated pathway and focuses on the role PGC-1α 
in the skeletal spinal muscular atrophy system by immobilization system. The 
Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) is the master 
transcription stimulates of mitochondrial biogenesis pathway system with up the 
regulating system of the nuclear respiratory factors (NRF-1,2) and mitochondrial 
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5q13 and the homozygous deletion of the SMN 1 gene result in Spinal muscular 
atrophy. Besides that, the SMN 2 gene it produces mostly a shortened, unstable the 
survival motor neuron mRNA and also to alternative splicing, a small amount of 
full – length on functional SMN mRNA. The SMN 2 gene is a good prognostic of 
the spinal muscular atrophy in clinical severity. The clinical severity management 
of spinal muscular atrophy disease is supportive to increase the survival motor 
neuron expression levels in motor neurons cells system. So, the management of 
spinal muscular atrophy depends on increase SMN expression levels in motor 
neurons [3].
The survival motor neuron 1 gene it should be sequenced mutations if both 
full SMN 1 present of diagnosis on spinal muscular atrophy is highly, but the SMN 
1 gene should be sequenced if the striking typical phenotype, where if sequenc-
ing indicates and intact SMN 1 gene of phenotype suggestive of spinal muscular 
atrophy neurogenic. The survival motor neuron 2 gene should be routinely assessed 
and it’s important to factor system influencing the severity of the spinal muscular 
atrophy phenotype [1].
4. Molecular oxidative stress factor of muscular atrophy
Factor oxidative stress of muscle atrophy it’s important to maintenance and 
quality to the rehabilitation of disease. The skeletal of muscle atrophy need continu-
ously produce oxidants like as a reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) to an imbalance of skeletal muscle mechanism process. The soluble 
atrophy it’s produced different oxidative stress state species such as O2−, H2O2 and 
OH−. Where, it also needs antioxidant species state such as catalase, glutathione 
peroxidase (GPx) and superoxide dismutase (SOD) and the last to imbalance 
denominated of oxidative stress, it’s can produce oxidative damage in lipids, 
Deoxyribonucleic acid (DNA) and protein to impairing functional protein factor of 
cellular system [14].
Generation of ROS could uptake of oxygen, activation of NADPH oxidase and to 
production of the superoxide anion radical, see the reaction:
 
oxidase
2 22O NADPH 2O NADP H
− + +
+ → + +  (1)
Where O2− is converted to H2O2 (Eq. (2) by SOD
 2 2 2 22O 2H H O O
SOD
+
+ → +  (2)
The skeletal of muscle atrophy could inactivity increase of mitochondrial reac-
tive oxygen species (ROS) production on the ways. The mitochondrial could uptake 
of calcium and increase mitochondrial levels state of fatty acid hydroperoxides and 
the last depressed protein could transport into the mitochondria system. So, if the 
mechanism responsible, it’s could increase mitochondrial fission [9].
The observation of muscle mass-specific overexpression of Peroxisome 
proliferator-activated receptor-y-coactivator-1α (PGC-1α) and the master regula-
tor of mitochondria biogenesis could prevent activation of catabolic system and 
disuse of muscle atrophy system. The Peroxisome proliferator-activated receptor-
y-coactivator-1α (PGC-1α) is mediated pathway and focuses on the role PGC-1α 
in the skeletal spinal muscular atrophy system by immobilization system. The 
Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) is the master 
transcription stimulates of mitochondrial biogenesis pathway system with up the 
regulating system of the nuclear respiratory factors (NRF-1,2) and mitochondrial 
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transcription factor A (Tfam) system, so it leads to increased mitochondrial DNA 
replication system and gene transcription system [15]. The Peroxisome proliferator-
activated receptor-y-coactivator-1α (PGC-1α) to appears key to the role-play a 
protective against of muscular atrophy linked skeletal muscle deterioration. The 
Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) interacts 
with the nuclear receptors and activate transcription factors to activated their target 
gene. The activity to responsive multiple stimuli including calcium ion, Reactive 
oxygen species (ROS) and ATP demand pathway system on the cell system in the 
spinal muscular atrophy. The metabolic stress mediated by PGC-1α downregulation 
plays a major role in muscle atrophy and to adaptation the soleus to mice hindlimb 
unloading (HU) in the defuse, we need antioxidant treatment (Trolox). Which, the 
HU caused of reduction in the cross-sectional area, redox status alteration (NRF2, 
Superoxide dismutase1 and catalase up-regulation) and the autophagy (Beclin1 
and P62 mRNA up-regulation) [16]. The attractive of PGC-1α states in muscle 
mass could restore and promote the muscle metabolic system when normal physi-
cal activity impossible. The observation of the muscle fiber – specific event until 
overexpression of the attractive of PGC-1α states, where a master regulator of the 
mitochondrial biogenesis, to prevent activation produce of the catabolic system and 
also disuse muscle atrophy.
5. Antioxidant mechanism and function
The natural antioxidant is one important to underlying to spinal muscular 
atrophy system. The natural antioxidant could effect to exercise the health- 
promoting increase muscle defenses [17]. The natural antioxidant which role-plays 
to activation integrity on the cell and to prevent the free radical configuration 
tissue damage of muscle atrophy to normal healthy condition system of muscle 
atrophy pathway [18].
The natural antioxidant increasing antioxidative defenses and develop a synthesis 
of endogenous enzymes or increased antioxidant utilization, practice to maintain 
optimal body function to especially of spinal muscular atrophy in the redox condi-
tion on cell [19]. The function from natural antioxidant: it reduces the free radical 
of spinal muscular atrophy, stimulates the growth of normal cells, to protects the 
cell against the premature and abnormal aging condition of spinal muscular atro-
phy, helps fight the age-related molecular degeneration of spinal muscular atrophy 
and the last to supports the body immune system [17]. The natural antioxidant is 
powerful electron donors and also to the reaction of free radicals to target molecules 
breaking damaged on skeletal muscular. The lipid phase of chain-breaking antioxi-
dant can scavenge the radicals in membranes and lipoprotein particles to preventing 
lipid peroxidation of skeletal muscular atrophy. The lipid phase such as tocopherols, 
ubiquinol, carotenoids and flavonoids and the aqueous phase such as ascorbate, 
urate, glutathione and other thiols [20, 21].
6. Flavonoids are group of antioxidants
Flavonoids are a group from based on natural substances by a variable phenolic 
structure, where are found from fruits, vegetables, grains, bark, roots, stems, flowers, 
tea and wine. Flavonoids are potential to anti-oxidative, anti-inflammatory and anti-
mutagenic on spinal muscular atrophy disease [22]. As an anti-inflammatory, we need 
of agent system, where the COX is an endogenous enzyme with catalyzes function, 
which the conversion of arachidonic acid into prostaglandins and thromboxanes, 
147
Total Antioxidant from Herbal Medicine as a Possible Tool for the Multifunctional Prevention…
DOI: http://dx.doi.org/10.5772/intechopen.94184
where the enzyme exists in two isoforms: COX - 1 is a constitutive enzyme and is 
responsible for the supply of prostaglandin and Cox – 2 is an inducible enzyme and is 
expressed an inflammatory stimulus and the stimulus prostaglandin to induction of 
inflammatory and pain. By using, the flavonoids can activate the molecular docking 
and knowledge bioinformatics in preventing chronic disease like as spinal muscular 
atrophy and to application and manufacturing in pharmaceutical medicinal industry 
[23]. Flavonoids subdivided of subgroup depending on the carbon of the C ring on 
which the B ring, which the degree of unsaturation and oxidation of the C ring. The 
firs isoflavone, which in the B ring is linked position 3 of the C ring. Second, the 
neoflavonoids, which the B ring is linked in position 4. Besides that, the subdivided 
into several subgroups on the basis which the B ring is linked position 2 on the basis 
of the structural features of the C ring. Flavonol (e.g. Quercetin, myricetin), flavone 
(eg. apigenin, luteolin), flavonolols (eg. taxifolin), flavan-3-ols (eg catechin, epigal-
locatechin), flavovone [24] (eg. hesperitin, naringenin), anthocyanidin (eg. cynidin, 
delphidin), isoflavone (eg. genistein, daidzein).
7. Abelmoschus manihot L. Medik is one of herbal medicine
Abelmoschus manihot L. Medik is have highest total antioxidant (Table 1). The 
leaf plant is a tropical plant from china, which is trapped by the name Huangkui. 
Ethanobotanical uses and phytochemical analysis of Abelmoschus manihot L. Medik, 
where the preliminary study shows the presence of alkaloid, carbohydrates, tan-
nins, steroid and glycosides [25].
8.  Ethanomedicinal, phytochemical and pharmacological  
of Abelmoschus manihot
Ethanomedicinal, phytochemical and pharmacological profile of genus 
Abelmoschus manihot L. Medik where the genus Abelmoschus manihot L. Medik 
has been reported to used for several ethnomedicinal practices and also dem-
onstrated diverse pharmacological activities and posses several phytochemical 
and nutritional properties as well as having and no adverse effect on living cells, 
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overexpression of the attractive of PGC-1α states, where a master regulator of the 
mitochondrial biogenesis, to prevent activation produce of the catabolic system and 
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5. Antioxidant mechanism and function
The natural antioxidant is one important to underlying to spinal muscular 
atrophy system. The natural antioxidant could effect to exercise the health- 
promoting increase muscle defenses [17]. The natural antioxidant which role-plays 
to activation integrity on the cell and to prevent the free radical configuration 
tissue damage of muscle atrophy to normal healthy condition system of muscle 
atrophy pathway [18].
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optimal body function to especially of spinal muscular atrophy in the redox condi-
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cell against the premature and abnormal aging condition of spinal muscular atro-
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and the last to supports the body immune system [17]. The natural antioxidant is 
powerful electron donors and also to the reaction of free radicals to target molecules 
breaking damaged on skeletal muscular. The lipid phase of chain-breaking antioxi-
dant can scavenge the radicals in membranes and lipoprotein particles to preventing 
lipid peroxidation of skeletal muscular atrophy. The lipid phase such as tocopherols, 
ubiquinol, carotenoids and flavonoids and the aqueous phase such as ascorbate, 
urate, glutathione and other thiols [20, 21].
6. Flavonoids are group of antioxidants
Flavonoids are a group from based on natural substances by a variable phenolic 
structure, where are found from fruits, vegetables, grains, bark, roots, stems, flowers, 
tea and wine. Flavonoids are potential to anti-oxidative, anti-inflammatory and anti-
mutagenic on spinal muscular atrophy disease [22]. As an anti-inflammatory, we need 
of agent system, where the COX is an endogenous enzyme with catalyzes function, 
which the conversion of arachidonic acid into prostaglandins and thromboxanes, 
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where the enzyme exists in two isoforms: COX - 1 is a constitutive enzyme and is 
responsible for the supply of prostaglandin and Cox – 2 is an inducible enzyme and is 
expressed an inflammatory stimulus and the stimulus prostaglandin to induction of 
inflammatory and pain. By using, the flavonoids can activate the molecular docking 
and knowledge bioinformatics in preventing chronic disease like as spinal muscular 
atrophy and to application and manufacturing in pharmaceutical medicinal industry 
[23]. Flavonoids subdivided of subgroup depending on the carbon of the C ring on 
which the B ring, which the degree of unsaturation and oxidation of the C ring. The 
firs isoflavone, which in the B ring is linked position 3 of the C ring. Second, the 
neoflavonoids, which the B ring is linked in position 4. Besides that, the subdivided 
into several subgroups on the basis which the B ring is linked position 2 on the basis 
of the structural features of the C ring. Flavonol (e.g. Quercetin, myricetin), flavone 
(eg. apigenin, luteolin), flavonolols (eg. taxifolin), flavan-3-ols (eg catechin, epigal-
locatechin), flavovone [24] (eg. hesperitin, naringenin), anthocyanidin (eg. cynidin, 
delphidin), isoflavone (eg. genistein, daidzein).
7. Abelmoschus manihot L. Medik is one of herbal medicine
Abelmoschus manihot L. Medik is have highest total antioxidant (Table 1). The 
leaf plant is a tropical plant from china, which is trapped by the name Huangkui. 
Ethanobotanical uses and phytochemical analysis of Abelmoschus manihot L. Medik, 
where the preliminary study shows the presence of alkaloid, carbohydrates, tan-
nins, steroid and glycosides [25].
8.  Ethanomedicinal, phytochemical and pharmacological  
of Abelmoschus manihot
Ethanomedicinal, phytochemical and pharmacological profile of genus 
Abelmoschus manihot L. Medik where the genus Abelmoschus manihot L. Medik 
has been reported to used for several ethnomedicinal practices and also dem-
onstrated diverse pharmacological activities and posses several phytochemical 
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and traditional remedies all over the world [26]. The protective effect on the 
total flavonoid of Abelmoschus manihot L. Medik on transient cereberal ischemia-
preperfusion injury is due to activation of the Nrf2-are pathway, where the highest 
total flavonoids 788,56 mg/g) of all the different part, the protective effects of 
an extract of the total flavonoids of Abelmoschus manihot L. Medik on transient 
cereberal ischemia–reperfusion injury (TCI-RI) were investigated, these data 
suggest that to protects against TCI-RI by scavengin free radical and activating 
NRF2-ARF pathway (Nuclear factor E2-related factor 2 contributes to neuropto-
tective immune system, antioxidation, antifatigue and anti-inflamatory properties 
[27]. The bioactive compounds from Abelmoschus manihot L. Medik alleviate the 
progression of multiple myeloma in mouse model and improve bone marrow envi-
ronment, where the Abelmoschus manihot L. Medik derived as a Huangkui capsules 
(HKC) represent a traditional Chinese medicine that has been widely applied to 
the clinical therapy of kidney and inflamatory disease by methods expressions 
of certain proteins were detected via western blotting, transcriptomic RNA-
sequencing as well as RT-qPCR, where the result revealed that MM-Prone animals 
appeared to be protected following HKC treatment as evidence by a prolonged 
survival rate, which four of the nine flavonoid compounds (Hyperin/hyperoxide, 
HK-2; cannabiscitrin, HK-3, 3-O-kaempferol-3-O-acetyl-6-O-(p-coumaroyl)-
β-D-glucopyranosid, HK-11, 8-(2-pyrolidione-5-yl)-3-O-β-D-glucopyranosid, 
HK-E3) suppressed osteoclastogenesis in murine raw 264.7 cells.HK-11 directly 
inhibited MM cells (ARP1 and h929) proliferation and induced G0/G1 cell cycle 
arrest, which may have involved suppressing β-catenin protein, increasing expres-
sion of IL-6 and TNF-α, as well as activating mature TGF-β1 and some other 
metabolic pathways [28]. Abelmoschus manihot L. Medik have supplementation as 
a Nephropathy system by methods a combined treatment of a high – fat diet and 
streptozotocin after unilateral nephrectomy and supplementation of Abelmoschus 
manihot L. Medik were tested, the results is preventive effects of the extracts on 
Nephropathy pathology system and changes on autophagy mitocondrial proteins 
were investigated to showed significant increase in fasting blood glucose, plasma 
creatinine, blood urea nitrogen and urinary albumin levels [29]. Abelmoschus 
manihot L. Medik as a Huangkui in Chinese, where as a traditional Chinese 
medicine, the Huangkui has been used for medication of the patients as a reduce 
inflammation anti-oxidative stress, improving immune response system, protect-
ing renal tubular epithelial cells, ameliorating podocyte apoptosis, glomeruloscle-
rosis and mesangial proliferation, as well as inhibiting on cellular and molecular 
mechanism [30]. So, with the natural antioxidant as a reduces the free radical of 
spinal muscular atrophy and stimulates the growth of normal cells. In Palu city 
of central Sulawesi Indonesia, where the plant is known as one of the raw based 
material of vegetables and is usually mixed with pulp.
9. Total antioxidant of Abelmoschus manihot (L.) Medik
This plant is believed to have medicinal based properties, because are many 
compound vitamins, like as: A, B1, B2, B3, C and E, compound the calcium, 
potassium, copper, zinc and many collagen. This plant also contains secondary 
metabolites like as: Flavonoids, Saponin and phonolite, where it has used as an 
antioxidant. The evaluate total antioxidant arrest activity using the DPPH (IC50) 
of Abelmoschus manihot (L.) Medik extracts from Palu of Central Sulawesi, the 
method is displayed in Table 2 and Figure 1, evaluate the potential activity of the 
test substances for the cytotoxicity against selected 4 T1 cell lines and Vero cell 
of Abelmoschus manihot (L.) Medik extracts from Palu of Central Sulawesi. The 
149
Total Antioxidant from Herbal Medicine as a Possible Tool for the Multifunctional Prevention…
DOI: http://dx.doi.org/10.5772/intechopen.94184
cytotoxicity potential of various concentration of ethanol, ethyl acetate, N-Heksan 
extracts with CTC50 values of leaf Abelmoschus manihot (L.) Medik is displayed in 
Tables 3 and 4 and Figures 2 and 3. Leaf Abelmoschus manihot (L.) Medik from 
Palu of Central Sulawesi extract plant shows the total antioxidant is 3,45 μg/ml 
from reports arrest of DPPH (IC50) is displayed in Table 2 and Figure 1. According 
to the criteria to the level of antioxidant power with DPPH (IC50) method, where 
the extract of natural ingredients with IC50 < 50 μg/ml is potential. The in-vitro 
cytotoxicity effects of leaf Abelmoschus manihot (L.) Medik from Palu of Central 
Sulawesi, where carried with various concentrations to the breast cancer cell lines 
4 T1 and have Potentially Toxicity, where the leaf of Abelmoschus manihot (L.) 
Medik of the medicinal plant was collected from Palu of central Sulawesi and 
extracted with ethanol solvent with use of Six different concentrations (31.25 μg/ml, 
62.5 μg/ml, 125 μg/ml, 250 μg/ml, 500 μg/ml and 1000 μg/ml) of leaf extracts were 
used to investigate study the in-vitro cytotoxicity concentration potential of the 
medicinal plant. The cytotoxicity potential of various extracts is N-Heksan extract 
of Abelmoschus manihot (L.) Medik with CTC50 values of Abelmoschus manihot (L.) 
Medik is displayed in Table 3 and Figure 2. The results that the cytotoxicity rate 
has increased when the concentrations of leaf Abelmoschus manihot (L.) Medik 
extracts increases. MTT assay measured the viability cell based on the reduction 
of yellow tetrazolium MTT to a purple formazan dye by mitochondrial succinate 
dehydrogenase enzyme. Where the amount of formazan produced reflected the 
number of metabolically active 4 T1 cells Line (Breast Cancer). The test substances 
Leaf Extract (ethanol), Leaf Extract (ethyl acetate) and Leaf Extract (N-Heksan) 
were exhibited a CTC50 value of 261.84 ± 0.13 μg/ml, 288.29 ± 0.10 μg/ml and 
185.06 ± 0.12 μg/ml. According to the criteria value of the cytotoxicity level of 
extracts, if an excerpt of natural ingredients with CTC50 < 100 μg/ml is very active, 
the CTC50 value of 100–200 μg/ml is quite active and > 200 μg/ml is weak [31]. The 
Name of Test
Substance
Antioxidant Activity DPPH IC50 (mg/mL)
Leaf Abelmoschus manihot (L.) Medik extract 3,45
Table 2. 
The antioxidant activity DPPH (IC50) of leaf Abelmoschus manihot (L.) Medik [32].
Figure 1. 
Graph of total antioxidant of Abelmoschus Manihot.
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[27]. The bioactive compounds from Abelmoschus manihot L. Medik alleviate the 
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β-D-glucopyranosid, HK-11, 8-(2-pyrolidione-5-yl)-3-O-β-D-glucopyranosid, 
HK-E3) suppressed osteoclastogenesis in murine raw 264.7 cells.HK-11 directly 
inhibited MM cells (ARP1 and h929) proliferation and induced G0/G1 cell cycle 
arrest, which may have involved suppressing β-catenin protein, increasing expres-
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metabolic pathways [28]. Abelmoschus manihot L. Medik have supplementation as 
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Nephropathy pathology system and changes on autophagy mitocondrial proteins 
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Palu of Central Sulawesi extract plant shows the total antioxidant is 3,45 μg/ml 
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dehydrogenase enzyme. Where the amount of formazan produced reflected the 
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results of N-Heksan leaf extract Abelmoschus manihot (L.) Medik has quite poten-
tially to the cytotoxicity. The N-Heksan leaf extract Abelmoschus manihot (L.) Medik 
shows the better percentage of growth inhibition CTC50 is 185.06 ± 0.12 μg/ml 4 T1 
cell lines. To the Doxorubicin of cytotoxicity CTC50 with value 4 T1 cells line is 
13,57 ± 0.10 μg/ml, where this value shows is toxic of Doxorubicin to 4 T1 cells Line 
(Breast Cancer). The cytotoxicity with various concentrations of all leaf extracts 
does not have potentially the cytotoxicity on Vero (normal) cell, where the cytotoxic-
ity with value CTC50 ≥ 200 μg/ml. The test substances Leaf Extract (ethanol), Leaf 
Extract (ethyl acetate) and Leaf Extract (N-Heksan), were exhibited a CTC50 value of 
588.39 ± 0.13 μg/ml, 451.41 ± 0.11 μg/ml and 559.12 ± 0.13 μg/ml. According to the cri-
teria value of the cytotoxicity level of extracts, if an extract of natural ingredients with 
CTC50 < 100 μg/ml is very active, the CTC50 value of 100–200 μg/ml is quite active 
and > 200 μg/ml is weak, where is displayed in Table 4 and Figure 3. Results that the 
cytotoxicity rate has increased when the concentrations of leaf Abelmoschus manihot 
(L.) Medik extracts increases. To the Doxorubicin cytotoxic CTC50 value to Vero 
(normal) cells is 60.85 ± 0.13 μg/ml, this shows is toxic from according to the criteria 
NO Name of Test
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Test Conc.  
(μg/ml)
% Cytotoxicity CTC50 (μg/ml)
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value of cytotoxicity level [32]. The medicinal plant of leaf Abelmoschus manihot (L.) 
Medik from Palu of Central Sulawesi extract, where can be used to prepare the natural 
antioxidant and to prepare the pharmaceutical-based natural drug with proper 
standardization methods. Medicinal plants are a source of important therapeutic 
for alleviating human ailments and the medicinal plants have bioactive compounds, 
which are used for curing various human disease and also play an essential role key in 
chronic disease to especially on spinal muscular atrophy cell system pathway [33]. The 
natural antioxidant as a reduces the free radical of spinal muscular atrophy, stimulates 
the growth of normal cells, to protects the cell against the premature and abnormal 
aging condition of spinal muscular atrophy, helps fight the age-related molecular 
degeneration of spinal muscular atrophy and the last to supports the body immune 
system [34, 35].
10. Summary
The muscular atrophy recessive autosomal in neuromuscular with characterized 
of alpha motor neuron in the spinal cord, the neuromuscular disorders is one factor 
genetic of infant mortality and the spinal muscular atrophy deletion or mutation 
the Survival motor neuron. Spinal muscular atrophy is a defect in survival motor 
neuron 1 (SMN 1) and it’s gene localized to 5q11.2-q13.3). SMN gene (SMN 1 and 
SMN 2) on chromosome 5q13 and the homozygous deletion of the SMN 1 gene 
result in Spinal muscular atrophy. The spinal muscular atrophy disease need of 
natural antioxidant as a reduces the free radical of the fiber muscle cell, stimulates 
the growth of normal cells, to protects the cell against the premature and abnor-
mal aging condition of spinal muscle fiber, helps fight the age-related molecular 
degeneration of spinal muscular cell and the last to supports the body immune 
system. The medicinal plant of leaf Abelmoschus Manihot (L.) Medik from Palu of 
Central Sulawesi extract, where can be used to prepare the natural antioxidant and 
to prepare the pharmaceutical-based natural drug with proper standardization 
methods. Medicinal plants are a source of important therapeutic for alleviating 
Figure 3. 
Graph of the cytotoxic effect of Abelmoschus Manihot (L.) Medik on Vero cell [32].
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human ailments and medicinal plants have bioactive compounds, which are used 
for curing various human disease and also play an essential role key in chronic 
disease to especially on spinal muscular atrophy cell system pathway.
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Management of Sarcopenic 
Obesity for Older Adults with 
Lower-Extremity Osteoarthritis
Tsan-Hon Liou, Chun-De Liao and Shih-Wei Huang
Abstract
Lower-extremity osteoarthritis (OA) is a prevalent musculoskeletal disease in 
elder population. The main symptom of OA is pain which leads to muscle weakness 
and physical disability. Recently, muscle weakness, function limitation, and severity 
of disease in OA are addressed to aging-related muscle attenuations. Therefore, elder 
individuals with OA are under potential sarcopenia risks. In addition, obesity, which 
exerts negative impacts on disease outcomes, has become a burden in OA population. 
Under multifactor risks of OA, it is important to identify effectiveness of multidis-
ciplinary management for such elder population to prevent sarcopenic obesity and 
maintain physical function. Previous studies have indicated that diet intervention 
(DI) using protein supplement, dietary protein, or weight loss enhances exercise 
efficacy in terms of additional muscle mass and strength gains to exercise training 
(ET) for elder individuals with high sarcopenia and frailty risks. However, it remains 
unclear whether DI in combination with ET augments any benefit for older adults 
with lower-extremity OA. This chapter aimed to review the effects of DI plus ET on 
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are accounted to the risks of physical limitation in elder individuals, especially those 
with hip or knee OA [9, 10]. The age-related muscle dysfunction can be addressed 
to impairments in musculoskeletal system as well as neuromuscular system [11, 12]. 
With respective to the underlying mechanisms of sarcopenia in older population, 
muscle atrophy (i.e., decline in muscle size) plays a key role in muscle attenuation 
[11], especially the type II myofiber [13]. The loss of muscle mass occurs progres-
sively from middle-age by a rate of 0.47% per year in men and 0.37% per year in 
women [14]; in people aged 75 years, muscle mass is decreased at a rapid rate of 
0.64–0.70% per year in women and 0.80–0.98% per year in men and in severe 
diseases can lead to a loss of approximate 50% by the 8–9th decade of life [15]. Loss 
of skeletal muscle mass is commonly accompanied with deficits in muscle function 
such as muscle weakness, which is relevant to clinical presentation of sarcopenia as 
well as OA. Reid et al. indicated that leg lean mass is strongly associated with muscle 
strength (r = 0.78, p < 0.01) [16]. Liu et al. further indicated that low handgrip 
strength is strongly associated with decreased skeletal muscle mass in elder indi-
viduals [17]. Because of that loss of muscle strength may lead to physical difficulty 
and disability, low muscle mass has been identified as a crucial factor of functional 
limitation of physical mobility such as walk capability and chair rise [8, 17, 18].
Recently, the disease progression of knee and hip OA has been attributed to 
age-related decline in muscle mass (i.e., sarcopenia). Toda et al. reported that older 
women with knee OA experienced significantly lower leg lean mass relative to body 
weight (%) by a mean ± standard deviation of 19.2 ± 2.7%, compared with the 
healthy control (21.0 ± 2.9%; P < 0.0001) [19]; Lee et al. observed similar results 
which indicated that older adults with knee OA had a mean appendicular skeletal 
muscle mass of 15.6 kg which is significant lower than that of healthy control 
(17.3 kg, P < 0.001) [20]. Additionally, Jeon et al. reported that lower skeletal 
muscle mass independently associated with knee radiographic OA [odds ratio (OR) 
1.34; 95% confidence interval (CI) 1.04, 1.75] [21]. Therefore, older people with 
knee OA are considered at high risk of sarcopenia [22]. Grimaldi et al. observed 
muscle mass decreased in patients with hip OA in terms of 2.6–14.4% muscle atro-
phy of gluteal muscle group in the affected side compared to those in the uninvolved 
side, whereas such asymmetry in muscle volume ranged from 0.4 to 3.7% in control 
peers [23]; in addition, the muscle volume asymmetry is positively associated with 
disease progression of hip OA, indicating that patients with moderate to severe 
OA may experience greater muscle mass loss than mild-severity or asymptomatic 
patients [24]. Therefore, the OA population faces not only age-related muscle 
attenuation (i.e., sarcopenia) but also the disease-induced muscle loss.
The sarcopenia, obesity, and OA are becoming major threats to aging society 
and have been recognized as important health issues [8, 25–27]. The relationships 
among sarcopenia, obesity (i.e., sarcopenic obesity), and OA have been discussed. 
Kemmler et al. conducted an observational study to investigate the prevalence of 
sarcopenia in community-dwelled women who aged 70 years and older; the results 
indicated that elder women with lower-extremity OA exhibited a significantly 
higher rate of sarcopenia (9.1%) than nonarthritic peers (3.5%) [28]. Jin et al. 
reported that elder men and women with sarcopenic obesity showed significantly 
higher risks of exhibiting knee OA (OR = 1.92–2.43) compared with the healthy 
control groups [29]. Misra et al. conducted a longitudinal study of the risk of 
radiographic OA in relation to sarcopenic obesity; the result showed that elder 
people with sarcopenic obesity (RR = 1.91) had increased risks of exhibiting knee 
OA within a 5-year interval of follow up [30]. Therefore, preventive efforts for the 
obese elder individuals may need to focus not only on reducing sarcopenia but also 
on improving sarcopenic obesity to reduce the growing incidence and prevalence of 
knee OA.
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2. Treatments and management for sarcopenia in elderly
Sarcopenic obesity originates from a multifactorial consequence of aging and 
its related physical inactivity [31], which especially exerts negative impacts to 
obese elderly populations [32]. Several approaches for management of sarcopenic 
obesity have been recommended including pharmacological interventions, exercise 
interventions, and nutrition interventions to counteract muscle loss and physical 
declines in obese older adults [33]. According to the recommendations from the 
European Society for Clinical Nutrition and Metabolism Expert Group [34], there 
are urgent needs for elder people with a risk of sarcopenic obesity to incorporate 
nutrition intervention and muscle strengthening exercise to prevent the functional 
decline.
2.1 Protein supplement plus exercise training for sarcopenic obesity
Obesity has become epidemic burden in elderly population [25]. Sarcopenic 
obesity, a recently identified phenotype of obese elderly population, is developed 
based on an underling additive effect of sarcopenia and obesity and is referred by 
the coexistence of diminished muscle mass and increased fat mass. Sarcopenia has 
been characterized by age-related muscle degeneration [35], and obesity with an 
increased body fat exerts negative impacts on the skeletal muscle turnover and its 
homeostasis [31]. Such deteriorations of muscle mass loss originated from aging 
process result in muscle dysfunction which may further lead to physical deficits 
in frail elderly [36]. Furthermore, older adults who are identified as overweight 
or obesity have been observed suffering high risks of physical disability [37, 38]. 
Accordingly, sarcopenic obesity had been identified to be associated with more 
physical limit than either pure sarcopenia or obesity and was served as a risk to 
disability and frail life style [8, 39]. Therefore, the preservation of muscle mass and 
strength are vital for obese older adults to yield physical activities in daily life.
Aging-related attenuation of skeletal muscle mass had been addressed to a 
smaller muscle fiber size rather than loss of fiber number and characterized of type 
II myofiber phenotype dominant [13, 40]. In addition, sarcopenic muscles remain 
in a state of failing compensatory effort in an attempt to stave off muscular degen-
eration and atrophy [41]. Given the facts that myofiber hypertrophy activated by 
satellite cells is largely dependent on both net muscle protein synthesis and satellite 
cell recruitment through serious cellular processing mechanism [42, 43], and that 
both age-associated sarcopenia and obesity are associated with an over expres-
sion of myostatin which functions as a protein inhibitor negatively regulating the 
skeletal muscle growth and homeostasis with inhibiting the myoblasts proliferation 
and differentiation [44–46], it is important to identify whether resistance exercises 
exert any effect on the myofiber type-specific muscle mass loss in obese aged 
people. In such scenarios, previous trials claimed that age-related Type II myofiber 
phenotype atrophy would be improved following resistance exercise training by 
means of satellite cell proliferation and an increase in the rate of muscle contrac-
tile and mitochondrial protein synthesis, which further contributed to myofiber 
hypertrophy [40, 42, 47–51].
Progressive resistance exercise training (RET) has been used as an effective way 
of improving muscle function and increasing muscle mass by stimulating muscle 
protein synthesis in elder people [31, 49, 52, 53]. Liao et al. further indicate that 
elastic RET exerts benefits on lean mass and physical mobility in older women with 
sarcopenic obesity [54]. With respective to multidisciplinary interventions for pre-
vention of sarcopenia in elder populations, an additional protein supplements (PS) 
has also been believed to augment the effects of resistance training on muscle mass 
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gain in older adults [55, 56]. For obese elderly individuals with energy restricted 
diet, PS has its effect on reduction of losing muscle mass during caloric restriction-
induced weight loss [57]. However, the effects of PS plus RET on muscle mass and 
strength gains for obese elder people remain controversy. While several studies 
identified the effects of PS on muscle mass accretion and strength gain during 
resistance training in sarcopenic or obese elderly individuals [58], some concluded 
that PS provides no additional benefit in resistance-trained obese elder individuals 
[59, 60]. Furthermore, few systemic review studies have summarized these results 
in obese elder individuals. Whether PS during RET exerts any benefit on augmenta-
tion of muscular and functional performance in obese elder people remains unclear.
Liao et al. conducted a systemic review and meta-analysis study to investigate 
effects of PS plus RET for obese elder people [61]. Main results of Liao’s study 
showed an overall effect on lean body mass (LBM) and fat mass with significant 
standardized mean differences (SMDs) of 0.58 (95% CI = 0.32, 0.84, P < 0.0001) 
and − 0.61 (95% CI = −0.93, −0.29; P = 0.0002) favoring PS plus RET, respec-
tively; similar results were observed in leg strength (SMD = 0.69, 95% CI = 0.39, 
0.98; P < 0.00001) and short physical performance battery test (SMD = 0.44, 
95% CI = 0.11, 0.78, P = 0.009). The results indicate that PS during RET inter-
vention may potentially positively contribute to changes in the body composi-
tion of overweight and obese older people. However, based on the lower body 
mass index (BMI) subgroup (mean BMI < 30 kg/m2) exhibited greater changes 
in muscle volume and handgrip strength whereas the subgroup with mean 
BMI ≥ 30 kg/m2 did not after PS, obese older individuals may be resistant to PS to 
some degree [61].
2.2  Associations of muscle mass changes with intervention effects on muscle 
strength and physical capability after protein supplement plus exercise training
Multidisciplinary approaches are recommended for elderly individuals who 
have high sarcopenia or frailty risks, including nutrient intervention alone, exercise 
training alone, or combination of both [62–66], and among which protein supple-
ment combined with exercise training (PS + ET) has been widely employed to 
augment lean mass gain, strength gain, and physical function enhancement in 
elderly individuals, irrespective of PS types and exercise protocols [65, 67–69]. 
However, whether intervention-induced changes in muscle mass contribute to 
strength gain and physical mobility improvement after PS + ET remains unclear. 
Several previous meta-analysis studies have reported that an increase in lean mass 
is accompanied by significant increases in strength gain [61, 68, 70–72] as well as 
physical mobility [68, 72] following PS + ET; however, such simultaneous increases 
in lean mass with strength [67, 73] (or physical function [61, 71]) were not observed 
by other researchers. Low muscle mass strongly predicts strength loss and mobility 
limitations in older adults [17, 74]; in addition, sarcopenia has been addressed to 
suppressed muscle protein turnover and homeostasis [75, 76]; therefore, identifica-
tion of relationship between the muscle mass changes and physical improvements in 
response to PS + ET can facilitate clinical practitioners to efficiently make optimal 
decisions and set appropriate intervention strategies for elderly patients who are 
diagnosed as sarcopenia or frailty.
Liao et al. conducted a systemic review and meta-regression study to determine 
the associations of lean mass changes with treatment effects on strength and physical 
mobility after PS + ET [77]. Main results of Liao’s study showed an overall effect on 
LBM and appendicular lean mass (ALM) with significant SMDs of 0.66 (95%CI: 
0.41–0.91, P < 0.00001) and 0.40 (95%CI: 0.15–0.66, P = 0.002) favoring PS + ET, 
respectively; similar results were observed in leg strength (SMD = 0.65, 95% CI: 
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0.39–0.90; P < 0.00001) and walking capability (SMD = 0.33, 95% CI: 0.14–0.52; 
P = 0.0006). Meta-regression analysis results of Liao’s study showed that significant 
associations were observed between changes in ALM (β = 0.08, P = 0.003) and 
SMDs of leg strength; the results further indicated that elderly individuals who 
achieved an increase in ALM of >2.5% in response to PS + ET may have obtained a 
positive effect size of leg strength. In addition, changes in ALM were significantly 
associated with effect sizes of walking capability (β = 0.17, P = 0.04). According to 
the Liao’s results, intervention-induced muscle mass gains have contributions in 
strength gain and function recovery after PS + ET, particularly the elderly who have 
sarcopenia and frailty risks.
3.  Management of muscle deficits for mild to moderate severity  
of osteoarthritis
Since OA has been recognized as a serious musculoskeletal disease [78], man-
agements of OA comprise multidisciplinary interventions including pain medica-
tions and nonpharmacological treatments for those patients who exhibit mild to 
moderate symptoms. However, surgical treatments such as total joint arthroplasty 
that could help to relief pain and improve joint function (e.g., range of motion and 
strength) [79] are commonly recommended at the end stage of OA.
Evidences regarding the effects of ET alone or PS plus ET on muscle mass, 
strength, and physical mobility have been well established in elderly populations 
with sarcopenia (Figure 1). However, whether ET alone or PS plus ET exert any 
benefit on muscle mass and function outcomes remains unclear. Based on that 
low muscle mass is closely associated with OA and elder individuals with OA have 
high sarcopenia risk [10, 28], it is urgent to generate effective strategy to manage 
this condition for the rapidly growing OA population. In addition, it is necessary 
Figure 1. 
Summary of evidences regarding effects of exercise and diet interventions on sarcopenia, sarcopenic obesity, and 
osteoarthritis. Black, green, and red arrow lines indicate exercise alone, protein supplement plus exercise, and 
diet interventions plus exercise, respectively. (+): significant intervention effect; (++): significantly additional 
effect; (?) unclear additional effect. RET, resistance exercise training; MET, multicomponent exercise training; 
PS, protein supplement; DP, dietary protein; WL, weight loss.
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associated with effect sizes of walking capability (β = 0.17, P = 0.04). According to 
the Liao’s results, intervention-induced muscle mass gains have contributions in 
strength gain and function recovery after PS + ET, particularly the elderly who have 
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3.  Management of muscle deficits for mild to moderate severity  
of osteoarthritis
Since OA has been recognized as a serious musculoskeletal disease [78], man-
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moderate symptoms. However, surgical treatments such as total joint arthroplasty 
that could help to relief pain and improve joint function (e.g., range of motion and 
strength) [79] are commonly recommended at the end stage of OA.
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strength, and physical mobility have been well established in elderly populations 
with sarcopenia (Figure 1). However, whether ET alone or PS plus ET exert any 
benefit on muscle mass and function outcomes remains unclear. Based on that 
low muscle mass is closely associated with OA and elder individuals with OA have 
high sarcopenia risk [10, 28], it is urgent to generate effective strategy to manage 
this condition for the rapidly growing OA population. In addition, it is necessary 
Figure 1. 
Summary of evidences regarding effects of exercise and diet interventions on sarcopenia, sarcopenic obesity, and 
osteoarthritis. Black, green, and red arrow lines indicate exercise alone, protein supplement plus exercise, and 
diet interventions plus exercise, respectively. (+): significant intervention effect; (++): significantly additional 
effect; (?) unclear additional effect. RET, resistance exercise training; MET, multicomponent exercise training; 
PS, protein supplement; DP, dietary protein; WL, weight loss.
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to identify evidence of intervention effects on muscle mass and strength gains for 
elder people with OA.
3.1 Exercise training
Among the interventions of OA, exercise therapy is recommended as one of 
the first-line treatments [80]. Exercise exerts benefits on pain reduction, muscle 
strength, and physical function in elder individuals with OA, regardless of exercise 
types [81]. Especially, the muscle strength-based exercise training (MSE) has been 
encouraged to minimize degenerative muscular function associated with aging 
[82, 83], because of that elder individuals experience well muscular adaptations 
in terms of muscle morphological and architectural changes responding to MSE 
[84]. Therefore, MSE has been recommended for elder people with OA to augment 
muscle volume and enhance muscle hypertrophy [80].
Previous results have shown that MSE exerts benefits on muscle mass gain in 
elderly people. Churchward-Venne et al. indicated that older individuals achieved 
significantly temporal changes in whole body lean mass at 12-week and 24-week 
follow up by 0.9 ± 0.1 kg (P < 0.001) and 1.1 ± 0.2 kg (P < 0.001), respectively, 
responding to prolonged resistance-type MSE with an intensity of 60–80% 1RM 
and an intervention duration of 24 weeks [85]. In a meta-analysis, Peterson et al. 
indicated that resistance exercise exerts significant effects on increasing LBM with 
a pooled mean difference of 1.1 kg (95% CI: 0.9–1.2 kg) compared to the controls in 
older people [53].
The MSE has been served as the most promising intervention for sarcopenic 
elderly [62, 86] as well as those with OA [87–90] to increase strength and improve 
mobility. Due to that MSE enables older adults to yield increased muscle anabolic 
resistance occurring with advancing age [91, 92], resistance-type exercise training 
(RET) as well as multicomponent exercise training (MET) have been considered 
beneficial for preserving lean muscle mass in older populations, even in those with 
sarcopenia [53, 93]. In addition, muscle protein synthesis and myofiber proliferation 
can be effectively activated through MSE [94], which further contribute to skeletal 
muscle hypertrophy and muscle mass gains even in elder population [42, 43]. 
Therefore, MSE is recommend to be employed for management of OA since elder 
individuals with OA has been considered having low muscle mass [10].
However, it remains unclear that whether MSE has any effect on muscle mass 
gain and morphological changes in older individuals with lower extremities of OA. 
Studies have reported that patients with OA exhibited increased changes in the 
muscle cross-sectional area or muscle thickness after MSE [95–97], whereas other 
authors have reported conflicting conclusions that MSE exerted no beneficial effects 
on fat-free mass or muscle remodeling [98–100]. In addition, both sarcopenia and 
OA are associated with decreased muscle protein synthesis and homeostasis [75, 76], 
and exercise-induced muscular hypertrophy contributes to the increase of muscle 
strength [101]. Moreover, most of previous systematic reviews investigating the 
treatment efficacy of MSE for individuals with OA have focused on muscular 
strength and physical outcomes rather than the muscle mass or volume measures 
[87–90]. Therefore, identifying the effects of MSE on increasing muscle mass and 
volume helps clinical practitioners to develop appropriate treatment strategies for 
older people with OA.
Liao et al. conducted a systemic review and meta-analysis study to investigate 
effects of MSE for elder people with lower extremity OA [77]. Main results of sys-
temic review and meta-analyses showed MSE has effects on changes in muscle mass 
gain (SMD = 0.49, 95% CI: 0.28, 0.71; P < 0.00001), muscle thickness (SMD = 0.82, 
95% CI: 0.20, 1.43; P = 0.009), and muscle cross-sectional area (SMD = 0.80, 95% 
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CI: 0.25, 1.35; P = 0.004) compared with nonexercise controls. Liao’s study demon-
strated that MSE exerts effects on lean mass gain as well as muscle morphological 
changes in older adults with knee or hip OA. In addition, the subgroup analysis 
results suggested that older men experienced greater MSE effects on muscle thick-
ness than did women peers and those who received MSE after arthroplasty may 
achieve greater changes in muscle volume compared to those who received preop-
erative an MSE intervention or those who did not undergo arthroplasty. According 
to the results in Liao’s meta-analysis, MSE may aid in offsetting muscle attenuation 
or prevent sarcopenia in older individuals with knee or hip OA, particularly in older 
men and in those undergoing knee or hip arthroplasty.
3.2 Protein supplement
Diet intervention such as dietary protein or protein supplementation (PS) has 
been incorporated to multidisciplinary managements for OA [102], since elder 
patients with OA have potential risks of age-related sarcopenia. In addition, alterna-
tive and complementary therapeutic approaches, such as the use of a wide array of 
nutritional and physical manipulations, are becoming popular for relieving symp-
toms of OA. Several previous studies had investigated clinical efficacy of protein 
supplementation (PS) for elder individuals with knee OA [103–106]. Colker et al. 
employed a 6-week milk PS for elder individuals with OA and the results showed 
that PS achieved significant improved changes of daily activity and the Western 
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) per week 
compared with the placebo group (P < 0.001) [104]; Zenk et al. conducted a similar 
study for older adults with OA and demonstrated that compared with the placebo 
supplement, a 6-week milk PS obtained significant effects on WOMAC and reduc-
tion of medication use as well as the glucosamine-supplement group did [106]. 
Arjmandi et al. further indicated that a 3-month soy-protein supplement achieved 
greater changes in pain, physical difficulty, and medical requirement than milk PS 
did, particularly for elder men with OA [103]. Regarding other types of PS, Miller 
et al. used an alternative PS of leucine enriched herbal and indicated that WOMAC 
and pain score were significantly reduced in PS group by 45% (P < 0.05) and 
21.8% (P < 0.002), respectively, compared to the placebo group (reduced 25.4% in 
WOMAC and 21.8% in pain) [105].
3.3 Protein supplement combined with exercise training
Nutritional intervention, especially the protein supplementation (PS), can 
influence outcomes for elder individuals undergoing exercise interventions such 
as resistance-based exercise training (RET) or multicomponent exercise training 
(MET). Several systematic review studies had identified benefits of PS plus exercise 
training for elder population. For healthy elder individuals, Morton et al. reported 
that prolonged PS plus RET has effects on fat free mass, mid-thigh cross-sectional 
area, and one-repetition maximum strength by significant pooled mean differences 
of 0.30 kg (95%CI: 0.09–0.52 kg; P = 0.007), 7.2 mm2 (95%CI: 0.20–14.30 mm2; 
P = 0.04), and 2.49 kg (95%CI: 0.64–4.33 kg; P = 0.01), respectively [67]. For 
overweight or obese elder individuals, Liao et al. indicated that PS plus RET exerts 
significant effects on LBM and muscle volume with the corresponding effect 
sizes being 0.58 (95% CI: 0.32–0.84; P < 0.0001) and 1.23 (95% CI: 0.50–1.96; 
P = 0.001), respectively, irrespective of the intervention period [61]. For frail 
elderly, Liao et al. demonstrated that PS plus either RET or MET exerts significant 
effects on LBM and leg strength with the corresponding effect sizes being 0.52 
(95% CI: 0.33–0.71; P < 0.00001) and 0.37 (95% CI: 0.23–0.51; P < 0.00001), 
Background and Management of Muscular Atrophy
162
to identify evidence of intervention effects on muscle mass and strength gains for 
elder people with OA.
3.1 Exercise training
Among the interventions of OA, exercise therapy is recommended as one of 
the first-line treatments [80]. Exercise exerts benefits on pain reduction, muscle 
strength, and physical function in elder individuals with OA, regardless of exercise 
types [81]. Especially, the muscle strength-based exercise training (MSE) has been 
encouraged to minimize degenerative muscular function associated with aging 
[82, 83], because of that elder individuals experience well muscular adaptations 
in terms of muscle morphological and architectural changes responding to MSE 
[84]. Therefore, MSE has been recommended for elder people with OA to augment 
muscle volume and enhance muscle hypertrophy [80].
Previous results have shown that MSE exerts benefits on muscle mass gain in 
elderly people. Churchward-Venne et al. indicated that older individuals achieved 
significantly temporal changes in whole body lean mass at 12-week and 24-week 
follow up by 0.9 ± 0.1 kg (P < 0.001) and 1.1 ± 0.2 kg (P < 0.001), respectively, 
responding to prolonged resistance-type MSE with an intensity of 60–80% 1RM 
and an intervention duration of 24 weeks [85]. In a meta-analysis, Peterson et al. 
indicated that resistance exercise exerts significant effects on increasing LBM with 
a pooled mean difference of 1.1 kg (95% CI: 0.9–1.2 kg) compared to the controls in 
older people [53].
The MSE has been served as the most promising intervention for sarcopenic 
elderly [62, 86] as well as those with OA [87–90] to increase strength and improve 
mobility. Due to that MSE enables older adults to yield increased muscle anabolic 
resistance occurring with advancing age [91, 92], resistance-type exercise training 
(RET) as well as multicomponent exercise training (MET) have been considered 
beneficial for preserving lean muscle mass in older populations, even in those with 
sarcopenia [53, 93]. In addition, muscle protein synthesis and myofiber proliferation 
can be effectively activated through MSE [94], which further contribute to skeletal 
muscle hypertrophy and muscle mass gains even in elder population [42, 43]. 
Therefore, MSE is recommend to be employed for management of OA since elder 
individuals with OA has been considered having low muscle mass [10].
However, it remains unclear that whether MSE has any effect on muscle mass 
gain and morphological changes in older individuals with lower extremities of OA. 
Studies have reported that patients with OA exhibited increased changes in the 
muscle cross-sectional area or muscle thickness after MSE [95–97], whereas other 
authors have reported conflicting conclusions that MSE exerted no beneficial effects 
on fat-free mass or muscle remodeling [98–100]. In addition, both sarcopenia and 
OA are associated with decreased muscle protein synthesis and homeostasis [75, 76], 
and exercise-induced muscular hypertrophy contributes to the increase of muscle 
strength [101]. Moreover, most of previous systematic reviews investigating the 
treatment efficacy of MSE for individuals with OA have focused on muscular 
strength and physical outcomes rather than the muscle mass or volume measures 
[87–90]. Therefore, identifying the effects of MSE on increasing muscle mass and 
volume helps clinical practitioners to develop appropriate treatment strategies for 
older people with OA.
Liao et al. conducted a systemic review and meta-analysis study to investigate 
effects of MSE for elder people with lower extremity OA [77]. Main results of sys-
temic review and meta-analyses showed MSE has effects on changes in muscle mass 
gain (SMD = 0.49, 95% CI: 0.28, 0.71; P < 0.00001), muscle thickness (SMD = 0.82, 
95% CI: 0.20, 1.43; P = 0.009), and muscle cross-sectional area (SMD = 0.80, 95% 
163
Management of Sarcopenic Obesity for Older Adults with Lower-Extremity Osteoarthritis
DOI: http://dx.doi.org/10.5772/intechopen.93487
CI: 0.25, 1.35; P = 0.004) compared with nonexercise controls. Liao’s study demon-
strated that MSE exerts effects on lean mass gain as well as muscle morphological 
changes in older adults with knee or hip OA. In addition, the subgroup analysis 
results suggested that older men experienced greater MSE effects on muscle thick-
ness than did women peers and those who received MSE after arthroplasty may 
achieve greater changes in muscle volume compared to those who received preop-
erative an MSE intervention or those who did not undergo arthroplasty. According 
to the results in Liao’s meta-analysis, MSE may aid in offsetting muscle attenuation 
or prevent sarcopenia in older individuals with knee or hip OA, particularly in older 
men and in those undergoing knee or hip arthroplasty.
3.2 Protein supplement
Diet intervention such as dietary protein or protein supplementation (PS) has 
been incorporated to multidisciplinary managements for OA [102], since elder 
patients with OA have potential risks of age-related sarcopenia. In addition, alterna-
tive and complementary therapeutic approaches, such as the use of a wide array of 
nutritional and physical manipulations, are becoming popular for relieving symp-
toms of OA. Several previous studies had investigated clinical efficacy of protein 
supplementation (PS) for elder individuals with knee OA [103–106]. Colker et al. 
employed a 6-week milk PS for elder individuals with OA and the results showed 
that PS achieved significant improved changes of daily activity and the Western 
Ontario and McMaster Universities Osteoarthritis Index (WOMAC) per week 
compared with the placebo group (P < 0.001) [104]; Zenk et al. conducted a similar 
study for older adults with OA and demonstrated that compared with the placebo 
supplement, a 6-week milk PS obtained significant effects on WOMAC and reduc-
tion of medication use as well as the glucosamine-supplement group did [106]. 
Arjmandi et al. further indicated that a 3-month soy-protein supplement achieved 
greater changes in pain, physical difficulty, and medical requirement than milk PS 
did, particularly for elder men with OA [103]. Regarding other types of PS, Miller 
et al. used an alternative PS of leucine enriched herbal and indicated that WOMAC 
and pain score were significantly reduced in PS group by 45% (P < 0.05) and 
21.8% (P < 0.002), respectively, compared to the placebo group (reduced 25.4% in 
WOMAC and 21.8% in pain) [105].
3.3 Protein supplement combined with exercise training
Nutritional intervention, especially the protein supplementation (PS), can 
influence outcomes for elder individuals undergoing exercise interventions such 
as resistance-based exercise training (RET) or multicomponent exercise training 
(MET). Several systematic review studies had identified benefits of PS plus exercise 
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respectively [68]. According to the previous established evidence regarding efficacy 
of PS plus exercise training, additional PS employed during exercise training may 
exert benefits for elder population with OA. However, most of the previous systematic 
review and meta-analysis studies investigated effects of PS plus exercise training for 
sarcopenic or frail elderly people, few studies focusing on OA population who are 
potentially with a high risk of sarcopenia. Further studies are necessary to investi-
gate treatment effects of PS plus exercise on elderly population with OA.
3.4 Weight loss plus exercise for sarcopenic obesity in osteoarthritis
Given that obesity has become a burden in OA population [25], weight loss 
(WL) should be considered as an option while setting the treatment goals and 
planning rehabilitation strategies for elder people with OA. Previous studies had 
shown that maintaining or lowering BMI to the normal range (usually within 
20.0–24.9, regardless of ethic) may reduce risks or improve symptoms of OA 
[107, 108]. Felson et al. indicated that a decrease of over 50% in odds of develop-
ing OA (odds ratio = 0.46; P = 0.02) occurred in older women along with a 2-unit 
decrease in BMI or a 5.1-kg reduction in weight over a 10-year period, especially 
for those who had a baseline BMI > 25 kg/m2 (odds ratio = 0.41; P = 0.02) [108]. 
Coggon et al. concluded similar results that proportion of knee OA patients can 
be reduced from 10.9 to 57.1% while overweight and obese populations reduced 
their weight by 2–5 kg or until reaching the normal-range BMI [107]. Weight loss is 
also efficacious in relieving symptoms of knee OA, most importantly alleviating the 
pain. Riddle et al. observed a significant dose-response relationship (P < 0.003) 
exists between percentage changes in body weight and the corresponding changes 
in WOMAC pain, as well as WOMAC physical function; Riddle further indicated 
that weight changes (gain or loss) of ≥10% potentially leads to clinical important 
changes in pain and function for older individuals with OA [109]. Messier et al. 
also identified a dose response to WL for pain (P = 0.01), 6-minute walk distance 
(P < 0.0001), and function (P = 0.0006) [110]. Accordingly, WL should be 
incorporated to the management for elder individuals with OA, especially those 
who are overweight or obese.
An WL intervention may exert negative impacts on lean mass since obesity 
often masks the age-associated loss of muscle mass. Recently, WL in combination 
with exercise has been recommended as the optimal approach to managing obese 
patients with OA. Several previous trials had targeted weight management for 
obese older adults with OA including the Intensive Diet and Exercise for Arthritis 
Trial [111], the Arthritis, Diet and Activity Promotion Trial [112], and the Physical 
Activity, Inflammation, and Body Composition Trial [113]. These registered clinical 
trials employed weight-loss protocols which targeted 5–10% reduction of body 
weight over 6–18 months and incorporated partial meal replacements, nutrition 
class, and behavior therapy for diet habit changes and lifestyle modifications. 
Results from such previous trials showed that exercise training in combination with 
a weight-loss program in obese adults with knee OA achieved significantly greater 
changes in pain and function compared to the control groups. In addition, several 
systemic reviews regarding WL with or without exercise for elder OA populations 
also provide evidences for treatment efficacy on pain relief and function recovery 
[114–117]. However, the effects of WL plus exercise on lean mass remain incon-
sistency among the results of previous trials and few systemic review and meta-
analysis studies focused on the treatment efficacy on muscle mass outcome in obese 
elder individuals with OA who received WL plus exercise. Future studies should 
be warranted to investigate effects of WL plus exercise on muscle mass in order to 
prevent sarcopenia in such elder population with OA.
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Liao et al. conducted a systemic review and meta-analysis study to investigate 
effects of diet intervention plus ET for elder people with mild to moderate OA 
[118]. Among the included trials in Liao’s study, all of the included trials which 
reported muscle mass outcomes conducted a WL plus ET intervention for obese 
elder patients with knee OA [118] and the results showed that during an overall 
follow-up duration, the WL plus ET group achieved significant effects on muscle 
mass gains (SMD = 0.61; 95%CI: 0.30–0.91, P = 0.0001) compared to the control 
groups, regardless of methodological design. The results indicated that WL 
plus ET exhibited significant effects on muscle mass for obese older individuals 
with OA.
4.  Management of muscle dysfunction after total joint replacement for 
patients with end-stage osteoarthritis
4.1  Postoperative rehabilitation for muscle recovery after total joint 
replacement
Total joint replacement has been recommended for patients with end-stage of 
OA who experience poor response to pharmacological medication or conventional 
therapy [119–121]. Total knee replacement (TKR) as well as total hip replacement 
(THR) has profound benefits for pain relief, which is the main determinant of 
functional recovery following surgery.
Enhanced recovery programs after a TKR or THR surgery, which require a 
multidisciplinary team of dedicated professionals, have been well-established 
[122]. Among the perioperative interventions producing better surgery outcome, 
rehabilitation plays an important role in physical reconditioning and functional 
recovery [123]. As mentioned in the Section 2.1, muscle strengthening exercise 
(MSE) exerts benefits on muscle mass and strength gains in elder people with OA, 
and an MSE has been effectively employed following TKR or THR surgery as well to 
improve postoperative muscle and joint function [124]. However, it remains unclear 
that whether MSE exerts any effect on muscle mass after total joint replacement. It 
is important to identify the effects of MSE on muscle mass outcome following total 
joint replacement since patient who were undergoing TKR or THR may experience 
acute sarcopenia immediately after surgery [125, 126]. Due to that sarcopenia may 
have impacts on function outcome after TKR or THR, further studies should be 
conducted to warrant effective interventions for preserve muscle mass for elderly 
population with OA who recently underwent total joint replacement.
Liao et al. conducted a randomized control trial to investigate effects of post-
TKR MSE for elder women with OA [127]. Liao’s study demonstrated that an 
intervention of 12-week elastic RET following TKR surgery exerted benefits for 
muscle mass gain and physical recovery among elderly women with KOA. The 
results of this study suggest that elastic RET should be incorporated to post-TKR 
rehabilitation for patients with KOA to achieve well postoperative outcomes, espe-
cially muscle mass gains and physical mobility improvements. Liao further stated 
that the elastic RET is relatively safe and easily performed at home. The elastic RET 
protocol used in Liao’s study will help clinical practitioners and physiotherapists 
and to establish prompt treatment strategies for elderly people with KOA, especially 
those who have undergone a recent TKR and are considered to have high sarcopenia 
risk. The findings of this study indicated post-TKR elastic RET exerted benefits 
on muscle mass and function and can potentially assist clinician decision-making 
concerning the optimal treatment strategy for elderly women who are undergoing a 
primary TKR.
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rehabilitation for patients with KOA to achieve well postoperative outcomes, espe-
cially muscle mass gains and physical mobility improvements. Liao further stated 
that the elastic RET is relatively safe and easily performed at home. The elastic RET 
protocol used in Liao’s study will help clinical practitioners and physiotherapists 
and to establish prompt treatment strategies for elderly people with KOA, especially 
those who have undergone a recent TKR and are considered to have high sarcopenia 
risk. The findings of this study indicated post-TKR elastic RET exerted benefits 
on muscle mass and function and can potentially assist clinician decision-making 
concerning the optimal treatment strategy for elderly women who are undergoing a 
primary TKR.
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4.2 Protein supplement plus exercise training after surgery
The previous observational study has indicated that low protein intake occur-
ring in patients with OA may place themselves at high risks of sarcopenia [128]. 
Therefore, perioperative interventions including protein supplement may prevent 
elder patients from suffering acute sarcopenia and poor surgical outcome at 
early stage after total joint replacement (i.e., TKR or THR) [129–131]. Alito et al. 
employed 5-day protein-contained (23%) supplements (PS) before surgery for 
patients who were undergoing THR and the results demonstrated that comparing 
with the non-supplement control group, the PS group experienced significantly a 
lower level of C-reactive protein (mean 80.6 vs. 66.5 mg/L, P < 0.01) and a shorter 
length of hospital stay (median 6 vs. 3 days, P < 0.01) after THR [129]. Yang et al. 
used high-dose PS on the day before and after THR surgery and the results showed 
that, comparing to the standard-care group, the PS group had less proportion of 
patients who required an intravenous albumin (45.1% vs. 26.8%, P = 0.023) and 
experienced a shorter length of hospital stay (mean 5.1 vs. 3.9 days, P < 0.001) 
[130]. Bai et al. used an oral ingestion of hydrolyzed PS for 5 postoperative days 
after TKR and the results indicated that PS enhanced postoperative nutrition status 
in terms of greater changes in blood prealbumin (P < 0.03) compared to the regular-
nutrition group [131]. The previous results had indicated that diet interventions, 
especially the PS, before or after total joint replacement can enhance postoperative 
nutrient status and shorten length of acute inpatient stay which further prevent 
elder patients from experiencing acute sarcopenia.
On the basis that either perioperative diet interventions or early rehabilitation 
programs exerts benefits on surgical outcome, combination of both may provide 
additional effects on function recovery after TKR or THR. The evidences regarding 
effects of PS plus exercise for healthy, sarcopenic, and frail elder populations 
have been well established by previous systemic review and meta-analysis studies 
[61, 68, 132]. However, the elder population with OA as well as those who under-
went total joint replacement are less targeted by previous systemic reviews investi-
gating efficacy of PS plus exercise. Future studies are necessary to be warranted in 
order to identify whether PS plus exercise following TKR or THR exerts any effect 
on postoperative function outcomes.
Liao et al. conducted a systemic review and meta-analysis study to investigate 
effects of diet intervention plus ET for elder people with OA [118]. Among the 
included trials in Liao’s study, all of the included trials which reported muscle mass 
outcomes conducted a PS plus ET intervention for older patients who recently 
received a TKR or THR [118] and the results showed that during an overall follow-
up duration, the PS plus ET group achieved significant effects on muscle mass gains 
(SMD = 0.81; 95%CI: 0.45–1.17, P < 0.0001) compared to the ET control groups, 
regardless of PS type. The results indicated that PS plus ET exhibited significant 
effects on muscle mass for older individuals with OA, especially for those who 
recently received a total joint arthroplasty.
5. Conclusions
This review provides evidence that DI incorporated with ET is effective for 
promoting gains in muscle mass and strength and enhancing performance in 
physical mobility for the elder adults with lower-extremity OA, compared to 
placebo, DI-alone or ET-alone controls. In addition, muscle mass gains have effects 
on strength gain and global function recovery. Furthermore, the results of this 
study showed that PS plus ET appears to be the optimal treatment strategy for 
167
Management of Sarcopenic Obesity for Older Adults with Lower-Extremity Osteoarthritis
DOI: http://dx.doi.org/10.5772/intechopen.93487
Author details
Tsan-Hon Liou1*, Chun-De Liao2 and Shih-Wei Huang1
1 Department of Physical Medicine and Rehabilitation, School of Medicine, College 
of Medicine, Taipei Medical University, Taipei, Taiwan
2 Department of Physical Medicine and Rehabilitation, Shuang Ho Hospital, Taipei 
Medical University, Taipei, Taiwan
*Address all correspondence to: peter_liou@s.tmu.edu.tw
those who were undergoing total joint replacement whereas WL plus ET is most 
preferred for those who experienced mild to moderate severity of OA disease. 
Therefore, we concluded that DI additional to ET may have extra effects to prevent 
or offset muscle loss and function decline for elder individuals with OA who have 
high sarcopenia risks.
6. Implications for clinical practice
This review adds current evidences of interdisciplinary approach practices 
which comprise effective nutrient and exercise intervention strategies for KOA 
populations who have potential risks of sarcopenic obesity. This review also pro-
vides references for clinical practitioners to develop efficient and effective interven-
tions for such population to prevent sarcopenic obesity.
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